Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2014

The Role of ADAM10 in the Immune System: Maintenance of
Lymphoid Architecture, MDSC Development and Function, B cell
Derived Exosomal Antigen Presentation, and B1 cell IgE
Production.
Rebecca Martin
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Medicine and Health Sciences Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/588

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Rebecca K. Martin 2014
All Rights Reserved

The Role of ADAM10 in the Immune System: Maintenance of Lymphoid Architecture,
MDSC Development and Function, B cell Derived Exosomal Antigen Presentation, and
B1 cell IgE Production.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University

by

Rebecca Kelley Martin
B.S., Virginia Commonwealth University 2009

Director: Daniel H. Conrad, PhD
Professor
Department of Microbiology and Immunology
School of Medicine
Virginia Commonwealth University
Richmond, VA
April 25, 2014

Dedication
This dissertation is dedicated to my children: Natalie, Savannah, and Garrett Martin. I
hope that one day they invest themselves in something they truly love. I also dedicate
this dissertation to my husband, Tim Martin, and to my parents, Kemper and Susan
Smith. Without them, all of this would not be possible.

ii

Acknowledgements
First, I would like to thank my advisor, mentor, and friend, Daniel H. Conrad,
Ph.D. He encouraged me to think for myself, push myself intellectually, and pursue
science in a passionate way. He was always available to discuss an idea or help me
troubleshoot a problem. Beyond financially supporting my research, Dr. Conrad
provided me with many great opportunities for growth as a scientist. He expanded my
horizons by sending me to several national and international meetings. He additionally
sent me abroad to work with a collaborator in Uppsala, Sweden. Dr. Conrad’s
enthusiasm for scientific discovery has motivated me to continue pursuit of a career in
academic research.
Second, I would like to thank all the past and current Conrad lab members. I am
especially thankful to Sheinei Saleem, Ph.D., for her initial work on the ADAM10Tg
mouse and for her collaboration on the MDSC/MC project. She always provided brevity
and humor to every situation. She is a wonderful friend. Hannah Zellner, my friend and
co-worker, provided unparalleled technical and emotional support. Lauren FolgosaCooley coached me in qPCR, western blotting, and delicious food. Her dedication to
research is motivating and inspiring. Sheela Damle collaborated on the IL-13/MDSC
project and always provided lots of late night laughter. Keith Brooks worked with me on
the exosome project and always kept me on my toes. Natalia Chaimowitz collaborated
on the ADAM10B-/- project. All of my independent study, summer and rotation students
contributed to my project, allowed me to share my research with them, and hopefully
learned something. I wish them all the upmost success in their careers. Emily Boice,
PhD, an honorary Conrad lab member, embarked with me on exciting expeditions,
iii

spent many late hours on encouragement sessions, and was my partner in crime,
committing general shenanigans. She helped me capture my ‘science spirit.’
Third, I thank our collaborators on the exosome project. Birgitta Heyman, Ph.D.
is known for her work on IgE/Ag IC feedback responses. She hosted me for several
weeks in Uppsala, Sweden to work on our collaboration. Zhoujie Ding introduced me to
the ‘Swedish’ ways of doing science and became my tour guide whilst in Uppsala. I
additionally thank all of our collaborators at VCU. Harry D. Bear, MD/Ph.D. provided
weekly guidance and feedback on the tumor project at his lab meetings. Masoud
Manjili, DVM/Ph.D., Anne-Marie Irani, MD, Mohey El Shikh, Ph.D., and John Tew, Ph.D.
all provided excellent advice, collaboration and help with review of my manuscripts.
Fourth, I am truly thankful to my graduate committee members, Suzanne
Barbour, Ph.D., John Ryan, Ph.D., Francine Cabral, Ph.D., and Andrew Larner, Ph.D. I
am especially thankful to Dr. Ryan for his collaboration and insight while working on the
MDSC/MC project.
Next, I am thankful to the American Association of Immunologists for the two
travel awards to attend and present at the 2013 meeting in Hawaii, USA. I am also
thankful to the International Society of Extracellular Vesicles for the travel award to
attend and present at the 2012 meeting in Gothenburg, Sweden.
Lastly, I would like to thank my family for their unwavering love and support.

iv

Table of Contents
List of Tables ..................................................................................................................xv
Table of Figures ............................................................................................................ xvi
List of Abbreviations ...................................................................................................... xxi
Abstract ........................................................................................................................... ii
Section 1 ......................................................................................................................... 1
Chapter 1: ADAM10 and the Maintenance of Secondary Lymphoid Architecture ....... 1
1.1.1 Introduction to ADAM10 ................................................................................... 1
1.1.2 ADAM10 in lymphocyte development .............................................................. 4
1.1.3 Introduction to secondary lymphoid tissues ..................................................... 6
Chapter 2: Materials and Methods ............................................................................. 12
1.2.1 Mice ............................................................................................................... 12
1.2.2 PCR and Quantitative PCR............................................................................ 12
PCR ..................................................................................................................... 12
Quantitative PCR ................................................................................................. 12
1.2.3 Immunization ................................................................................................. 13
1.2.4 Cell Isolation .................................................................................................. 14
Tissue preparation ............................................................................................... 14
Magnetic Bead Isolation ...................................................................................... 14
1.2.5 Enzyme Linked Immunosorbant Assay (ELISA) ............................................ 15

v

Total antibody levels ............................................................................................ 15
NP-specific ELISA ............................................................................................... 15
1.2.6 Flow cytometry, immunofluorescence and confocal microscopy ................... 16
Flow cytometry .................................................................................................... 16
Immunofluorescence and confocal microscopy ................................................... 16
Antibodies............................................................................................................ 17
1.2.7 In vitro activation ............................................................................................ 19
1.2.8 Statistical analysis ......................................................................................... 19
Chapter 3: B cell ADAM10 deficient mice have altered responses to T-dependent
antigens ..................................................................................................................... 22
1.3.1 Generation of mature B cell specific ADAM10 deficient mice ........................ 22
1.3.2 ADAM10 is essential for secondary lymphoid architecture ............................ 27
ADAM10 is highly expressed in GC B cells ......................................................... 27
Humoral immune responses in ADAM10B-/- mice ................................................ 27
Germinal Center formation is impaired in ADAM10B-/- mice................................. 28
ADAM10B-/- mice have altered splenic and lymph node architecture ................... 28
ADAM10B-/- mice have dysregulated chemokine expression following antigen
challenge ............................................................................................................. 42
Defect in humoral in ADAM10B-/- mice is Notch2 and CD23-independent ........... 42
1.3.3 Discussion ..................................................................................................... 50

vi

ADAM10 is important for B cell follicle formation and maintenance of lymphoid
architecture.......................................................................................................... 52
Conclusions ......................................................................................................... 53
Chapter 4: B cell ADAM10 expression and activity is increased during active allergy
................................................................................................................................... 55
1.4.1 Introduction to CD23 ...................................................................................... 55
1.4.2 ADAM10 in allergic asthma models ............................................................... 56
1.4.2 ADAM10 in allergic patients ........................................................................... 57
Chapter 5: Materials and Methods ............................................................................ 58
1.5.1 Human studies ............................................................................................... 58
1.5.2 Flow cytometry............................................................................................... 58
Staining protocol .................................................................................................. 58
Antibodies............................................................................................................ 59
1.5.3 In vitro cultures .............................................................................................. 59
1.5.4 Enzyme Linked Immunosorbent Assay .......................................................... 59
sCD23 ELISA ...................................................................................................... 59
1.5.5 Reagents ....................................................................................................... 60
1.5.6 Statistical analyses ........................................................................................ 60
Chapter 6: Characterizing ADAM10 in allergic patients PBMC ................................. 62
1.6.1 Allergic Patients B cells have increased ADAM10 levels and activity. .......... 62

vii

Allergic patients have increased total B cell ADAM10 ......................................... 62
ADAM10 is not elevated on T cells or monocytes of allergic patients ................. 63
sCD23 is increased in culture supernatant of stimulated allergic patient PBMC
over control in an ADAM10 dependent manner ................................................... 63
Section 2 ....................................................................................................................... 71
Chapter 1: ADAM10 in MDSC development and function .......................................... 71
2.1.1 ADAM10 and myeloid cell development ........................................................ 71
2.1.2 Development of MDSCs ................................................................................ 72
2.1.3 Development of the ADAM10Tg mouse ........................................................ 75
2.1.4 Introduction to MDSC Function ...................................................................... 76
2.1.5 Survival and Proliferation ............................................................................... 80
2.1.6 Polarization and differentiation....................................................................... 81
2.1.7 Oxidative Metabolism of MDSCs ................................................................... 82
2.1.8 Cytokine production ....................................................................................... 84
2.1.9 Cell Signaling ................................................................................................. 85
STAT signaling .................................................................................................... 85
Notch signaling .................................................................................................... 85
2.1.10 Cytokine induced MDSC expansion ............................................................ 86
2.1.11 Subset accumulation in pathological conditions........................................... 87
Neoplasia. ........................................................................................................... 87

viii

Infection ............................................................................................................... 89
2.1.12 Interaction with cells other than T cells ........................................................ 91
Macrophages ....................................................................................................... 91
Dendritic Cells ..................................................................................................... 92
Mast Cells............................................................................................................ 93
2.1.13 Introduction to the Mast Cell ........................................................................ 93
Mast Cell secreted histamine on MDSC function ................................................ 94
Mast Cell secreted IL-13 on MDSC function........................................................ 94
Chapter 2: Methods and Materials ............................................................................. 97
2.2.1 Mice ............................................................................................................... 97
2.2.2 Cell Lines ....................................................................................................... 97
2.2.3 Isolation of MDSCs and AT, T cell depletion, and dye labeling...................... 98
2.2.4 Arginase1 and iNOS detection....................................................................... 98
2.2.5 T cell suppression assays .............................................................................. 98
2.2.6 BMMC co-culture with ADAM10Tg MDSCs ................................................... 99
2.2.7 Migration Assays ........................................................................................... 99
2.2.8 Survival curve and proliferation assays ......................................................... 99
2.2.9 Adoptive immunotherapy of B16 melanoma ................................................ 100
2.2.10 PCR and quantitative PCR ........................................................................ 100
PCR ................................................................................................................... 100
ix

qPCR ................................................................................................................. 100
2.2.11 Flow cytometry........................................................................................... 101
Sample preparation ........................................................................................... 101
Immunohistochemistry....................................................................................... 101
Antibodies.......................................................................................................... 101
2.2.12 N. brasiliensis infection, GEM treatment, CET treatment, CIM treatment, B16
melanoma or LLC injection, and AT of MDSCs .................................................... 104
Eggs per gram of feces enumeration................................................................. 104
L4 and L5 enumeration...................................................................................... 104
Serum collection, drug administration, and AT of MDSCs ................................. 105
B16 melanoma or LLC injection ........................................................................ 105
2.2.13 Human MDSCs .......................................................................................... 106
2.2.14 Statistical analysis ..................................................................................... 106
Chapter 3: Results .................................................................................................. 107
2.3.1 Mast Cells critically augment MDSC activity ................................................ 107
MDSCs from ADAM10Tg mice are phenotypically and functionally analogous to
tumor-induced MDSCs ...................................................................................... 107
Monocytic MDSCs promote B16 metastasis ..................................................... 108
MDSCs enhance the immune response against N. brasiliensis ........................ 116
Mast Cells are essential for MDSC-mediated parasitic clearance ..................... 118

x

MCs also contribute to MDSC-mediated immune suppression in B16 melanoma
.......................................................................................................................... 119
MCs promote MDSC trafficking and parasite clearance .................................... 120
MDSC interaction with MCs maintains the granulocytic population in vitro. ...... 121
2.3.2 Mast cell histamine promotes immunoregulatory activity of MDSCs ............ 156
MDSCs express HR1 and HR2 ......................................................................... 156
Histamine induces MDSC proliferation and differential gene expression in
monocytic versus granulocytic MDSCs ............................................................. 156
Histamine antagonist prevents MDSC-mediated N. brasiliensis expulsion and
tumor progression ............................................................................................. 157
MDSCs are increased in allergic patients .......................................................... 158
IL-13-/- mice have reduced MDSC accumulation in the periphery...................... 159
2.3.3 Discussion ................................................................................................... 187
Section 3 ..................................................................................................................... 195
Chapter 1: B1 B cell IgE production in helminth infection ........................................ 195
3.1.1 Introduction to B1 cells ................................................................................ 195
3.1.2 Introduction to IgE ........................................................................................ 198
3.1.3 Correlation between allergy and helminth infections .................................... 199
Chapter 2: Methods and Materials .......................................................................... 201
3.2.1 Mice ............................................................................................................. 201

xi

3.2.2 Isolation of MDSCs and AT, T cell depletion, and dye labeling.................... 201
3.2.3 ELISA .......................................................................................................... 202
Total IgE ELISA ................................................................................................. 202
Total IgG1 ELISA .............................................................................................. 202
3.2.4 Flow cytometry, cell sorting and immunohistochemistry .............................. 203
Flow cytometry .................................................................................................. 203
Cell sorting ........................................................................................................ 203
Immunohistochemistry....................................................................................... 203
Antibodies.......................................................................................................... 203
3.2.5 B1 cell culture .............................................................................................. 205
CHAPTER 3: Th2 helminth infected mice induce a strong B1 cell IgE response that is
augmented by MDSCs. ............................................................................................ 206
3.3.1 ADAM10Tg mice lack B2 cell development, but elicit a strong IgE response
during N. brasiliensis infection .............................................................................. 206
ADAM10Tg mice lack B2 cells but have an intact B1 cell compartment ............ 206
ADAM10Tg mice have increased B1 IgE production ......................................... 211
B1 cells have augmented IgE production that is independent of IgG1 and GCs 228
ADAM10Tg mice lack GC development ............................................................ 211
B1 cells from WT N. brasiliensis infected mice stain positive for IgE ................. 212

xii

B1 cells from N. brasiliensis infected mice make IgE in vitro after stimulation with
IL-4 and anti-CD40 ............................................................................................ 212
MDSCs enhance B1 IgE production in WT mice ............................................... 228
MDSC AT into naïve mice increases IgE production by B1 cells....................... 228
3.3.2 Discussion ................................................................................................... 235
Section 4 ..................................................................................................................... 238
Chapter 1: CD23+ B cell-derived exosomes mediate IgE-antigen complex mediated
immune stimulation .................................................................................................. 238
4.1.1 Introduction .................................................................................................. 238
Chapter 2: Materials and Methods ........................................................................... 241
4.2.1 Mice ............................................................................................................. 241
4.2.2 Exosomal Cell Cultures ............................................................................... 241
4.2.3 Exosomal Isolation ....................................................................................... 242
4.2.4 Western Blotting .......................................................................................... 242
4.2.5 Specific T cell proliferation: .......................................................................... 243
In vitro................................................................................................................ 243
In vivo ................................................................................................................ 243
4.2.6 Flow Cytometry/Immunohistochemistry ....................................................... 244
4.2.7 BMDC culture .............................................................................................. 244
4.2.8 Statistical Analysis ....................................................................................... 244

xiii

Chapter 3: IgE/Antigen Complexes stimulate OVA specific T cell proliferation ........ 245
4.3.1 Results and Discussion ............................................................................... 245
IgE is associated with bexosomes in a CD23 dependent manner. .................... 245
Increased in vivo antigen specific T cell proliferation is seen with bexosomes from
anti-CD40/IL4 activated B cells when IgE/antigen complexes are present in the
culture................................................................................................................ 246
Bexosomes must first go through DCs in order to stimulate T cells in vivo. ...... 247
References .................................................................................................................. 263

xiv

List of Tables
Table 1. Primer sequences………………………………………………………………….18
Table 2. Flow cytometry and immunohistochemistry antibodies…………………………20
Table 3. Antibodies for flow cytometry……………………………………………………...61
Table 4. List of primers used for PCR and qPCR………………………………………..102
Table 5. List of antibodies used for flow cytometry……………………………………….103
Table 6. Antibodies used in section 3……………………………………………………...204

xv

Table of Figures
Figure 1. ADAM10 and Notch signaling ....................................................................... 23
Figure 2. ADAM10 B cell-specific knockout................................................................... 25
Figure 3. ADAM10 expression on GC B cells ............................................................... 30
Figure 4. ADAM10B−/− mice have impaired humoral responses. ................................... 32
Figure 6. GC formation after T-dependent immunization .............................................. 36
Figure 7. Immunohistochemistry analysis of GC formation and LN architecture after Tdependent immunization ............................................................................................... 38
Figure 8. Immunohistochemistry analysis of GC formation and splenic architecture after
T-dependent immunization ............................................................................................ 40
Figure 9. Chemokine expression in draining LNs .......................................................... 44
Figure 10. Defects in humoral responses in ADAM10B-/- mice seem to be Notch2independent .................................................................................................................. 46
Figure 11. CD23Tg mice have a normal IgG response to NP-KLH .............................. 48
Figure 12. Allergic patients have increased total B cell ADAM10 .................................. 65
Figure 13. ADAM10 is not elevated on T cells or monocytes of allergic patients ......... 67
Figure 14. sCD23 is increased in culture supernatant of stimulated allergic patient
PBMC over control in an ADAM10 dependent manner ................................................. 69
Figure 15. MDSCs from ADAM10Tg mice are phenotypically and functionally analogous
to tumor-derived MDSCs. ............................................................................................ 110

xvi

Figure 16. MDSC depletion restores the antitumor response and prevents metastatic
progression of B16 melanoma in ADAM10Tg mice ..................................................... 112
Figure 17. Gemcitabine selectively depletes MDSCs, which allows for effective AIT with
tumor specific T cells ................................................................................................... 114
Figure 18. ADAM10Tg mice are resistant to N. brasiliensis infection .......................... 122
Figure 19. ADAM10Tg MDSCs have increased cytokine expression over WT during N.
brasiliensis infection. ................................................................................................... 124
Figure 20. MDSCs accumulate in mesenteric lymph nodes in N. brasiliensis infection
.................................................................................................................................... 126
Figure 21. Gemcitabine depletion of MDSCs restores WT response to N. brasiliensis
infection to ADAM10Tg mice. ...................................................................................... 128
Figure 22. Adoptive transfer of MDSCs from ADAM10Tg mice or LLC-tumor bearing
mice induce increased parasitic clearance of N. brasiliensis....................................... 130
Figure 23. Granulocytic MDSCs are responsible for MDSC enhanced parasitic
clearance in a T cell independent manner................................................................... 132
Figure 24. T cell depleting antibodies completely deplete T cells. ............................... 134
Figure 25. Monocytic MDSCs promote B16 melanoma colonization to the lungs. ..... 136
Figure 26. MCs are required for MDSC-mediated N. brasiliensis clearance ............... 138
Figure 27. MC/MDSC interaction augments cytokine production. ............................... 140
Figure 28. MC/MDSC interaction is required for MDSC-mediated immune suppression.
.................................................................................................................................... 142

xvii

Figure 29. MDSCs preferentially migrate to the liver in a MC-dependent manner ...... 144
Figure 30. PKH26GL+ MDSCs are functional .............................................................. 146
Figure 31. MDSCs do not traffic to livers of MC-deficient mice during N. brasiliensis
infection ....................................................................................................................... 148
Figure 32. MDSCs migrate preferentially to mast cells................................................ 150
Figure 33. MCs are required for MDSC-mediated tumor progression ........................ 152
Figure 34. Mast cells help maintain the granulocytic population of MDSCs in vitro..... 154
Figure 35. MDSCs express HRs ................................................................................. 161
Figure 36. Histamine increases MDSC survival and proliferation ................................ 163
Figure 37. Histamine influences MDSC gene expression ........................................... 165
Figure 38. Ly6C+ MDSCs express increased Arg1 protein with Histamine ................. 167
Figure 39. HR1 and HR2 antagonists blocks MDSC mediated N. brasiliensis clearance
.................................................................................................................................... 169
Figure 40. HR antagonization inhibits MDSC mediated tumor progression................. 171
Figure 41. Allergic patients have increased circulating MDSCs. Symptomatic allergic
patients were compared with non-allergic controls. ..................................................... 173
Figure 42. MDSC gating strategy for allergic patient study. ........................................ 175
Figure 43. Human MDSCs have increased survival in the presence of histamine. .... 177
Figure 44. IL13 is important for MDSC-driven suppression of tumor immunity ........... 179
Figure 45. IL13 deficiency decreases MDSC accumulation in the liver ....................... 181

xviii

Figure 46. IL13 deficiency decreases MDSC accumulation in the spleen ................... 183
Figure 47. IL13 deficiency does not affect committed progenitor cells of the bone
marrow ........................................................................................................................ 185
Figure 48. Model of MDSC/MC interaction .................................................................. 193
Figure 49. ADAM10 Overexpression blocks B2 B cell development ........................... 207
Figure 50. ADAM10 overexpression does not affect B1 cell development .................. 209
Figure 51. ADAM10Tg mice make increased IgE during N. brasiliensis infection ....... 214
Figure 52. ADAM10Tg mice lack GCs......................................................................... 216
Figure 53. ADAM10Tg mice lack normal secondary lymphoid architecture ................ 218
Figure 54. Peritoneal lavage and spleens from N. brasiliensis infected mice contain B1a,
B1b and B2 cells ......................................................................................................... 220
Figure 55. B1a cells from peritoneal lavage and spleens of N. brasiliensis infected WT
mice stain for IgE ........................................................................................................ 222
Figure 56. B1 cells sorted from peritoneal lavage fluid of N. brasiliensis infected mice
make IgE in vitro after stimulation ............................................................................... 224
Figure 57. Naïve B1 cells secrete very little IgE without N. brasiliensis infection ........ 226
Figure 58. ADAM10Tg mice make increased IgE during N. brasiliensis infection that is
reduced upon GEM treatment ..................................................................................... 229
Figure 59. ADAM10Tg mice do not make increased IgG1 and GEM does not affect total
IgG1 levels in N. brasiliensis infection ......................................................................... 231

xix

Figure 60. Adoptive transfer of MDSCs into Naïve WT mice induces B1 IgE production
.................................................................................................................................... 233
Figure 61. IgE and CD23 are associated with bexosomes .......................................... 249
Figure 62. Bexosomes express co-stimulatory molecules CD80 and CD86 ............... 251
Figure 63. B cell derived exosomes by electron micrograph ....................................... 253
Figure 64. Bexosome-induced antigen specific T cell proliferation is enhanced by IgE,
only when CD23 is present and in vivo IgE immune complex T proliferation is enhanced
in ADAM10B-/- mice ..................................................................................................... 255
Figure 65. Bexosome-induced antigen specific T cell proliferation is enhanced by IgE in
C57BL/6 model of OVA-specific T cell proliferation ..................................................... 257
Figure 66. Increased in vivo T proliferation with i.v. injected DCs incubated with
bexosomes .................................................................................................................. 259
Figure 67. Model for the mechanism of IgE immune complex mediated humoral
immunity enhancement ............................................................................................... 261

xx

List of Abbreviations
-/-

Homozygous deletion of a gene

2.4G2

mAb recognizing the stalk region of murine CD23

5-LO

5-Lipoxygenase

ADAM

A disintegrin and metalloproteinase

ADAM-TS

ADAM-thrombospondins

AID

Activation induced cytosine deaminase

AIT

Adoptive Immunotherapy

Ag

Antigen

APC

Allophycocyanin

APC

Antigen Presenting Cell

AP

Alkaline Phosphatase

AT

Adoptive transfer

Arg1

Arginase-1

ASC

Antibody secreting cell

AT

Adoptive transfer

BALF

Bronchiolar lavage fluid

BALT

Bronchiolar-associated lymphoid tissue
xxi

BBS

Borate buffered saline

BCR

B cell Receptor

BM

Bone marrow

BMDC

Bone marrow derived dendritic cell

BMMC

Bone marrow derived mast cell

BMP

Bovine metalloprotease

Breg

B regulatory cell

BSA

Bovine serum albumin

CCL

Chemokine ligand

CCR

Chemokine receptor

CD

Clusters of differentiation

C/EBP-β

CAAT/enhancer binding protein β

CHO

Chinese hamster ovary

CIM

Cimetidine

CK2

Casein Kinase 2

CLP

Common lymphoid progenitor

CMEP

Common myelo-erythroid progenitor

xxii

CMLP

Common myelo-lymphoid progenitor

CMP

Common myeloid progenitor

CNS

Central nervous system

CPM

Counts per minute

CSR

Class switch recombination

CoA

Co-Activators

CoR

Co-Repressors

CTL

Cytotoxic T lymphocyte

CT

Cetirizine

CYP

Cyclophosphamide

DC

Dendritic Cell

DLL

Delta-like Notch ligand

DLN

Draining lymph node

DMSO

Dimethyl sulfoxide

DNP

Dinitrophenol

EAE

Experimental autoimmune encephalomyelitis

ELISA

Enzyme linked immunosorbent assay

xxiii

EMT

Epithelial-mesenchymal transition

EPG

Eggs per gram of feces

ER

Endoplasmic reticulum

FACS

Fluorescence active cell sorting

FBS

Fetal bovine serum

FcεRI

The high affinity IgE receptor

FDC

Follicular dendritic cell

FITC

Fluorescein isothiocyanate

FO

Follicular

FSC

Forward scatter

GALT

Gut-associated lymphoid tissue

GATA3

GATA-binding protein 3

G-CSF

Granulocyte-colony stimulating factor

GEM

Gemcitabine

GI

Gastrointestinal

GM-CSF

Granulocyte macrophage-colony stimulating factor

GMP

Granulocyte macrophage progenitor

xxiv

GPCR

G-protein coupled receptors

GVHD

Graft versus host disease

HDC

Histidine decarboxylase

HEV

High endothelial venule

HGF

Hepatocyte growth factor

HLX

H2.0-like homeobox

HNSCC

Head and neck squamous cell carcinoma

HR

Histamine receptor

HRP

Horseradish peroxidase

HSC

Hematopoietic stem cells

ICD

Intracellular domain

IFN

Interferon

Ig

Immunoglobulin

IL

Interleukin

iNOS

Inducible nitric oxide synthase

i.p.

Intra-peritoneal

IRF-8

Interferon regulatory factor 8

xxv

ITAM

Immunoreceptor tyrosine-based activation motif

ITIM

Immunoreceptor tyrosine-based inhibitory motif

i.v.

Intravenous

Jak

Janus kinase

kuz

Kuzbanian

L-Arg

L-arginine

Lin

Lineage

LLC

Lewis lung carcinoma

LPS

Lipopolysaccharide

LM

Littermate

LN

Lymph node

LSK

Lineage-Sca+c-Kit+ bone marrow cells

LT

Lymphotoxin

LTi

Lymphoid tissue inducer

M1

Classically activated macrophage

M2

Alternatively activated macrophage

mAb

Monoclonal antibody

xxvi

MACS

Magnetic cell sorting

MCs

Mast cells

MCP-1

Monocyte Chemotactic Protein 1

M-CSF

Macrophage-colony stimulating factor

MDSCs

Myeloid derived suppressor cells

MEF

Mouse embryonic fibroblast

MFI

Mean fluorescence intensity

MHC

Major histocompatibility complex

MEP

Myeloid erythroid progenitor

MIF

Macrophage inhibitory factor

MLN

Mesenteric Lymph node

MMP

Matrix metalloprotease

MM

Multiple myeloma

MPP

Multipotent progenitor

mRNA

Messenger ribonucleic acid

MS

Multiple sclerosis

MVB

Multi-vesicular bodies

xxvii

MZ

Marginal zone

ND

No difference

NICD

Notch intracellular domain

NKT

Natural killer T cell

NO

Nitric oxide

NP-KLH

4-Hydroxy,3-Nitrophenylacetyl Keyhole limpet hemocyanin

NS

Not significant

OCT

Optimal Cutting Temperature medium

ONOO2

Peroxynitrites

OVA

Ova albumin

PALS

Peri-arteriolar lymphoid sheath

PB

Peripheral blood

PBMC

Peripheral blood mononuclear cells

PBS

Phosphate buffered saline

PC

Plasma cell

PCR

Polymerase chain reaction

PE

Phycoerythrin

xxviii

PerCP

Peridinin chlorophyl protein

PIR-A/B

Paired immunoglobulin-like receptors A and B

PL

Peritoneal lavage

PMN

Polymorphonuclear

PNA

Peanut agglutinin

PP

Peyer’s patches

RAG1

Recombination activation gene 1

RASV

Salmonellla enterica Serovar Typhimurium vaccine

RBC

Red blood cell

RBP-Jĸ

Canonical Notch transcription factor

RCC

Renal cell carcinoma

RIP

Receptor intramembrane proteolysis

RNA

Ribonucleic acid

ROS

Reactive oxygen species

RTK

Receptor tyrosine kinase

RUNX3

Runt-related transcription factor 3

s.c.

Subcutaneous

xxix

SCF

Stem cell factor

SD

Standard deviation

SDF-1α

stromal cell derived factor 1a

SEM

Standard error of the mean

SHP-1

SH2-homology-contaiing protein-tyrosine phosphatase-1

SHM

Somatic hypermutation

SSC

Side scatter

STAT

Signal transducer and activator of transcription

TACE

TNF-α converting enzyme

T-ALL

T cell acute lymphocytic leukemia

TCR

T cell receptor

TFH

T follicular helper

Tg

Transgenic

TGF-β

Transforming growth factor - Beta

Th1

T helper cell type 1

Th2

T helper cell type 2

TIMP

Tissue inhibitor of metalloprotease

xxx

TLR

Toll-like receptor

TNF

Tumor necrosis factor

TNP

Trinitrophenol

VCU

Villus/Crypt Unit

VEGF

Vascular endothelial growth factor

WPG

Whole β-glucan particle

WT

Wild type

YFP

Yellow fluorescent protein

xxxi

Abstract

THE ROLE OF ADAM10 IN THE IMMUNE SYSTEM: MAINTENANCE OF LYMPHOID
ARCHITECTURE, MDSC DEVELOPMENT AND FUNCTION, B CELL DERIVED
EXOSOMAL ANTIGEN PRESENTATION, AND B1 CELL IGE PRODUCTION.

Rebecca Kelley Martin
B.S., Virginia Commonwealth University, 2009

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University 2014

Director: Daniel H. Conrad, PhD
Professor
Department of Microbiology and Immunology
School of Medicine

ADAM10 is a zinc-dependent metalloprotease. ADAM10 has emerged as a key
regulator of cellular processes by cleaving and shedding extracellular domains of
multiple transmembrane receptors and ligands. In this study, we examined the role of
ADAM10 in the immune system. Here, we show that knocking out ADAM10 on the
mature B2 cell causes a defect in the development of secondary lymphoid architecture
that becomes more severe post-immunization. We also show that overexpression of
ADAM10 leads to a defect in hematopoiesis, which eliminates B2 lymphocyte
development. This defect additionally induces accumulation of myeloid derived
suppressor cells, MDSCs. ADAM10Tg MDSCs function synonymous to tumor MDSCs.
Of the two subpopulations of MDSCs, granulocytic MDSCs increase parasitic clearance
in a model of N. brasiliensis. Monocytic MDSCs are more immunosuppressive in
regards to tumor. Both subpopulations are dependent on the presence of mast cells for
activity. It is thought that this relationship is mediated through histamine and IL-13.
During N. brasiliensis infection, ADAM10Tg mice, lacking B2 B cells but having intact
B1 B cells, makes increased IgE over WT mice. This production of IgE is thought to be
produced by the B1 cells. Of the two types of B1 cells, B1a cells make the majority of
the IgE. This IgE production is enhanced by MDSC accumulation and can be induced
by MDSC adoptive transfer in a parasite-free mouse. Lastly, ADAM10 is the key
sheddase for CD23 on B2 cells. When IgE is bound to its antigen to form an immune
complex, IC, it binds CD23 and is internalized. After CD23 bound to IgE ICs is
internalized, it is sorted into bexosomes. These bexosomes are transferred to dendritic
cells which are responsible for presenting to T cells and inducing an increased antigen-

specific immune response. Overall, ADAM10 is important for many aspects of the
immune response

Section 1
Chapter 1: ADAM10 and the Maintenance of Secondary Lymphoid Architecture
1.1.1 Introduction to ADAM10
ADAM10 is a member of a family of a disintegrin and metalloproteases (ADAMs).
ADAMs belong to the metzincin superfamily, along with matrix metalloproteases (MMP)
and ADAM-thrombospondins (ADAM-TS). While all functionally active metzincin
proteases contain a zinc binding motif, ADAMs are unique in that they also contain a
transmembrane domain and are active while membrane bound. ADAMs are
membrane-anchored and are therefore responsible for the processing of receptors and
ligands expressed on the membrane surface, known as ectodomain shedding. ADAMs
can mediate ectodomain shedding and regulated intramembrane proteolysis (RIP) of
transmembrane proteins. ADAMs cleave mainly type I and type II transmembrane
proteins and shedding of these extracellular domains releases soluble fragments into
the extracellular space1. This ectodomain shedding can lead to down-regulation of
events that depend on transmembrane receptor-ligand expression or can activate
paracrine and/or autocrine signaling by the production of a soluble mediator. Typical
substrates of ADAMs are growth factors, cytokines, chemokines and their receptors, as
well as cell adhesion molecules and differentiation factors1,2. While ectodomain
shedding is thought to occur constitutively, RIP requires receptor-ligand interaction3.
ADAMs are widely expressed and are key in many developmental processes. ADAMs
regulate cell-cell and cell-matrix interactions, they modulate differentiation, migration,
receptor-ligand signaling or repulsion1,4. The prototypical ADAM is composed of a
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prodomain, metalloprotease domain, a disintegrin domain that confers substrate
specificity, a cysteine-rich region, a transmembrane domain, and a cytoplasmic tail5,6.
ADAMs were initially discovered as type I transmembrane proteins with shared
homology to snake venom integrin ligands7. ADAMs and ADAM-related proteins have
been described in many different species. These include everything from the yeast,
Schizosaccharomyces pombe to the nematode worm, Caenorhabditis elegans, and the
fruit fly, Drosophila melanogaster 8–10. Forty different ADAM family members have been
currently identified in the mammalian genome, with 37 expressed in the mouse and 22
in humans11,12. ADAMs shown to possess zinc-dependent protease activity are termed
active ‘sheddases’13,14. These are ADAMs 8,9,10,12,15,17,19,20,21,28,30 and 33. All
of these ADAMs share a typical consensus sequence (HEXGHXXGXXHD)15.
ADAM10 was characterized through study of its homolog, Kuzbanian (kuz), in
Drosophila. In 1996, kuz was initially identified and studies of embryos deficient in kuz
elucidated essential roles in lateral inhibition required for development of peripheral and
central nervous systems16. Cloning and sequencing of kuz demonstrated the presence
of disintegrin and metalloproteinase domains highly homologous to bovine
metalloprotease (BMP)16. BMP was later named ADAM10 and was found to have αsecretase activity and cleave myelin basic protein. It was then well characterized in the
cleavage of amyloid plaque proteins and Alzheimer’s disease17. Through subsequent
studies involving dominate negative mutants of kuz, it was demonstrated that kuz
initiated RIP of Notch and the nervous system defects seen in initial studies were due to
defective Notch signaling18. Murine studies of ADAM10-deficient embryos reveal early
mortality at embryonic day 9.5, resulting from multiple defects in the cardiovascular and
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central nervous systems19,20. In the beginning, it was highly controversial that ADAM10
was responsible for Notch cleavage21,22. ADAM17, or TNFα converting enzyme
(TACE), was thought to be responsible for S2 cleavage of the Notch1 receptor and was
reported by several groups23–27. It is now thought that ADAM10 and ADAM17 may be
functionally redundant and when one is absent, a compensatory mechanism will
increase the other one and visa-versa28,29. Increased evidence emerged that ADAM10
was exclusively involved in Notch signaling by examination of murine embryos deficient
in ADAM10. These embryos mimicked features of Notch1-deficient murine
embryos22,30. This was further supported by ADAM17-deficient embryos, as they lacked
similarity to the Notch1-deficient embryo31. Following these observations, two groups
utilizing ADAM10-deficient mouse embryonic fibroblasts (MEFs) reported that while
multiple proteases can perform ligand-independent proteolysis of Notch1, ADAM10 is
required for ligand-dependent cleavage27,32. Thus, ADAM10 may play a more critical
role in Notch signaling than earlier in vitro studies predicted.
Some of ADAM10’s most well characterized substrates are Notch receptors,
such as Delta-like 1-4 and Jagged 1-2. Notch receptors regulate cellular differentiation.
Notch signaling is initiated by ADAM10 mediated proteolysis of the extracellular domain
of the Notch receptor. The extracellular domain is released and endocytosed by
adjacent ligand-expressing cells. This cleavage event, termed S2 cleavage, produces a
substrate that can be cleaved by the γ-secretase complex (S3 cleavage). This releases
the Notch intracellular domain (NICD), that translocates to the nucleus where it
complexes with transcription factor RBP-Jκ and induces transcription of Notch target
genes, such as CD21, Hes 1, Hes 5 and Deltex-1 as diagramed in Figure 133.
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Other substrates for ADAM10 include CD23, TNFα, and many others3,5. It is well
accepted that ADAM10 mediates cleavage of membrane-bound substrates, but recent
evidence shows that ADAM10 is not restricted to the plasma-membrane and can cleave
substrates on the exosomal membrane34,35. Additionally, ADAM10 is highly expressed
in the endoplasmic reticulum (ER), providing a potential new location of activity36.
ADAM10 normally cleaves in cis, but recent studies of the substrate, ephrin, have
shown that trans-cleavage is possible37. Little is known about the regulation of
ADAM10. ADAM10 is expressed as a zymogen and activation occurs after the prodomain is cleaved by a furin protease38,39. Following activation, in vitro ADAM10 activity
can be inhibited by tissue inhibitors of metalloproteases (TIMP)-1 and TIMP-317,40.
Additionally, enhancement of proteolytic activity can be achieved by calcium influx,
retinoic acid receptor signaling, PKC signaling, cholesterol depletion, kainite receptor
signaling and N-glycosylation41–46.
1.1.2 ADAM10 in lymphocyte development
Notch1 signaling is essential for the commitment to T cell lineage, thus ADAM10
is important given its role in Notch signaling47,48. Enforced Notch1 signaling in bone
marrow (BM) progenitors, expressing the constitutively active NICD, promote T cell
development48. In fact, human mutations surrounding the S2 cleavage site of Notch1
results in ligand-independent proteolysis and excessive Notch1 activation. This
ultimately leads to T cell acute lymphocytic leukemia (T-ALL). This mutation accounts
for approximately 50 percent of all T-ALL cases21.
B2 lymphocytes comprise the majority of circulating B cells. They develop from
common lymphoid progenitors (CLPs) and differentiate into pro-, pre-, and ultimately
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immature B cells prior to exiting the BM. Given that the Notch1 cleavage site recognized
by ADAMs is not present in murine Notch2, and that B cells express Notch2 rather than
Notch1, ADAM10 was initially not thought to be involved in B2 cell development24,25,49–
52

. Just as Notch signaling promotes CLP commitment to the T cell lineage, it prevents

B lineage fate. Thus, multiple studies have demonstrated that enforced expression of
active NICD in BM progenitors completely abrogates B2 cell development48,52. Following
exit from the BM, B2 cells enter a transitional stage and undergo further maturation in
the spleen, where the majority differentiates into follicular (FO) B cells. A small subset
of these cells, develop into the marginal zone (MZ) B cell lineage, including pre-MZ B
cells and MZ B cells. By generating B cell-specific Notch2 knockout mice, it was
demonstrated that Notch2 signaling is required for the balance in development of the
MZ B cell lineage versus the FO B cell lineage. MZ B cells initiate immune responses to
blood-borne infections and assist in transporting antigen into the splenic follicles25,53. B
cell specific deletion of the downstream transcription factor RBP-Jκ, which binds the
NICD fragment released after S3 cleavage, also resulted in a severe loss of MZ B cell
development with a concomitant increase in FO B cell development54. It is thought that
Notch signaling induces a high turnover of E proteins, HEB, E2A, and E2-2, which are
implicated in the regulation of peripheral B cell maturation54. In mouse models where B
cell-E proteins are deleted, an increase in MZ B cell lineages occurs to the detriment of
the FO B cell lineage54,55. Moreover, by deleting ADAM10 in a mature B cell-specific
manner using the CD19-cre (ADAM10B-/-), Gibb et al. demonstrated an absolute
requirement for ADAM10 in MZ B development56. Analysis of Notch target gene
expression in these mice revealed a dramatic defect in Notch2 signaling. Furthermore,
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in contrast to WT B cells, ADAM10-null cells were completely unresponsive to DLL-1induced Notch stimulation. These findings not only revealed the importance of ADAM10
in B cell development, but also demonstrated that ADAM10 is responsible for activating
RIP-mediated signaling through Notch2. No compensatory cleavage of Notch2 by other
proteases occurs, thus ADAM10 may be the only protease that can recognize the
Notch2 cleavage site, which is distinct from the Notch1 site24. Notch signaling has also
been implicated in other B cell functions. Notch signaling alongside B cell receptor
(BCR) and CD40 signaling enhances B cell activation as well as, B cell differentiation
into antibody secreting cells (ASC) in vitro. Notch signaling has also been implicated in
germinal center (GC) formation50,57,58. This is thought to be due to defects in
development of follicular helper T cells (TFH), which are essential to the GC response
and T cell specific Notch1 and Notch2 defects lead to reduced GC B cell numbers and
decreased high affinity antibody59.
1.1.3 Introduction to secondary lymphoid tissues
Secondary lymphoid tissues are the primary sites of adaptive immune responses.
Most lymphocytes within these tissues are mobile and transitory, yet secondary
lymphoid structure is highly organized and tightly maintained. The development of
these tissues occurs when hematopoietic lymphoid tissue inducer cells (LTi) expressing
lymphotoxin αβ (LT) and mesenchymal cells expressing LTβ receptor interact60–62. LTdeficient mice completely lack LNs, peyer’s patches (PP) and have disrupted splenic
architecture60–64. LT signaling induces mesenchymal cells to differentiate into stromal
organizer cells and to induce chemokine expression, leading to the recruitment of naïve
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lymphocytes62. Disruptions in the TNFα level, a cytokine in the same family as LT,
results in abnormal LN and splenic architecture as well29,65,66.
Secondary Lymphoid organs consist of lymph nodes (LN), spleen, bronchiolarassociated lymphoid tissues (BALT), gut-associated lymphoid tissues (GALT), tonsils,
PP and other organized lymphoid tissues associated with mucosal surfaces. These
organs are located at strategic sites where they can trap foreign antigens entering the
body61,67–69. The segregation of cells within these organs is thought to enhance the
efficiency of immune responses by arranging B and T cells into zones that provide them
interaction with certain antigen presenting cells (APC) and regulatory cells61. It is also
thought that the organization provides a framework for circulating naïve lymphocytes to
encounter concentrated foreign antigen61.
Lymphatic vasculature delivers antigen-presenting cells from the periphery, as
well as foreign antigen into the LN. This lymph enters the LN through the afferent
lymphatics into the marginal sinuses, directly underneath the LN capsule. Under the
marginal sinuses lies the outer cortex, or B cell zone consisting of B cell follicles.
Directly beneath this is the paracortex or T cell zone. Underneath this lies the medullary
chords containing macrophages and plasma cells, and in the center of the LN medullary
sinuses are where the efferent lymphatics remove lymph fluid from the LN61,62.
Circulation enters the LN through high endothelial venules (HEV) in the
paracortex, bringing naïve lymphocytes in contact with antigen on APCs70. A dendritic
cell (DC) or other APC carrying an antigen migrates to the paracortex71. This is
dependent on the chemokine CCR7 binding to its ligands CCL19 and CCL2172,73. This
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DC up-regulates CD80/CD86 co-stimulatory molecules as well as processes and
presents the antigen on major histocompatibility class (MHC) II. MHC II binds to the
specific T cell receptor (TCR) providing the initial signal needed for an immune
response. Co-stimulation of CD28 by CD80/CD86 provides the second signal that is
essential for the activation of the T cell. An additional specific cytokine milieu induces
differentiation of the T helper (Th) cell60,74,75.
Three lineages of CD4+ Th cells diverge at this point with respect to the antigen
type and signals from APC. The Th1 lineage responds to intracellular pathogens and
when inappropriate responses occur, can result in autoimmunity76,77. Differentiation to
Th1 cell is initiated by signal transducer and activator of transcription 1 (STAT1)
activation through interferon γ (IFN-γ) and or (interleukin) IL-27. This induces the
transcription factor T-bet up-regulation. In conjunction with H2.0-like homeobox (HLX)
and other transcription factors activated post TCR signal, ifnγ transcription is increased
and the transcription factor GATA-binding protein 3 (GATA3) is antagonized. This leads
to the downstream up-regulation of IL-12 receptor that binds to IL-12 produced by the
APC. This IL-12 signaling induces the transcription factor STAT4 and paired with runtrelated transcription factor-3 (RUNX3), drives Th1 differentiation78–83. The Th2 lineage
responds to helminthes, but when responding to innocuous particles can lead to allergic
disease77. Th2 cell differentiation involves STAT5 and STAT3 and/or Notch mediated
immunoglobulin-κ J region (RBPJ) induction of GATA3 through STAT6 and IL-4. A
positive feedback loop drives Th2 differentiation and IL-4, IL-5, IL-13 production84–86. A
third Th cell lineage, the Th17 cell responds to extracellular bacteria and fungi. This
differentiation is started with activation of STAT3, inducing IL-21. IL-21 signaling in
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conjunction with transforming growth factor β (TGFβ) by the APC induces the
expression of transcription factor retinoic-acid-receptor-related orphan receptor-γt
(RORγt), IL-17, and IL-23R. IL-21 and IL-17 drive Th17 cell differentiation87–91.
Th cells then up-regulate CXCR5 and traffic to the B-T border of the B cell
follicle, where Th cells activate B cells92–94. The initial signal is delivered via antigen
specific BCR binding native epitopes on the antigen and the second signal is costimulation with Th cell CD40 ligand binding CD40 on the B cell95. This is also
influenced by particular Th lineage cell-secreted cytokine milieu. These B cells can then
choose three particular fates: a short-lived extra FO plasma cell that secretes low
affinity antibody, an early memory B cells, or give rise to the GC reaction60,74,75,96.
GC reaction occurs in the B cell follicles of the LN. Within the GC, B cells
undergo extensive differentiation and proliferation during the process called affinity
maturation96. The GC is divided into two zones morphologically, the light zone and dark
zone60,97. B cells were traditionally thought to move through the GC from dark zone to
light zone, but can move from light to dark or intra-zonally98. Within the dark zone, the B
cell undergoes extensive proliferation, somatic hypermutation (SHM) and class switch
recombination (CSR)60. Initially, the B cell moves to the center of the follicle, where they
rapidly divide as centroblasts99. This is where B cells begin SHM, the result of point
mutations in the variable regions of heavy and light chain in an attempt to create higher
affinity antibody19,99. CSR allows replacement of the µ gene with either γ, α, or ε60.
Different cytokines drive CSR to different antibody classes100. This occurs though a
process of excising loops of DNA involving activation induced cytidine deaminase (AID)
and results in the same antibody specificity with new antibody classes, thus new
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antibody function60,100. CSR is rare outside the GC reaction, but can occur60. Follicular
dendritic cells (FDCs) are essential for the GC reaction60n92-n94). FDCs and TFH are
found mainly in the light zone and are essential for positive selection and affinity
maturation60,74,101. After SHM and CSR, centroblasts exit the cell cycle and move the
light zone of the GC as centrocytes96. Centrocytes sample antigens bound to immune
complexes on FDCs or antigen on TFH cells. This drives the positive signal through the
BCR for high affinity, antigen-binding B cells to survive74,102,103. Low affinity or selfreactive B cells are deleted from the GC by apoptosis104–106. These B cells move on to
become long-lived plasma cells, memory B cells or reenter the dark zone for further
rounds of SHM and CSR107,108.
The spleen, as a secondary lymphoid organ, undergoes many of the same
processes as the LN. It is organized differently as it contains two types of tissue. The
red pulp is mainly a filter for damaged and aging erythrocytes, and the white pulp
contains the peri-arteriolar lymphoid sheaths (PALS)61. Directly surrounding the central
arteriole is a T cell rich compartment. This compartment is encircled by B cell follicles
containing pockets of FDCs61,68. The red pulp is separated from the white pulp by a MZ
made up of MZ B cells and MZ macrophages61. MZ B cell development requires CD19,
Notch2 and ADAM10 protein expression and signaling as reviewed earlier25,56,109.
Regardless of the organ, B cells and T cells segregate into specific zones based
upon chemokine secretion by stromal cells and chemokine receptor expression. When
these chemokine gradients are disrupted, B and T cell positioning changes, which
cripples the adaptive immune response.
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Here we aim, in this section, to address the role of ADAM10 in secondary
lymphoid architecture and GC formation. We utilize ADAM10 deletion in mature B cells
utilizing the CD19-cre (ADAM10B-/-) to show dramatic defects in GC formation and
antibody responses, accompanied with changes in splenic and LN architecture110.
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Chapter 2: Materials and Methods
1.2.1 Mice
ADAM10B-/- mice were previously described56. To generate ADAM10B-/- N2ICD-TgB+.
ADAM10B-/- were mated to N2ICD-Tgflox/flox mice111. CD19-cre mice were wild type (WT)
littermates of ADAM10B-/- and ADAM10B-/-N2ICD-TgB+mice. CD23Tg mice have been
previously described112. BALB/CJ mice were used as littermate controls of CD23Tg
mice.
1.2.2 PCR and Quantitative PCR
PCR
For genotyping, DNA was isolated using Direct Tail PCR Solution as directed by the
manufacturer (Viagen). Mangomix (Bioline) was used for amplification of CD19 crelines, ADAM-10 floxed alleles, YFP-Rosa and N2ICD transgenes. Cycling conditions
were as follows, 95°C for 3 minutes then 35 cycles of 94°C for 1 minute, 55°C for 1
minute, 72°C for 2 minutes, and a final extension at 72°C for 10 minutes. Sequences of
all primers described above are listed in Table 1.
Quantitative PCR
Total RNA was extracted and purified from draining and non-draining mouse LNs using
TRIzol reagent (Invitrogen). Samples were treated with DNase (Takara Bio), mixed with
phenol/chloroform/isoamyl alcohol solution (25:24:1 USB), and precipitated with etyl
alcohol. The purity of RNA was quantified by a spectrophotometer (ND-100;
NanoDrop). One microgram of RNA was reverse transcribed using High Capacity
cDNA RT kit (Applied Biosystems). Real-time quantitative PCR was performed with a
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real-time PCR machine (iQ5; Bio-Rad Laboratories). Primers and probes for running a
TaqMan quantitative PCR assay were purchased from Applied Biosystems. Taqman
gene expression assays used included: CCL19: Mm00839967_g1, IL-21:
Mm00517640_m1. Primers for CCL21 were synthesized by IDT as previously
described113. PCR products, labeled with 6-FAM-conjugated probes, were amplified
with 18S as an internal control. Reaction parameters were as follows: hold at 48°C for
30 minutes and hold at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15
seconds and 60°C for 60 seconds. Results were analyzed with iQ5 real-time PCR
software (version 2.0). Sequences of all primers and probes, except those included in
purchased Taqman gene expression assays described above, are listed in Table 1.
1.2.3 Immunization
For all immunization protocols, mice were of 6-12 weeks of age, unless otherwise
stated. When experiments were terminated, mice were euthanized via isofluorane
inhalation and cervical dislocation. All mouse protocols were approved by Virginia
Commonwealth University’s Institutional Animal Care and Use Committee.
Mice were immunized with a single 10µg 4-Hydroxy-3-nitrophenylacetyl injection
coupled to keyhole limpet hemocyanin at a ratio of 27:1 (NP27KLH – from this point
called NP-KLH) (Biosearch Technologies). For intra-peritoneal injections, mice were
given 200µL of immunization mixture, made as follows: 10µg of NP-KLH in 100µL of
PBS and 100µL of alum (4mg). For footpad injections, mice were given 25µL of
immunization mixture, made as follows: 10µg of NP-KLH in 10µL of PBS and 15µL of
alum (0.6mg). Mice were bled weekly via tail vein nick and cardiac punctured when the
experiment was terminated.
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1.2.4 Cell Isolation
Tissue preparation
Single cell suspensions of peripheral LN cells and splenocytes were generated by
disrupting tissue between frosted glass slides. Red blood cells (RBCs) were then lysed
using ACK lysis buffer (Quality Biological). Cells were plated or stained depending on
experimental design.
Magnetic Bead Isolation
Cellular isolations were carried out using magnetic bead selection (Miltenyi Biotec).
Briefly, single cell suspension was generated as described above. Cells were
resuspended in MACS buffer (PBS pH 7.2, 0.5% BSA, and 2mM EDTA) and incubated
with the corresponding magnetic beads for 15 minutes at 4°C. Cells were then washed
and passed through a magnetic column via manufacturer’s protocol (Miltenyi Biotec).
When cells were isolated via negative selection, LD columns were used and flowthrough was harvested. On the other hand, when cells were isolated via positive
selection, LS columns were used. In this case, after cells were passed through the
column, columns were washed and flushed with MACS buffer and the eluted cells were
utilized for experiments. For B cell isolation, cells were isolated via positive selection
(B220+ cells) for all cells or via negative selection (CD43-) for isolation of naïve or
untouched B cells.
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1.2.5 Enzyme Linked Immunosorbant Assay (ELISA)
Total antibody levels
For total Ig ELISAs, ELISA plates were coated with 5µg/mL of goat-anti Ig (Southern
Biotech) in BBS (0.15M sodium choloride, 0.01 M borate buffer, pH=8.5). Plates were
then incubated at 37°C for an hour or at 4°C overnight. Plates were then washed three
times with ELISA wash (PBS with 0.02% Tween20). Blocking solution (PBS with 0.02%
Tween20 and 2% FBS) was added to plates. Plates were then washed three times with
ELISA wash and samples were added, diluted in block. For standard curve, normal
mouse Ig (Southern Biotech) was used. Plates were then incubated at 37°C for an hour
or at 4°C overnight. Plates were washed three times with ELISA wash and goat-anti IgAP was diluted in block (1:400 dilution) (Southern Biotech). After 1 hour incubation at
37°C, plates were washed and developed with phosphate tablets (Sigma-Aldrich)
dissolved in substrate buffer (0.1g MgCl2.6H20, 0.2 NaN3, 50mL diethanolamine, pH to
9.8 per 500mL). Absorbance at 405nm was measured.
NP-specific ELISA
For NP-specific ELISAs, ELISA was carried out as previously described with minor
modification. Plates were coated with NP14BSA (Biosearch Technologies) (15µg/mL in
PBS) for samples and with 5 µg/mL of goat-anti-Ig (Southern Biotech) in BBS for
standards. The remaining steps were carried out as previously described (see total
antibody levels). For measurement of high affinity antibodies, the protocol was carried
out as described except that plates were coated with NP4-BSA (both low and high
affinity antibodies bind NP14BSA). The described NP-specific ELISA protocol allows for
the relative quantification of high vs. low affinity antibodies114.
15

1.2.6 Flow cytometry, immunofluorescence and confocal microscopy
Flow cytometry
Cell isolation was conducted as previously described (1.2.4). Cells were labeled
following RBC lysis and filtered through 40µm cell strainers. For surface staining, cells
were washed in FACS buffer (2% FBS in PBS). 1-3x106 cells were resuspended in 50100µL. Cells were then incubated on ice with 1-5µg of Fc block (2.4G2) for 10 minutes
to prevent non-specific staining. Subsequently, cells were incubated for 30 minutes on
ice with different combinations of 0.25-0.5µg of anti-mouse antibodies. Cells were then
washed with FACS buffer and analyzed. Flow cytometry analysis was performed using
a Canto or Aria ll (BD Biosciences) using DIVA software at the Flow Cytometry Core at
Virginia Commonwealth University. Flow cytometry data analysis was conducted with
Flowjo v8.8.7 (Tree Star).
Immunofluorescence and confocal microscopy
Spleen and LNs were flash frozen on dry ice in OCT compound (Tissue-Tek; Sakura).
Serial 10µm sections were cut from frozen blocks using a cryostat (Frigocut 2800E;
Jung), mounted on Superfrost Plus slides (VWR), fixed in absolute acetone for 15
minutes, and air-dried. Slides were blocked with 10% Normal Horse Serum with 3%
BSA in PBS for 20 minutes to prevent background staining and then washed in ice cold
PBS. Antibody was incubated in block solution for 60 minutes in the dark with different
anti-mouse antibodies (concentrations varied for each antibody, see Table 2). Slides
were washed in ice cold PBS 3 times for 5 minutes on oscillation in the dark. Slides
were mounted with #1 cover slips (CORNING) using Vectashield Hardset mounting
medium (Vector Labs). Slides were allowed to dry in the dark at room temp for 2 hours
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before storage at 4°C until visualization. Slides were examined with a confocal laser
scanning microscope (TCS-SP2 AOBS; Leica) fitted with an oil Plan-Apochromat 40x
objective. Two lasers were used: argon (488nm) for FITC, and HeNe (543 nm) for PE
and APC. Parameters were adjusted to scan at a 512x512 pixel density and an 8-bit
pixel depth. Emissions were recorded in three separate channels. Digital images were
captured, overlayed, and processed with the Confocal and LCS Lite programs (Leica).
Antibodies
All antibodies used for flow cytometry are listed in Table 2.
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Table 1. Primer sequences
S- sense, AS- anti-sense
PCR

5’ > 3’

ADAM10: Intron8

CAGTGTAAATGTGAACTCACCC

ADAM10: Intron9

CGTATCTCAAAACTACCCTCCC

N2ICD: N2AD1

CCTTATGATGTTCCCGATTATGC

N2ICD: N2AD2

AGTACACCCATCTGGGCCTCG

YFP: oMIR4982

AAGACCGCGAAGAGTTTGTC

YFP: oMIR8545

AAAGTCGCTCTGAGTTGTTAT

YFP: oMIR8546

GGAGCGGGAGAAATGGATATG

CD19-cre: oMIR1084

GCGGTCTGGCAGTAAAAACTATC

CD19-cre: oMIR1085

GTGAAACAGCATTGCTGTCACTT

Quantitative PCR
18S S

AAAATTAGAGTGTTCAAAGCAGGC

18S probe

CGAGCAGCCGCCTGGATACCGC

18S AS

CCTCAGTTCCGAAAACCAACAA

CCL21 S

AGACTCAGGAGCCCAAAGCA

CCL21 AS

GTTGAAGCAGGGCAAGGGT

CCL21 probe

CCACCTCATGCTCCAATAAGT
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1.2.7 In vitro activation
For IgG1 and IgE production, B cells or splenocytes were cultured with CD40Ltransfected Chinese hamster ovary (CHO) cells as a B cell stimulant (6x104cells/well) or
with 1µg/mL of stimulating anti-CD40 antibody (Invitrogen) and IL-4 (10,000U/mL; NIH)
for seven days. Supernatants were then harvested and analyzed for IgG1 and IgE
production by ELISA. Cells were also stimulated with 50µg/mL of LPS (Sigma-Aldrich).
Four days later, supernatants were harvested and analyzed for IgM and IgG3
production.
1.2.8 Statistical analysis
When dealing with two groups, p-values were calculated using unpaired two-tailed
Student’s t-tests in GraphPad Prism, unless samples did not form a Gaussian
distribution, indicated by a failed D-Agostino and Pearson omnibus normality test. In
the case of non-parametric populations, p-values were calculated using two-tailed ManWhitney test. When more than two were compared, p-values were calculated using a
one-way analysis of variance with a Tukey post-test. Error bars represent the standard
error of the mean (SEM) between samples. p<0.05 is considered significant.
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Table 2. Flow cytometry and immunohistochemistry antibodies
Specificity

Clone

Label

Source

Concentration
Used

Immunohistochemistry
B220/CD45R

RA3-6B2

FITC, PE

Biolegend

3µg/mL

CCL21

59106

Unlabeled

R&D

7.5µg/mL

CD19

6D5

PE

Biolegend

3µg/mL

CD21/CD35

7G6

FITC

Biolegend

3µg/mL

CD3ε

17A2

PE, FITC

Biolegend

2µg/mL

GL7 (B and T

GL7

FITC

eBioscience

3µg/mL

activation marker)

BD Bioscience

IgD

11-26c.2a

PE

Biolegend

3µg/mL

Thy1.2

30-H12

FITC, PE

Southern

3µg/mL,5µg/mL

Biotech
Rat IgG
ADAM-10

139712

Dylight 549

AbD Serotec

1:200

FITC

R&D

3µg/mL

Flow cytometry
ADAM-10

139712

FITC, PE

R&D

B220/CD45R

RA3-6B2
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Chapter 3: B cell ADAM10 deficient mice have altered responses to T-dependent
antigens
1.3.1 Generation of mature B cell specific ADAM10 deficient mice
Our lab generated B cell-specific ADAM10 knockout mice (ADAM10B-/-). These
mice were generated by crossing homozygous floxed ADAM10 animals with CD19-cre
animals115. These ADAM10B-/- mice lacked MZ B cells, had drastically reduced
numbers of pre-MZBs and a significant increase in FO B cells56. In order to follow
recombination in the CD19+ cells, ADAM10B-/- mice were crossed with the YFP reporter
mouse. This mouse only expresses YFP after cre-driven recombination, in cells where
the recombination occurs56. The generation of these mice is outlined in Figure 2.
The CD19-cre mediates efficient recombination of loxP-flanked gene sites in
mature cells116. CD19 is expressed starting at the pro-B cell stage, but CD19-cre
recombination is limited in the immature B cell, the pre-B cell117. Only ten percent of
CD19+ B cells in CD19-cre+ YFP+ mice have undergone cre-mediated recombination in
the BM118.
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Figure 1. ADAM10 and Notch signaling
ADAM10 mediated RIP of Notch2 is required for MZ B cell development25. The Notch2
heterodimer on B cells binds ligands Jagged 1-2 and Delta-like-1 that are present on
stromal cells or APCs. Binding initiates sequential cleavage events by ADAM10 (S2
cleavage) and γ-secretase complex (S3 cleavage). Cleavage releases the Notch2
intracellular domain (N2ICD). Transport of the N2ICD to the nucleus followed by
binding to the transcription factor RBP-Jκ allows the release of co-repressors (CoR) and
attraction of co-activators (CoA) to the transcriptional complex. The activated complex
transcribes Notch target genes, including CD21/35, Deltex-1, Hes 1, and Hes 5, that
promote development of MZ B cells. Deletion of ADAM10, Notch2, and RBP-Jκ from B
cells, or Delta-like 1 from stromal cells prevents MZ B cell development.
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Figure 2. ADAM10 B cell-specific knockout
CD19-cre mice express cre-recombinase under the CD19 promoter. When CD19
expression is turned on in cells that normally express CD19, such as mature B cells, cre
is expressed. Note, that this allele is kept heterozygous with the WT CD19 allele to
avoid disruption in CD19 expression. In our ADAM10 floxed mice, loxP sites flank the
ADAM10 gene. Upon expression of cre, recombination occurs at loxP sites, excising
the gene and knocking out ADAM10. Additionally, these mice utilize the YFP reporter
gene. With expression of cre, recombination occurs at loxP sites flanking a STOP
sequence upstream of the YFP-Rosa gene. With the excision of the STOP sequence,
the YFP-Rosa gene is transcribed. This yellow fluorescent molecule allows cre
expression to be monitored as well as ADAM10-deletion. (A) Normal ADAM10
expression occurs without cre-recombinase. Thus, ADAM10 is not deleted and YFP
expression is not induced. (B) Cre-recombinase is expressed when CD19 is turned on,
this ADAM10 is knocked out and YFP is expressed.
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1.3.2 ADAM10 is essential for secondary lymphoid architecture
ADAM10 is highly expressed in GC B cells
ADAM10 cleaves many substrates closely linked to humoral immune responses,
not only Notch1 and 2, but TNFα and CD23 as well28,47,119. We therefore sought to
examine the role of B cell ADAM10 in humoral responses. First, in collaboration with
Joanna Cichy from Jagiellonian University, Krakow, Poland, we examined the
expression of ADAM10 with in secondary lymphoid tissue undergoing GC response.
PPs are located in the gut and have a high level of GC activity. Flow cytometry of PPs
demonstrated that while less than 2% of naïve B cells expressed ADAM10, over 80% of
GC B cells were ADAM10+ (Figure 3A,B). These results were confirmed by
immunoflourescent staining of sectioned PPs for ADAM10, PNA, and IgD. Consistent
with the flow cytometry results, ADAM10 was highly expressed by cells within GCs
(Figure 3C).
Humoral immune responses in ADAM10B-/- mice
Given the significant expression of ADAM10 in GC B cells, we investigated its
role in humoral responses by using B cell-specific ADAM10-deficient mice
(ADAM10B−/−). Basal levels of serum IgM, IgG1, IgG2a, and IgG2b were significantly
reduced in ADAM10B−/− mice when compared with WT, suggesting a defect in antibody
production (Figure 4A). To directly assess antigen-specific antibody production, we
immunized ADAM10B−/− mice intra-peritoneally (i.p.) with NP-KLH and examined serum
levels of NP-specific antibody. ADAM10B−/− mice showed reduced levels of NP-specific
IgM 7 d post-immunization. However, levels reached control values by day 14 and
through the remainder of the experiment (Figure 4B). In contrast, NP-specific IgG
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levels, both total and high affinity, were reduced 4 weeks post-immunization (Figure
4B). This reduction in IgG was not specific to a particular isotype, as antigen-specific
IgG1, IgG2a, and IgG2b were dramatically reduced in ADAM10B−/− mice (Figure 5A).
Furthermore, even when immunization with a high antigen dose, 1 mg NP-KLH, was
performed, ADAM10B−/− mice failed to mount a normal antibody response,
demonstrating that the defect in antibody production cannot be overcome by simply
providing more antigen (Figure 5B).
Germinal Center formation is impaired in ADAM10B-/- mice
As demonstrated in Figure 5, antigen-specific ASCs were reduced in immunized
ADAM10B-/- mice. Being that long lived plasma cells (PC) and memory cells are
generated within the GC120, GC formation in ADAM10B−/− mice was examined. GC B
cells, defined as IgMloIgDloB220+IgG1+CD38lo, were enumerated by flow cytometry121
(Figure 6A). Remarkably, the number and percentage of GC B cells within the spleen
was dramatically decreased in ADAM10B−/− mice (Figure 6B,C).
ADAM10B-/- mice have altered splenic and lymph node architecture
To better understand the relationship between decreased GC B cells and the
defects in antibody production depicted in Figure 4, we assessed GC formation in
immunized mice by immunohistochemistry. As depicted in Figure 7A, although several
GCs could be detected in littermate controls, as determined by GL7+ cells, draining LNs
of ADAM10B−/− mice contained a paucity of GL7+ clusters. Interestingly, GL7+ cells were
scattered throughout the LNs of ADAM10B−/− mice (Figure 7A). Given the unusual
pattern of GL7 expression, we then analyzed B and T cell localization within the LNs.
Surprisingly, the distribution of B and T cells was aberrant, suggesting that B cell28

specific ADAM10 deletion leads to changes in LN structure (Figure 7B). In contrast, LN
structure in non-draining nodes or unimmunized mice, were relatively normal with
regard to B and T cell segregation, but B cell follicles appear thin, reminiscent of TNFα
or LTβ-deficient mice (Figure 7D)65,122.
Given that FDCs play a crucial role in GC formation and lymphoid tissue
structure123–125, we stained draining LN sections for FDCs with CD21/CD35 (CR2).
FDCs are known to up-regulate CD21/CD35 subsequent to activation126. Consistent
with the absence in GCs and disorganized lymphoid architecture, FDC networks were
not detectable in LN and spleen from ADAM10B-/- mice (Figure 7C, 8D). Unlike the
draining LNs, GL7 staining was not detected in spleen of ADAM10B−/− mice (Figure 8A).
However, although normal in unimmunized mice, splenic architecture was also clearly
altered post-immunization (Figure 8B,C).
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Figure 3. ADAM10 expression on GC B cells
A and B, Expression of ADAM10 on gated GC PNAhiIgDlo (blue) and naive PNAloIgDhi
(red) B (CD19+) cells isolated from PPs. Flow cytometry gates used to define the GC
and naive B cell populations are indicated on the left. To demonstrate specificity of
staining, we used isotype-matched monoclonal antibody (mAb) (isotype). A, Gating
protocol is shown. B, Percentage of ADAM10+ cells in naive and GC B cells. C, Frozen
serial sections of PPs were stained to detect B cell follicles (B220+, blue), GCs (PNA+,
green), and ADAM10 (red) (right panel). To demonstrate specificity of staining, we used
isotype-matched mAb instead of mAb against ADAM10 (left panel). Original
magnification ×20. The mucosal epithelium (E) also reacts with PNA and anti-ADAM10.
Figure courtesy of Joanna Cichy, from Jagiellonian University, Krakow, Poland.
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Figure 4. ADAM10B−/− mice have impaired humoral responses.
A, Serum IgM, IgG1, IgG2a, and IgG2b were measured by capture ELISA from nonmanipulated 8- to 12-wk-old mice. B, ADAM10B−/− mice and WT littermate controls were
immunized with 10μg NP-KLH emulsified in alum. At the indicated times, serum
samples were collected and total NP-specific IgM, total IgG, and high-affinity IgG
antibody titers were determined by ELISA, with NP-16–BSA as capture Ag for total and
NP-4–BSA as capture Ag for high-affinity ELISA. C, Mice were immunized with NP-KLH
emulsified in alum, rested for 42 d, and boosted with 10 μg NP-KLH for 5 d. Mice were
bled weekly throughout the course of the experiment. Total and high-affinity Ag-specific
IgG levels were measured by ELISA at each time point. The relative unit (RU) values for
alum-injected mice were <0.001. ADAM10B-/- (filled bars) and WT (open bars). Bars
represent the mean ± SE of five to nine mice per group (*p < 0.05, **p < 0.01, ***p <
0.001). Data represent results obtained in at least two independent experiments.
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Figure 5. Decreased NP-specific IgG secretion is not IgG subset dependent and
cannot be overcome by high antigen dose
A. ADAM10B-/- mice and WT controls were immunized with NP-KLH emulsified in alum.
Twenty-eight days after primary immunization, samples were collected and NP-specific
IgG1, IgG2a and IgG2b antibody titers were determined by ELISA with NP14BSA as
capture antigen. B. ADAM10B-/- and WT controls were immunized i.p. with 1mg of NPKLH emulsified in alum. Samples were collected at the indicated time post
immunization, and NP-specific antibodies were measured. The relative unit (RU) values
for alum-injected mice were less than 0.001. Bars represent the mean ± SEM of 5 mice
per group. Data represents results obtained in two independent experiments. (*p<0.05,
**p<0.01, ***p<0.001).
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Figure 6. GC formation after T-dependent immunization
ADAM10B−/− and WT mice were immunized with 10μg NP-KLH emulsified in alum.
Fourteen and 21 days post-immunization, flow cytometry was carried out and the
presence of GC B cells (IgMloIgDloB220+IgG1+CD38−) in the spleen of WT and
ADAM10B−/− mice was assessed. Staining protocol is depicted (A). Both percentage (B)
and total number (C) of GCs were enumerated. ADAM10B-/- (filled bars) and WT (open
bars). Bars represent the mean ± SE of eight mice per group. *p < 0.05, **p < 0.01.
Data are representative of three independent experiments.
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Figure 7. Immunohistochemistry analysis of GC formation and LN architecture
after T-dependent immunization
ADAM10B−/− and WT mice were immunized with 10μg NP-KLH emulsified in alum.
Fourteen days after immunization, draining LN sections were stained for (A) GL7
(green) and IgD (red); (B) Thy1.2 (green) and B220 (red); (C) CD21/35 (green) and
B220 (red). D, Non-draining LNs were also stained with CD3 (green) and B220 (red).
Photomicrographs are representative of three independent experiments. Original
magnification ×20.
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Figure 8. Immunohistochemistry analysis of GC formation and splenic
architecture after T-dependent immunization
ADAM10B−/− and WT mice were immunized with 10μg NP-KLH emulsified in alum.
Fourteen days after NP-KLH immunization, spleens were isolated and sectioned.
Sections were stained for (A) GL7 (green) and IgD (red). Photomicrographs are
representative of three independent experiments. B, Spleens isolated from naive
animals or (C) isolated 14 d post-immunization, were stained with CD3 (red) and B220
(green). Photomicrographs are representative of three independent experiments.
Original magnification ×20 (A, B); ×10 (C).

40

IgD/GL7

41

CD3/B220

CD3/B220

Naive

Immunized

ADAM10B-/- mice have dysregulated chemokine expression following antigen challenge
Chemokine gradients maintain tight control over the organization of secondary
lymphoid tissue. To determine if altered chemokine expression was contributing to the
structural changes observed in the ADAM10B-/- mouse, we assessed draining and nondraining LN chemokine expression by quantitative PCR. As expected, non-draining LNs
from control and ADAM10B−/− mice had similar CXCL13, CCL19, and CCL21 expression
(Figure 9A). In sharp contrast, draining LNs isolated from ADAM10B−/− mice exhibited
increased CCL21 expression, whereas CXCL13 levels were comparable. CCL19 levels
trended higher, but the increase was not statistically significant (Figure 9B). Analysis of
CCL21 expression by immunohistochemistry revealed diffuse staining in the
ADAM10B−/− LNs consistent with the localization of T cells within draining LNs (Figure
9B). These results demonstrate that B cell-expressed ADAM10 is important for
maintenance of lymphoid architecture by regulating chemokine expression during active
immune responses.
Defect in humoral in ADAM10B-/- mice is Notch2 and CD23-independent
Recent studies have suggested that Notch signaling might be involved in antibody
production and ASC differentiation50,57. ADAM10 is critical for Notch signaling.
ADAM10B−/− mice that have constitutively active Notch2 signaling in B cells
(ADAM10B−/−N2ICD-TgB+) were immunized, and antibody production, GC formation, and
LN architecture were examined to determine whether the antibody production defects
were due to impaired Notch signaling. As expected, expression of N2ICD recovered MZ
B development in these mice, demonstrating that the transgene was indeed active
(Figure 10A). Littermate controls, ADAM10B−/−, and ADAM10B−/− N2ICD-TgB+ mice were
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immunized. Consistent with previous experiments, ADAM10B−/− mice had significantly
reduced levels of NP-specific antibodies. Importantly, introduction of N2ICD transgene
failed to rescue the defect in antibody production and GC formation, and did not prevent
changes in LN architecture (Figure 10B,C). These results demonstrate that increased
Notch signaling cannot rescue the defects in humoral responses observed in
ADAM10B−/− mice.
Our lab reported that ADAM10 is responsible for the cleavage of the low-affinity
IgE receptor, CD23119, and consequently, ADAM10B−/− B cells have increased CD23
expression56,127. Studies have revealed that CD23 overexpression leads to decreased
IgG1 and IgE production112,128. However, when CD23Tg mice were immunized with NPKLH, analysis of NP-specific IgG indicated that CD23Tg mice had a normal antibody
response to NP-KLH (Figure 11). Furthermore, it has been previously reported that
CD23Tg mice form GCs post-immunization with T-dependent antigens. It should be
noted that the GCs observed in CD23Tg mice had a more globular appearance than
WT129. These results suggest that the humoral defect observed in ADAM10B−/− mice is
not secondary to CD23 overexpression, however, this should be more carefully
addressed.
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Figure 9. Chemokine expression in draining LNs
Mice were immunized in the footpad with 10μg NP-KLH. Fourteen days postimmunization, draining and non-draining LNs were isolated and chemokine expression
was analyzed by quantitative PCR for CCL19, CCL21, and CXCL13. Non-draining (A)
and draining (B) LNs are shown. (C) Draining LNs were stained for CCL21 and CD3.
Pictures are representative of three mice per group *p < 0.05. Bars represent the mean
± SE of eight mice per group. Data are representative of two independent experiments.
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Figure 10. Defects in humoral responses in ADAM10B-/- mice seem to be Notch2independent
(A) Splenocytes isolated from ADAM10B-/-, ADAM10B-/-N2ICD-TgB+ and WT mice were
stained with B220, CD23, CD21/35 and IgM. MZ B cells were defined as B220+CD23/lo

CD21/35hiIgM+. (B) ADAM10B-/-, ADAM10B-/-N2ICD-TgB+, and WT mice were immunized

i.p. with NP-KLH emulsified in alum. At the indicated times, serum samples were
collected and total NP-specific IgG was determined by ELISA. Bars represent the mean
± SE of 5 mice per group. (C) Mice were immunized in the footpad with NP-KLH, 14
days later draining LNs were isolated and stained for GL7 and IgD (top) and Thy1.2 and
B220 (bottom). Data represents results obtained in two independent experiments.
(*p<0.05, **p<0.01, ***p<0.001, One-way ANOVA with Tukey post-test). Significance
refers to ADAM10B-/- compared to WT and ADAM10B-/-N2ICD-TgB+ compared to WT.
ADAM10B-/- and ADAM10B-/-N2ICD-TgB+ were not different from each other at any time
point.
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Figure 11. CD23Tg mice have a normal IgG response to NP-KLH
CD23Tg and WT mice were immunized with NP-KLH emulsified in alum. At the
indicated times, serum samples were collected and total NP-specific IgG was
determined by ELISA. Bars represent the mean ± SE of 8 mice per group. Data
represent results obtained in two independent experiments.
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1.3.3 Discussion
Members of the ADAM family regulate a wide range of functions, including cell
migration, proliferation, and adhesion130. ADAM10, in particular, has been recently
shown to be critical for lymphocyte development through initiation of the canonical
Notch signaling pathway47,56. We report that ADAM10 is essential for the maintenance
of splenic and LN architecture during responses to T-dependent Ags. A decrease in Agspecific IgG production is seen both with respect to serum levels and IgG ASCs,
indicating that PC differentiation is influenced. Cells producing high-affinity antibodies
were particularly affected, consistent with a defect in GC reactions and markedly
repressed FDC-reticula. Moreover, ADAM10-deficient B cells are able to class switch
normally when stimulated in vitro. Therefore, the defective humoral response in
ADAM10B−/− mice results from impaired B cell activation in vivo.
Impaired Notch signaling and increased CD23 expression, are not likely to contribute to
the phenotype observed in ADAM10B-/- mice
To determine the mechanism for the observed severely impaired humoral
functions and lymphoid architecture disruption, we investigated the two clear substrates
for ADAM10 in B cells: Notch and CD2347,56,119. The role of notch signaling in mature B
cell function is controversial. Although some studies have clearly shown a role for Notch
in antibody production, others fail to identify such a role57,131. To assess the role of
Notch signaling in antibody production, we overexpressed N2ICD in a B cell-specific
manner. In this study, we show that restoration of Notch2 signaling in ADAM10B−/− mice
is not sufficient to rescue antibody production or GC formation. Studies have shown that
N2ICD and N1ICD have redundant functions. Our results, therefore, suggest that the
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phenotype observed in ADAM10B−/− mice is not dependent on Notch1 or Notch2
signaling132. However, the role of Notch1 in B cell biology should be more thoroughly
studied. In vitro studies have demonstrated that Notch signaling enhances B cell
activation133 and support GC B cell survival134. Although Notch signaling enhances
humoral responses in vitro, decreased Notch signaling does not explain the phenotype
observed in ADAM10B−/− mice. Because Notch signaling also enhances CD21
expression, this finding also suggests that CD21 is not involved in the ADAM10B−/−
phenotype. In addition, unlike CD21/CD35−/− mice, ADAM10B−/− mice had impaired
affinity maturation and failed to mount an antibody response comparable with controls
even after immunization with large Ag dosages (i.e., 1 mg)135.
CD23 is also known as the low affinity IgE receptor and is another B cell-expressed
ADAM10 substrate is CD23119. We have recently demonstrated that CD23 surface
expression is significantly enhanced after deletion of ADAM10 in B cells56. Defects
observed in ADAM10B−/− could result from CD23 overexpression. Previous studies with
CD23Tg mice, however, demonstrated that elevated CD23 levels resulted in inhibition
of IgE and IgG1 production, whereas other classes were not significantly affected.
Furthermore, the defect was evident only after boosting112,129. In contrast, in
ADAM10B−/− mice, all classes of IgG were influenced, and this defect was observed
after one injection. Moreover, when immunized with NP-KLH, CD23Tg mice had Ig
levels comparable with that of WT. In contrast, ADAM10B−/− mice showed diminished
levels of both low- and high-affinity anti-NP antibodies. These results indicate that
elevated CD23 levels do not explain the phenotype of ADAM10B−/− mice. It is likely that
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B cells express another ADAM10 substrate that is responsible for the observed
phenotype in ADAM10B-/- mice.
ADAM10 is important for B cell follicle formation and maintenance of lymphoid
architecture
In lymphoid organs, the correct positioning of cells, such as B and T cells, is
dictated by the local production of chemokines by stromal cells, as well as the
coordinated expression of chemokine receptors by migrating cells125. The positioning of
these cells and the migration during an immune response are critical for adequate
interaction between them134. Our results demonstrate that although B cell-expressed
ADAM10 is dispensable for proper cellular positioning during LN and spleen
development, ADAM10 is critical for the maintenance of the correct position of cells
after immune stimulation.
CCL21, CCL19, and CXCL13 have been shown to play a key role in inducing
and maintaining normal cellular compartments1. Draining LNs from ADAM10B−/− mice
showed increased CCL21 expression. This increase in CCL21 was also confirmed at
the protein level by immunohistochemistry. Interestingly, ADAM10B−/− mice had a larger
area of CCL21 staining. The larger area of production is consistent with the aberrant T
cell localization seen in draining LNs.
FDCs are important for GC development, CSR, SHR, and affinity maturation, as
well as induction of recall responses136–139. FDCs also secrete CXCL13 and are thus
important for recruitment of CXCR5-expressing B cells and T cells into the follicle140,
and are important for the maintenance B and T cell zones134. The loss of B and T cell
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segregation and the lack of GCs in the draining secondary lymphoid tissues of
ADAM10B−/− mice is thus consistent with fewer activated FDC networks. TNFα is
another ADAM10 substrate, and it has been implicated in the formation of primary B cell
follicles and GCs. TNFα global knockout mice have severe defects in T-dependent
immune response as well as have defective FDC networks, GC formation and B cell
follicle maintenance141. Additionally studies done with mice expressing non-cleavable
TNFα on B cells have defective secondary lymphoid tissue formation142. The primary
sheddase for TNFα is ADAM17, the ADAM most closely related in structure to
ADAM1012,143. Recent work done by Folgosa et al. has shown that ADAM10 deletion
results in up regulation of ADAM17 in a compensatory mechanism29,144. This up
regulation of ADAM17 increases the cleavage of membrane bound TNFα, converting its
active soluble form144. Additionally, these studies show that the compensatory increase
in ADAM17 and thus increased cleavage of TNFα induces a feedback loop to further
increase TNFα production29. Folgosa et al. shows that ADAM10B-/- mice express
increased levels of ADAM17, decreased levels of ADAM10 and increased TNFα on B
cells29. This increase in TNFα is also seen within the immunized LNs of ADAM10B-/mice. This work implicates that increased TNFα in ADAM10B-/- mice results in the
observed defects see in secondary lymphoid architecture29.
Conclusions
In conclusion, examination of humoral responses in B cell-specific ADAM10deficient mice has demonstrated that ADAM10 is critical for the maintenance of splenic
and LN architecture during active immune responses. ADAM10B−/− mice have impaired
GC formation, affinity maturation, and CSR. Therefore, B cell-expressed ADAM10 is
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required for proper humoral responses. Thus, B cell-expressed ADAM10 is essential for
the maintenance of lymphoid structure after Ag challenge.
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Chapter 4: B cell ADAM10 expression and activity is increased during active
allergy
1.4.1 Introduction to CD23
The low affinity IgE receptor, (FcεRII) is also known as CD23. Through an
unknown mechanism, when IgE is bound, signaling though this receptor shuts down IgE
synthesis, creating a negative feedback loop145,146. CD23 is a 45kDa (in humans), type
II transmembrane protein and is a member of the calcium-dependent (C-type) lectin
family. CD23, in its membrane bound form is a trimer145,146. It has two isoforms, CD23a
and CD23b, in mice the first being found on B cells and FDCs and the latter found
mainly on gut epithelial cells and FDCs139,147,148. In humans CD23a is found on B
lymphocytes and CD23b is found on a variety of hematopoietic cells and others cell
types including epithelial cells149.
Murine models of CD23 expression have given insight into the in vivo effects of
CD23 on IgE synthesis. CD23 deficient mice show increased antigen specific IgE when
immunized with T-dependent antigens150. They also show increased specific-IgE and
airway hyper-responsiveness to murine asthma models151. CD23Tg mice created using
the MHC class I promoter and IgH enhancer have decreased basal serum IgE levels as
well as IgG1. These mice also have decreased IgE and IgG1 in response to ova/alum
immunization and helminth infections112. Both strains of mice show evidence, that
CD23 is an important negative regulator of IgE synthesis. CD23 can be cleaved into a
soluble form. Soluble CD23 (sCD23) can still bind IgE, but with much lower affinity than
it’s membrane bound form146,152. Soluble CD23 has also been shown to bind CD11bCD18 on monocytes, leading to activation, differentiation into macrophages and release
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of inflammatory mediators153,154. Soluble CD23 has been shown to be increased in sera
of allergic patients in active allergy season, correlative with increased IgE levels155.
Increased cleavage of CD23 leaves less membrane bound CD23 to negatively regulate
IgE response as well as increased sCD23 to interact with other ligands to increase
inflammation. This makes blocking cleavage of CD23 an important target in regulating
IgE synthesis and allergic response. This has been demonstrated using an antibody
against CD23 in a mouse model of human rheumatoid arthritis resulting in reduction of
clinical symptoms that was dose dependent156.
ADAM10 has been shown as the principal protein responsible for cleaving
CD23119. ADAM10 is ubiquitously expressed on all cells types. ADAM10 has many
other important substrates (previously described, see section 1.1.1). ADAM10B-/- mice
have decreased sCD23 and increased membrane bound CD23, but similar CD23
message levels56. This supports the model of CD23 cleavage where CD23 is
internalized by the B cell and moved into Multi-vesicular bodies (MVBs) where it then
interacts with ADAM10 with increased binding152. ADAM10, being a major regulator of
CD23 has potential to be an important therapeutic target in regulating IgE synthesis in
allergic disease. ADAM10’s importance in cleavage of many other essential proteins
makes regulating it difficult, but local drug delivery systems could potentially allow local
benefits without global negative side effects.
1.4.2 ADAM10 in allergic asthma models
In a previous study in our lab, Mathews et al. showed that when surface levels of
CD23 are increased, the features of IgE-dependent experimental asthma are reduced.
This was shown using CD23Tg mice and ADAM10B-/- mice, which both have high levels
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of surface CD23 as well as with WT mice treated intranasally with ADAM10 inhibitor152.
It was also shown that when ADAM10 was blocked either genetically or with an inhibitor,
there was a decrease in antigen-specific IgE, Th2 cytokines in the lung, lung AHR, lung
inflammation, and infiltration of eosinophils152. Additionally, with the ADAM10 inhibitor,
Th2 transcription factor, GATA3 expression was decreased, but Th1 transcription factor,
Tbet, was not152. Overall, these results demonstrate that ADAM10 is important to the
Th2 driven allergic response beyond control over IgE synthesis by CD23 cleavage.
1.4.2 ADAM10 in allergic patients
Previous studies have shown that increased serum IgE in allergic patients with
seasonal allergic rhinitis correlate with increased sCD23155. This argues that ADAM10
levels are responsible for this increase in sCD23 in active allergic patients. Moreover,
given the data showing that B cell ADAM10 plays an important role in regulating Th2
immune responses in mouse models of asthma, we wanted to characterize the ADAM
levels on patients in active allergic disease. Here, we show that symptomatic allergic
patients have increased total ADAM10 expression on B cells, but not on T cells or
monocytes. We additionally show that allergic patients have increased ADAM10 activity
on B cells as measured by sCD23 output.
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Chapter 5: Materials and Methods
1.5.1 Human studies
Allergic rhinitis (allergic) patients and non-allergic, control patients were recruited to the
study by Dr. Anne-Marie Irani in pediatric allergy clinic at Virginia Commonwealth
University. Patients were consented and completed an IRB approved survey before
enrollment into the study was permitted. Twenty mLs of peripheral blood was obtained
from either allergic or non-allergic controls. Peripheral blood mononuclear cells (PBMC)
were separated using Ficoll-Paque Plus (GE Healthcare), then stained for flow
cytometry or set up for in vitro cultures.
1.5.2 Flow cytometry
Staining protocol
Human PBMC were washed with PBS and 100,000 cells were resuspended in 50µL
FACs Buffer (see section 1.2.6 for recipe). Samples were blocked on ice for 15 minutes
with Human Fc Block (Milltinyi Biotec). Anti-human antibodies were then added at
concentrations according to manufacturer’s protocol. For intracellular total staining,
cells were fixed with 500µL x for 15 mins on ice (add fixative name here). Samples
were then washed with PBS and permeabilized with 1X Perm Wash (company) for 10
minutes on ice. Samples were washed in PBS and resuspended in 50µL PBS.
Samples were then Fc blocked and stained as described above. Samples were run on
the Canto (BD) with Diva software and data was analyzed with Flowjo v7.6.5 software
(Tree Star).
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Antibodies
All antibodies used for Allergic patient flow cytometry are listed in Table 3.
1.5.3 In vitro cultures
Allergic patient or control PBMC was counted and plated in cRPMI 1640 containing 10%
FBS, 2mM L-glutamine, 50µM 2-mercaptoethanol,100 U/mL penicillin, 100g/mL
streptomycin, 1mM HEPES (Quality Biological), and 1mM sodium pyruvate (Cellgro).
PBMC was cultured at set cell concentrations with 200ng/mL human IL-21 (American
Type Culture Collection (ATCC)), anti-CD40 (Clone G28-5, ATCC), and 10ng/mL rhIL-4
(R&D). 10µM ADAM10 inhibitor or DMSO vehicle control were added where described.
Cell-free Supernatants were harvested on Day 5 for sCD23 ELISA.
1.5.4 Enzyme Linked Immunosorbent Assay
sCD23 ELISA
Plates were coated with mouse anti-human CD23 (the Binding Site) at 2µg/mL in
BBS (see previous section 1.2.5 for recipe) and incubated at 37°C for 1 hour. Plates
were then washed three times with ELISA wash (section 1.2.5). Plates were blocked in
PBS with 10%FBS for 1 hour at 37°C and were washed as above. Samples were
added at various concentrations, diluted in media. EcCD23LZ (in house) standards
started at 1µg/mL and were serially diluted in media. Plates were incubated and
washed as previous. Sheep anti-human CD23 (the Binding Site) was added at 1:200
dilution in block. Plates were incubated as previous. Plates were then washed five
times with ELISA wash and the detection antibody, Rabbit anti-Sheep IgG conjugated to
horseradish peroxidase HRP (Southern Biotech) was added at 1:1000 diluted in block.
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Plates were again incubated as previous and were then washed seven times with
ELISA wash. TMB substrate was added at a 1:1 mixture and incubated for 15 minutes
at room temperature in the dark. When plates were fully developed, STOP solution
(0.18M H2SO4) was added to stop the reaction by denaturing the HRP enzyme. Plates
were read at 450nm.
1.5.5 Reagents
The ADAM10 hydroxamate inhibitors, INC008765157, were synthesized by the Incyte
Corporation. These inhibitors are very selective for ADAM10 as shown by both cell free
as well as cell-based assays requiring at least 5 fold higher concentrations to inhibit
MMP12 and at least 20 fold to inhibit any other enzymes including ADAM17157.
1.5.6 Statistical analyses
Data was analyzed as in section 1.2.8 except that when noted, error bars represent a
95% confidence interval.
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Table 3. Antibodies for flow cytometry
Specificity

Clone

Conjugate

Company

Human-ADAM10

163003

FITC

R&D

Human-CD19

HIB19

PE

Biolegend

Human-CD3

HIT3A

PE

Biolegend

Human-CD14

HCD14

APC

Biolegend
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Chapter 6: Characterizing ADAM10 in allergic patients PBMC
1.6.1 Allergic Patients B cells have increased ADAM10 levels and activity.
Allergic patients have increased total B cell ADAM10
Previous studies have shown that increased serum IgE in allergic patients with
seasonal allergic rhinitis correlate with increased sCD23155. This argues that ADAM10
levels are responsible for this increase in sCD23 in active allergic patients. Therefore,
we examined total ADAM10 levels in allergic patients versus control. Allergic patients
were identified by Dr. Anne-Marie Irani. Patients were consented and asked to fill out
an IRB approved questionnaire. Twenty milliliters of blood was collected with
venipuncture from each patient enrolled in our study, allergic or control.
Clinical diagnosis, Nasal cytology, symptom score and sensitization information
such as skin-prick testing or RAS test are all standard of care at the clinic where our
patients are recruited. The study clinicians, Dr. Anne-Marie Irani, MD and Dr. Neil
Roberts, MD, have access to this information to better classify the patients, without
patients having to undergo any additional procedures. Our patient questionnaire asks if
the patient has had a positive skin test result and what they are allergic to. It confirms
that the patients are having allergic symptoms at the time of blood draw and provides a
checklist of symptoms for easy description. Symptoms listed are sneezing, itchy nose
or eyes, runny nose, redness in the eyes, wheezing or coughing. It also asks what
medications that the patients are currently taking. It specifically asks if the patient is on
anti-histamines or steroids. This information helped us classify each patient as being in
active allergy as well as to exclude medicated patients for this study. We recruited
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patients with asthma and allergic rhinitis, both conditions known to have elevated serum
IgE levels158–160.
Total ADAM10 levels were measured on B cells and T cells. Membrane bound
ADAM10 was traditionally thought to be involved in the cleavage of CD23. Though
some plasma membrane bound ADAM10 may be cleaving CD23, we consider this to be
a minimal contribution. Recent data has shown that the majority of cleavage takes
place inside the cell35. This makes it necessary to stain intracellular for ADAM10 as well
as staining for membrane bound ADAM10. In Figure 12A and B, we show that total
ADAM10 is significantly elevated in patients with allergic disease over control, whereas
membrane ADAM10 levels alone are comparable.
ADAM10 is not elevated on T cells or monocytes of allergic patients
ADAM10 levels on T cells and monocytes were used as controls to show that this
is a B cell specific phenomenon and that ADAM10 is not constitutively elevated in all
peripheral leukocyte varieties in active allergy. Total ADAM10 levels were not different
on CD3+ T cells or CD14+ monocytes from allergic vs. control PBMC (Figure 13A,B)
sCD23 is increased in culture supernatant of stimulated allergic patient PBMC over
control in an ADAM10 dependent manner
ADAM10 was identified as the primary ‘sheddase’ for CD23119. This makes the
soluble product of ADAM10 cleavage of CD23 or sCD23, a good indicator of ADAM10
activity. PBMC from allergic patients or controls was plated with conditions to stimulate
B cell proliferation. After five days of culture, sCD23 was analyzed from the
supernatants. Allergic patient cultures were found to have higher levels of sCD23
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(Figure 14A). To confirm this was from ADAM10, an ADAM10 inhibitor was added to
the culture. Compared to vehicle, ADAM10 inhibition reduced both allergic and control
sCD23 (Figure 14B). This shows that CD23 cleavage is due to ADAM10 activity.
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Figure 12. Allergic patients have increased total B cell ADAM10
(A) Peripheral blood CD19+ B cells from 16 control (square) and 16 allergic (circle)
patients were fixed, permeabilized, and analyzed for total ADAM10 (A) Error bars
indicate 95% confidence interval. (B) Peripheral blood CD19+ B cells from control
(circle) and allergic (square) patients were analyzed for surface ADAM10 expression.
***p <0.0005.
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Figure 13. ADAM10 is not elevated on T cells or monocytes of allergic patients
Peripheral blood CD3+ T cells (A) and CD14+ monocytes (B) were fixed, permeabilized,
and analyzed for total ADAM10 expression by flow cytometry. Gated off of live cells
based on FSC and SSC. In A, Allergic are represented by (square) and control (circle).
In B, Allergic are represented by (red circle) and control (black square). There is no
significant difference between columns (A,B). Error bars represent ± SEM.
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Figure 14. sCD23 is increased in culture supernatant of stimulated allergic patient
PBMC over control in an ADAM10 dependent manner
Cell-free culture supernatants were measured for sCD23 levels by ELISA. A. After five
days of stimulation with IL-21, IL-4 and anti-CD40 sCD23 was measured of control
(triangle) or allergic (circle) culture supernatants. B. 10µg ADAM10 inhibitor INC008765
was added to cultures of allergic (closed bar) or control (open bar) PBMC. ADAM10
inhibitor was dissolved in DMSO. Statistical analyses compare DMSO vehicle and
inhibitor. Error bars represent ± SEM. *p<0.05, ***p<0.0005.
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Section 2
Chapter 1: ADAM10 in MDSC development and function
2.1.1 ADAM10 and myeloid cell development
In the classical model of hematopoiesis, hematopoietic stem cells (HSCs)
differentiate to yield common myeloid progenitors (CMP) and CLP161. CMPs undergo
further differentiation into mature myeloid cells, including myeloid-derived suppressor
cells (MDSC). Due to the negative role of these suppressor cells in anti-tumor
responses, myeloid differentiation has been the subject of many recent
investigations162. As discussed further below, numerous hematopoietic pathways,
including Notch signaling, have been implicated but remain controversial. Several
investigators have reported that alterations in Notch signaling have minimal effects on
the myeloid compartment48,163,164.Yet, Kawamata et al. reported that constitutive Notch
signaling promotes myeloid differentiation in a non-cell autonomous manner52.This is
supported by a report of abrogated B cell and myeloid cell development in mice
deficient in downstream targets of Notch165. However, other studies have indicated that
Notch signaling inhibits myeloid differentiation166,167. Qyang et al. demonstrated that
blockade of Notch signaling at the γ-secretase cleavage site induces myeloid
accumulation167.
Many of these alterations were observed in mice with altered lymphocyte
development. This suggests that ADAM10 directed Notch signaling may modulate the
differentiation pathway of CLPs and CMPs from a common upstream progenitor. Two
groups have recently described common myelo-lymphoid progenitors (CMLPs) that are
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indistinguishable from HSC161,168. Although these multipotent cells often commit to the B
or T cell lineage, they retain the potential for myeloid development. Therefore,
alterations in Notch signaling during lymphocyte development could also affect
myelopoiesis. Collectively, these findings indicate that myeloid differentiation may be
regulated by the signal strength and temporal stage of Notch signaling. Therefore,
examination of other Notch regulators, including ADAM10, could clarify the role of Notch
signaling in myeloid differentiation.
2.1.2 Development of myeloid derived suppressor cells (MDSCs)
The hierarchal differentiation of multipotent progenitors into mature blood cells of
various lineages is known as hematopoiesis. The microenvironment of the BM provides
a complex network of cytokines, transcription factors, and intercellular signaling
pathways that regulate this process169. HSCs are characterized as lacking lineage
markers. They express the receptor tyrosine kinase (RTK) c-kit and the surface protein
Sca-1, together termed Lin- Sca-1+c-kit+ (LSK)170. The expression of Flt3 RTK and
CD34 further subdivide the LSK compartment into self-renewing long and short-term
HSC populations as well as a multipotent progenitor (MPP) population. This hierarchy
descends deeper into lymphoid and myeloid compartments where the progenitors are
again subdivided into three distinct populations based upon CD34 and low affinity IgG
Fc receptors (FcγRII/RIII). These include CD34+FcgRII/IIIlo common myeloid progenitors
(CMP), CD34+FcgRII/IIIhi granulocyte-macrophage progenitors (GMP), and CD34FcgRII/IIIlo megakaryocyte-erythroid progenitors (MEP)171. MPPs then give rise to either
lineage restricted common myelo-erythroid progenitors (CMEP) or CLPs172. This
process is dependent upon the expression of three proteins: c-kit, the IL-7 receptor and
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recombination activation gene 1 (RAG1)173. The relative expression of these act as a
‘switch’ that determines the ultimate hematopoietic destination. While RAG1 and IL-7R
expressing CLPs become T and B cells, c-kit+ CMEPs generate myeloid and erythroid
cells174,175.
This classical model has been recently challenged by the idea that lineage
restriction is not necessarily permanent. Several independent observations indicate that
early thymocyte and B cell progenitors retain myeloid potential, leading to an alternative,
‘myeloid-based’ mechanism of hematopoiesis161,168. In this model, CMLPs are observed
give rise to either B cells, T cells, or myeloid cells. The myeloid-based mechanism
excludes the existence of CLPs, stating that differentiation occurs from these CMLP and
CMEP progenitors176. This suggests that, although committed toward T or B lineage,
progenitor cells retain the potential towards myeloid lineage. The existence of progenitor
myeloid, B and T (p-MBT) cells which are committed B or T cells, yet retain the ability to
revert back to myeloid cells further support this possibility177. Additionally, the
observation of several leukemic disease states containing cells of both myeloid and
lymphoid origin indicate that a close relationship exists between p-MTB progenitors161.
This process is heavily influenced by the microvasculature in terms of cytokines and
signaling pathways it can provide to a developing HSC. Therefore, the cytokine profiles
in any given pathologic state can also heavily impact hematopoiesis and thus the
subsequent immune response.
During acute inflammatory reactions, the host enters a state of ‘emergency’
hematopoiesis characterized by increased recruitment of myeloid lineage cells such as
neutrophils and macrophages178. Unresolved inflammation increases myelopoiesis,
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shifting the distribution of myeloid subpopulations179. This results in the premature
release from the BM, a heterogeneous population of mononuclear (CD11b+Gr-1intLy6GLy6C+) and polymorphonuclear (CD11b+Gr-1highLy6G+ Ly6C-) MDSCs162. These cells
accumulate in a spectrum of disease states including cancer, the natural aging process,
solid organ transplantation, parasitic infections, sepsis, autoimmune disease, trauma,
and burns180–183. The phenotypic and functional characteristics of MDSCs strongly
underscore their myeloid origin. Common cytokines involved in myeloid development
have been implicated in the induction of MDSCs. These factors include macrophagecolony stimulating factor (M-CSF), granulocyte-macrophage colony stimulating factor
(GM-CSF), IL-6, vascular endothelia growth factor (VEGF), and granulocyte-colony
stimulating factor (G-CSF). Several transcription factors involved in myelopoiesis are
interferon-regulatory factor 8 (IRF-8), CAAT/enhancer binding protein-beta (C/EBP-β),
and PU.1. These have also been demonstrated to regulate MDSC development184. In
addition to myeloid differentiation antigen Gr-1 and CD11b, MDSCs also express
various other markers that are traditionally used to define myeloid cells such as
CX3CR1, CCR2, CXCL10, CD206, and IL-1β. Recent investigations demonstrate that,
at the tumor site, MDSCs bear several classically activated (M1) and alternatively
activated (M2) macrophage phenotypic and functional characteristics185. MDSCs
express IL-1β, TNFα, CXCL10, and inducible nitric oxide synthase (iNOS) that is
characteristic to M1 macrophages as well as CD206, and arginase I (Arg I), which are
M2 specific. Since MDSC development and proliferation occur in an asynchronous
manner along the differentiation of CMPs and GMPs toward mature myeloid cells, it is
not surprising that they retain a wide spectrum of myeloid cell characteristics.
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2.1.3 Development of the ADAM10Tg mouse
ADAM10Tg mice that overexpress murine ADAM10 cDNA under control of the H2Kb promoter and the IgH enhancer region were generated by our lab to study the role
of ADAM10 in lymphocyte development. The H-2Kb vector allows expression in early
lymphocyte progenitors112,186,187. Inclusion of the IgH enhancer results in preferential
expression on B lineage cells. This overexpression of ADAM10 was observed on BM
cells and markedly reduced the numbers of pro, pre, and immature B cells in the BM
and an almost complete loss of peripheral B2 B cells56. The only B cell population
unaltered by ADAM10 overexpression were peritoneal lavage fluid resident B1a
(B220intCD11b+CD5+) and B1b cells (B220intCD11b+CD5-)56. ADAM10 overexpression
did not alter peripheral T cell levels56.
ADAM10Tg animals also exhibited significant myeloid accumulation. In the BM of
these mice, CD11b+Gr-1+ cells constitute over 90% of the BM cells. These cells leave
the BM and migrate to all secondary lymphoid organs. Spleens of ADAM10Tg mice are
increased at least 300% in size, filled with these cells. CD11b+Gr-1+ cells outside the
BM are classified as MDSCs, consisting of monocytic (CD11b+Ly6C+Ly6G-) and
granulocytic (CD11b+Ly6CintLy6G+) subsets188. This heterogeneous population was
observed within the MDSCs in the ADAM10Tg56.
This expansion of myeloid cells and blockade of B2 cell development in
ADAM10Tg mice indicates that ADAM10 regulates the commitment of BM progenitors
to myeloid or lymphoid lineages. Investigations by Gibb et al. showed that
hematopoietic alterations in ADAM10Tg mice occur prior to the commitment of CLPs to
the B cells169. Additionally, LSKs are unaffected in the ADAM10Tg but myeloid
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progenitors are drastically altered. The profile of myeloid progenitors in ADAM10Tg
mice shows an almost complete reduction in GMPs and MEPs, with a dramatic increase
in CMPs, accounting for the overexpression of CD11b+Gr-1+ myeloid cells169. This was
confirmed to be a cell intrinsic result of overexpression of ADAM10 and not to be
alterations in the stromal compartment of the BM56.
As previously described, ADAM10 disruption and thus defunct Notch signaling
dramatically effects embryonic, thymocyte, and MZB development22,47,56. Studies done
by Gibb et al. suggest that ADAM10 overexpression may cause myeloid development
by dysregulating Notch signaling in the absence of sufficient ligand engagement. This is
caused by generating excessive S2 product that is not processed in the absence of
ligand-induced γ-secretase activity169. They additionally found evidence that ADAM10
activity blocks B cell development169.
Although MDSC accumulation is a byproduct of ADAM10 overexpression in early
hematopoietic progenitors, ADAM10 expression is not altered in these cells. Here, we
examined whether ADAM10Tg mice could be exploited to study MDSC-mediated
immune regulation in an environment devoid of confounding tumor-derived factors.
2.1.4 Introduction to MDSC Function
Despite the ambiguity surrounding their origin, MDSCs are most prominently
recognized for their role in the anti-tumor immune response. MDSCs are a
heterogeneous population divided into two main subpopulations: monocytic and
granulocytic. In mice, CD11b+Ly6G-Ly6C+ and CD11b+Ly6G+Ly6Clo surface markers
define these cells, respectively162,169,189. Although human markers differ, both subsets
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are represented. The heterogeneity of these cells allows for a broad range of cellular
functions within the total population. MDSCs have been extensively studied in the
context of cancer and exert their pro-neoplastic effects through the release of small
soluble oxidizers, the impairment of T cell/antigen recognition, and the depletion of
essential amino acids from the local extracellular environment resulting in T cell
suppression190. Both subpopulations of MDSCs have been shown to play integral roles
in this suppression190. The cumulative effect is increased tumor progression and
diminished therapy results191. MDSCs additionally accumulate in and contribute to
other disease states, such as parasitic infection where MDSCs have been shown to
play an immunosupportive role183,192,193.
MDSCs collectively represent a heterogeneous cell population with different
patterns of surface protein expression. In the murine system are unified by expression
of Gr-1 and CD11b. The Gr-1 epitope comprises of Ly6C and Ly6G molecules that are
members of the Ly-6 family of low molecular weight phosphatidylinositol-anchored cell
surface glycoproteins194–196. Expression of the two distinct epitopes of Gr-1, allow the
differentiation between the two major subpopulations of MDSCs. Ly6G+Ly6Clo MDSCs
are considered granulocytic and morphologically resemble polymorphonuclear (PMN)
granulocytes while Ly6C+ MDSCs are considered monocytic and resemble
mononuclear monocytes. In humans, MDSCs are defined as Lin-HLA-DR-CD34-CD33+
and further categorized into monocytic and granulocytic MDSCs by CD14+ and CD15+
expression, respectively190. In mice, studies indicate that engagement of the Gr-1
epitope through Ly6G or Ly6C can differentially regulate myeloid cell activity and the
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subsequent immune response194,197,198. For example, ligation through Ly6G can induce
cell death while Ly6C can lead to cellular expansion and differentiation194,198.
Many groups have reported the utilization of other protein makers to further
delineate monocytic MDSCs and granulocytic MDSCs. In humans, granulocytic MDSCs
are defined as CD11b+CD33+CD14loCD15hi and can be further characterized by
expression of CD66b, a member of the carcinoembryonic antigen family that is
commonly expressed on human neutrophils. Additionally, human granulocytic MDSCs
have also been indicated to express VEGFR1 and low levels of CD62L199–201. Although
these surface proteins are often associated with neutrophils, the main differentiating
factor between granulocytic MDSCs and neutrophils in humans is that in contrast to
conventional neutrophils, granulocytic MDSCs are purified from the mononuclear cell
fraction in density gradients of peripheral blood202. Another marker, CD124 or IL-4Rα,
can be used to mark granulocytic MDSCs in patients with non-small cell lung cancer,
but in melanoma and colorectal cancers it is found on both subpopulations203–205.
Granulocytic MDSCs, as demonstrated by Trellakis et al., exhibit higher levels of the
S100 protein, S100A8/A9 complex as compared to S100A9 on monocytic MDSCs in
patients with head and neck squamous cell cancer (HNSCC)206. Human granulocytic
MDSCs express IL-13R under suppressive conditions and lower levels of CD33 as
compared to monocytic MDSCs190,202,206,207. Work by Duffy et al. on sorting and storage
of MDSC subsets from gastrointestinal (GI) tumors identifies that CD33 expression may
not be a beneficial marker for MDSC isolation from human patients. They show that
CD33+ and CD33- CD15+ MDSCs have equivalent CD8+ T cell suppression208.
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Human monocytic MDSCs are mainly defined as CD11b+CD33+CD14hiCD15lo.
The preferential markers to delineate human monocytic MDSCs from granulocytic
MDSCs favor granulocytic MDSCs. But work done by Mandruzzato et al. shows that IL4Rα found on both subpopulation of human MDSCs, is important as a suppressive
marker only in the monocytic MDSC population205. A third subpopulation of MDSCs is
often described. These MDSCs are considered immature MDSCs and are defined by
Lin-HLA-DRlo/-CD33+CD14-CD15-204. These MDSCs are thought by many groups to be
the lineage precursors in humans to granulocytic and monocytic MDSCs188,205,209–214.
Murine MDSCs have been studied extensively, thus markers identifying the two
subpopulations are many. Granulocytic MDSCs in mice are defined as
CD11b+Ly6CloLy6G+. Researchers have also been known to separate these cells out
by Gr-1 expression, as granulocytic MDSCs are Gr-1high. Other groups also indicate
that granulocytic MDSCs express SLAMF4 (CD244) and/ or CSF-R (CD115) in tumor
bearing mice203. Furthermore, Youn and colleagues reported the expression of MCSFR on granulocytic MDSCs and utilization of CD244 as a marker of granulocytic
MDSC identification and T cell suppressing nature. The authors indicate that CD244+
granulocytic MDSCs are capable of inhibiting antigen specific T cell responses while
CD244- granulocytic MDSCs are unable to do so215. Additionally, Toh et al, reports that
granulocytic MDSCs express CXCR2 (IL-8Rβ), which binds CXCL1, CXCL2, and
CXCL5. Granulocytic MDSCs also express CXCL1 and CXCL2 while tumors express
CXCL5. The ligation of these particular molecules leads to the accumulation of
granulocytic MDSCs and not monocytic MDSCs in the murine tumor microenvironment.
In fact, inhibition of CXCR2 inhibited granulocytic MDSC trafficking to primary
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melanoma tumor216. This is supported by another finding in a murine model of traumatic
spinal cord injury, indicating the expression of CXCR1 and CXCR2 on granulocytic
MDSCs217.
Murine monocytic MDSCs are defined by markers CD11b+Ly6G- Ly6C+.
Monocytic MDSCs are additionally Gr-1 intermediate and can be differentiated from
high Gr-1 expressing granulocytic MDSCs without the use of the Ly6G or Ly6C
epitopes. In addition, monocytic MDSCs are also characterized by expression of CCR2,
which is expressed mainly by monocytic MDSCs and not granulocytic MDSCs218. In
tumor conditions, CCR2 induces monocyte trafficking from the BM, limits entry of tumor
specific T cells into the tumor microenvironment, and leads to T cell inhibition by
MDSCs in contact-dependent manner. Murine monocytic MDSCs are further define by
CD49d, CCR7, and CX3CR1 expression217,219,220. Another group reported the presence
of F4/80 and CD93 on monocytic MDSCs in Experimental Autoimmune
Encephalomyelitis (EAE)221.
In addition to Gr-1 and CD11b in the murine system, both populations are also
identified by functional markers such as Dectin-1, a non-toll like pattern recognition
receptor, death receptor FAS, and ADAM1747,198,200. Both populations of MDSCs also
express TNFR1 and TNFR2222.
2.1.5 Survival and Proliferation
Like neutrophils, granulocytic MDSCs have a reduced life-span, similar to the 3.8
days reported for neutrophils and are more sensitive to cryopreservation as compared
to monocytic MDSCs196,208,215. However, granulocytic MDSCs are quickly repopulated
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from the BM and exhibit up to 80% survival when exposed to tumor explant supernatant
and GM-CSF177,196,201,223. This has been attributed to delayed apoptosis by increased
CXCL8224. Despite the prolonged life-span, these conditions did not induce granulocytic
MDSC proliferation, just survival. This has led to the current notion that monocytic
MDSCs are the only subset capable of proliferation. In fact, in the same study, Youn et
al. demonstrates that splenic monocytic MDSCs incorporated more than two-fold BrdU
as compared to granulocytic MDSCs in tumor bearing mice207.
2.1.6 Polarization and differentiation
In addition to a shorter life span, granulocytic MDSCs are also incapable of
differentiation while monocytic MDSCs can give rise to mature myeloid cells207. In fact,
CD11b+Gr-1+CCR2+CX3CR1low monocytic MDSCs are capable of differentiating into
DCs and macrophages under appropriate stimuli219. A recent study indicates that
monocytic MDSCs can also differentiate into granulocytic MDSCs via epigenetic
silencing of the retinoblastoma gene. Interestingly, the same study also suggests that
granulocytic MDSCs can lose their immunosuppressive characteristics and become
phagocytic upon ex vivo exposure to tumor explant supernatants and GM-CSF225.
In addition to differentiating into mature cells, MDSCs can be polarized towards
immunostimulatory type1 or immunoinhibitory type2 cells. Paired immunoglobulin-like
receptors A and B (PIR-A and PIR-B) along with human PIR homologues belong to the
immunoglobulin super family. These molecules have recently been demonstrated to
differentially regulate MDSC polarization. PIR-A and PIR-B were first identified as
homologues to the human Fc receptor for immunoglobulin A (IgA). It has recently been
reported that PIR signaling can alter polarization of monocytic MDSCs between the
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classically activated proinflammatory phenotype (M1) to an alternatively activated antiinflammatory (M2) phenotype and vice versa. PIR-A delivers activation signals in
complex with a homodimeric Fc common γ chain, which harbors an immunoreceptor
tyrosine-based activation motif (ITAM), resulting in cytokine production in myeloid
cells226–228.In contrast, PIR-B engagement results in negative signal transduction upon
phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and
recruitment of SH2-homology–containing protein-tyrosine phosphatase-1 (SHP-1) and
SHP-2. Yan et al. reports that PIR-A ligation induces immunostimulatory M1 like
monocytic MDSCs while PIR-B inhibits this interaction, in favor of M2-like M-MDSCs. In
fact, SHP1 inhibition can shift M2 monocytic MDSCs to M1-MDSCs. Furthermore,
Fridlender et al. also demonstrate that granulocytic MDSCs can also be polarized
between G1 and G2 phenotypes but this is dependent upon TGF-β signaling. MDSCs
and tumor cells secrete large amounts of TGF-β that induces pro-tumor G2 granulocytic
MDSCs. However, blockade of TGF-β signaling via TGF-βR antagonization
reprogrammed G2 granulocytic MDSCs to tumoricidal G1 granulocytic MDSCs229.
2.1.7 Oxidative Metabolism of MDSCs
While both subpopulations of MDSCs express Arg1. Granulocytic MDSCs and
Monocytic MDSCs specifically generate reactive oxygen species (ROS) and inducible
nitric oxide (iNOS), respectively162. Arg1 is widely expressed in murine myeloid lineage
cells, yet is limited to neutrophil lineage in humans215. The expression of Arg1 allows
granulocytic MDSCs to contribute to cancer progression via T cell suppression. Arg1
acts by consuming the essential amino acid L-arginine (L-Arg) and metabolizes it to Lornithine and urea, both essential components of cellular proliferation and
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detoxification230. This in vitro L-Arg depletion by MDSCs, inhibited antigen-specific T cell
proliferation in OT-1 and OT-2 transgenic mice231,232. Furthermore, in the absence of LArg, T cells exhibit decreased CD3ζ expression, Jak-3, NFκB-p65 translocation and
IFN-γ production232. CD3ζ is an essential component of the TCR, as it is imperative for
the intracellular signaling cascade and subsequent T cell activation233. Loss of L-Arg
decreases cyclin D mRNA transcriptional rates as well as translation, thus arresting T
cells in G0-G1 phase234. However the depletion of L-Arg does not result in apoptosis
and both CD3ζ expression and proliferative potential can be restored upon L-Arg
administration235. Nonetheless, Kusmartsev et al. report that under limited L-Arg
concentration, NOS produces peroxynitrites (ONOO2), which are strong oxidizing
agents that nitrate proteins and cause T cell apoptosis236. Arg1 production can be
induced through IL-13/IL-4Rα signaling and in a murine model of graft versus host
disease (GVHD) limits disease through T cell suppression182.
In addition to Arg1, granulocytic MDSCs induce T cell suppression via the
production of ROS. Although ROS can be produced by several mechanisms, NADPH
oxidase (NOX2) is primarily responsible for ROS production in leukocytes237. The main
consequence of MDSC-mediated ROS production is inhibition of T cells in an antigenspecific manner by inducing MHC class-I restricted T cell tolerance238. Nagaraj et al.
report that ROS nitrates tyrosine residues on CD8 and the TCR to alter peptide
recognition but does not induce T cell deletion239. Finally, Granulocytic MDSCs limit
natural kill cell (NK) responses via H2O2 production240. However, additional experiments
are required to further elucidate the mechanism of this interaction215.
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Monocytic MDSCs are more potent suppressors of the immune response188.
Perhaps one of the main contributions of monocytic MDSC in pathologic conditions is
the up regulation of iNOS, which generates nitric oxide (NO). Mazzoni et al. report that
NO production by MDSCs blocks peptide-specific T cell proliferation. Further analysis
revealed this is due to the prevention of T cells from entering the cell cycle.
Interestingly, this was reversible. When T cells were stimulated with Con A in the
presence of MDSCs, they only regained their proliferative potential once the MDSCs
were removed. Thus, it is plausible that although monocytic MDSCs prevent T cell
proliferation, they do not induce apoptosis but transiently induce T cell suppression241.
The contribution of NO is further elucidated by the observation that MDSCs generated
from iNOS deficient mice are not suppressive242. Another consequence of iNOS is the
consumption of L-arginine as discussed above.
2.1.8 Cytokine production
Although the cytokine expression profile of each subset is dependent on disease
state, each subset has been identified with certain cytokines. For example, granulocytic
MDSCs secrete TNFα upon exposure to LPS, IFNγ, and TGF-β. Monocytic MDSCs
have been shown to secrete IL-6, IL-10, IL-23, TGF-β, and VEGF-α219,220. The
concomitant secretion of IL-10 and TGF-β also allows monocytic MDSCs to be potent
inducers of CD4+CD25+Foxp3+ T-regulatory cells219,220.
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2.1.9 Cell Signaling
STAT signaling
Both monocytic MDSCs and granulocytic MDSCs signal through Janus Kinase
(Jak) / signal transducer and activator of transcription (STAT) pathways243. STAT
proteins are latent cytoplasmic transcription factors activated by a variety of
hematopoietic and immune-mediated cytokine receptors. Monocytic MDSCs utilize
STAT1 to induce downstream T cell suppression188. Of the STAT signaling pathways,
STAT3 has been strongly linked with MDSC proliferation and survival162,183. STAT3
additionally promotes the activity of MDSCs, particularly Arg1 in CD14+ monocytic
MDSCs244. Using the receptor tyrosine kinase inhibitor, sunitinib, Ko and colleagues
demonstrate differential STAT3 and STAT5 signaling in murine monocytic MDSCs and
granulocytic MDSCs. The authors indicate that sunitinib down regulates STAT3,
subsequently abrogating monocytic MDSC proliferation and impairing granulocytic
MDSC survival. However, the addition of GM-CSF provides protection via STAT5
signaling245. Tumor derived factor induction of STAT3 and STAT5 signaling has also
been implicated in MDSC accumulation through down-regulation of IRF-8 in tumor
bearing mice as well as late stage breast cancer patients. Mice overexpressing IRF-8
have decreased MDSC accumulation and attenuated tumor progression246.
Notch signaling
Altered Notch signaling is implicated in MDSC accumulation in the ADAM10Tg
mice247. Notch signaling was found to be severely decreased in granulocytic MDSCs
from breast cancer patients and from tumor bearing mice248. Serine/Threonine casein
kinase 2 (CK2) is ubiquitously expressed and implicated in Notch signaling248. Recent
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work by Cheng et al. showed that in tumor bearing mice CK2 catalytic activity is
increased in granulocytic MDSCs, but not monocytic MDSCs248. This enhanced
catalytic activity of CK2 disrupts the interaction between Notch and transcriptional
repression CSL, which is needed for normal Notch signaling and DC formation.
Inhibition of CK2 decreased tumor conditioned media-induced proliferation of murine
tumor generated granulocytic MDSCs, but had no effect on monocytic MDSCs248. This
work implicates tumor derived factors as driving CK2 activity and thus altered Notch
signaling and the accumulation of MDSCs in cancer.
2.1.10 Cytokine induced MDSC expansion
Granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocytecolony stimulating factor (G-CSF) are two cytokines predominately associated with in
vivo MDSC accumulation and in vitro MDSC generation in humans and mice162,169,220.
GM-CSF is recognized as a critical hematopoietic cytokine, mediating the differentiation
of myeloid progenitors into granulocytes, eosinophils, monocytes, megakaryocytes, and
erythrocytes. G-CSF and its receptor are critical regulators of steady state and
emergency granulopoiesis. G-CSF promotes the survival, mobilization, and proliferation
of myeloid progenitor cells alongside neutrophil differentiation. Several studies indicate
that each cytokine preferentially induces granulocytic or monocytic MDSCs. Exposure of
GM-CSF alone induces immunosuppressive monocytic MDSCs while G-CSF induces
granulocytic MDSCs249,250. In fact, in human glioblastoma patients, they exhibit high
levels of G-CSF concomitant with granulocytic MDSC accumulation251. Under steady
state conditions, G-CSF acts in concert with CXCR2 ligands, CXCL1 and CXCL8 to
induce mobilization and recruitment of neutrophils, respectively. Therefore, it has been
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proposed that G-CSF may induce expansion of granulocytic MDSCs via CXCL1 and
mobilization via CXCL8196. In terms of GM-CSF, Dolcetti et al. demonstrates that 4T1
mammary cancer cell line, deficient in GM-CSF but not G-CSF, is less
immunosuppressive due to the differential expansion of G-MDSCs over M-MDSCs250.
The reduced tumor growth is accompanied by an increase in antigen specific T cells
lymphocytes in LNs of mice challenged with GM-CSF deficient 4T1. These mice also
exhibited an accumulation of G-MDSCs that did not affect the generation of tumor
specific T cells197. Moreover, Greten et al. indicate that human CD14+ monocytes
purified from healthy donors can be differentiated into suppressive M-MDSCs upon coculture with IL-4 and GM-CSF220. Interestingly, the combination of GM-CSF and G-CSF
induces monocytic MDSCs from BM cells after 4-days of co-culture. Additionally, IL-1β
has been indicated to inhibit NK cell differentiation in favor of granulocytic MDSCs in
4T1 mammary carcinoma208,216,252. Recently, murine hepatic stellate cells were found to
mediate MDSC induction via the complement factor C3 upon adoptive transfer253. In
humans, activated hepatic stellate cells induced monocytic MDSCs in a contact
dependent and CD44 dependent manner204. Lastly, Simpson and colleagues
demonstrated that the inflammatory cytokine, macrophage inhibitory factor (MIF),
induces monocytic MDSC differentiation rather than granulocytic MDSCs254.
2.1.11 Subset accumulation in pathological conditions
Neoplasia.
The expansion of MDSC phenotypes is dependent upon the immunoregulatory
factors altered by a given tumor or tumor model in mice. In humans, monocytic MDSCs
are mostly associated with melanoma, prostate, lung, gastrointestinal, and
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hepatocellular carcinoma while G-MDSCs are associated with breast, colon, pancreatic,
bladder, and HNSC carcinoma220. Granulocytic MDSCs are found to be the most
abundant population in solid tumors while monocytic MDSCs are more frequent in
leukemia255. A detailed list is summarized elsewhere, but the overall trend is the
dominant accumulation of granulocytic MDSCs in human cancer196,225. However, in
patients with hepatocellular carcinoma, CD14+ monocytic MDSCs continue to be the
most frequent population in the peripheral blood and tumor220. In humans with renal cell
carcinoma (RCC) and HNSCC, granulocytic MDSC accumulation is associated with an
increase in tumor and serum expression of CXCL8 (IL-8), a potent inducer of neutrophil
motility to site of inflammation224.
In naïve mice, MDSCs comprise 2-4% of total nucleated splenocytes with a 3:1
ratio of granulocytic MDSC to monocytic MDSC220. However, MDSCs can increase up
to 50% with a 5:1 granulocytic MDSC to monocytic MDSC ratio in tumor bearing
mice225. The population of granulocytic MDSCs becomes consistently increased in all
tumor models, whereas the frequency of monocytic MDSCs is only significantly
increased in a few models such as EL-4 lymphoma and ANV mammary carcinoma.
Only in Lewis Lung Carcinoma (LLC), granulocytic MDSCs and monocytic MDSCs are
equally elevated212. Moreover, in a given host, granulocytic MDSCs tend to localize at
the primary tumor site (24.5% vs 4.2%) while monocytic MDSCs are found in cutaneous
tumors (3.9% vs. 2.8%)218. In a mouse model of multiple myeloma (MM), monocytic
MDSCs begin to accumulate within one week of tumor induction while granulocytic
MDSCs accumulate weeks later. Despite the delay in kinetics, granulocytic MDSCs
continue to be the dominant population both in the BM and peripheral blood256. In tumor
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bearing mice, granulocytic MDSCs are recruited out of the BM in response to stromal
cell derived factor 1α (SDF-1α), the ligand for CXCR4. This was also supported by a
separate observation indicating the importance of CXCR2 ligand in the recruitment of
granulocytic MDSCs to primary tumor site. In fact, granulocytic MDSCs were 5 times
more abundant as monocytic MDSCs and CXCR2 inhibition significantly abrogated this
observation256.
While most attention has been given to the pathogenic mechanism of monocytic
MDSCs, granulocytic MDSCs are now beginning to be appreciated for their contribution
to tumor progression. Using a model of spontaneous melanoma, Toh and colleagues
indicate that granulocytic MDSCs are needed for the early stages of cancer
dissemination, as late depletion did not alter metastasis to skin, LNs, or lung.
Additionally, upon co-culture with granulocytic MDSCs, NBT-II bladder carcinoma cells
acquired a mesenchymal morphology, consisting of actin microfilament redistribution
and down regulation of E-Cadherin. This was attributed to the production of Hepatocyte
Growth Factor (HGF) and TGF-β, known inducers of epithelial-mesenchymal transition
(EMT). Moreover, the same study reported that granulocytic MDSCs promoted tumor
cell proliferation in a contact-independent manner218.
Infection
MDSCs, predominantly granulocytic MDSCs, have been shown to accumulate in
infections with microorganisms. In this context, they can play a beneficial role in limiting
unwanted inflammation as mice unable to expand MDSCs exhibit markedly higher
mortalities to sepsis-associated inflammation183,256,257. As mentioned earlier, bacterial
infections can skew MDSCs towards antitumor properties. The administration of
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attenuated Salmonella enterica serovar Typhimurium vaccine (RASV) results in an
accumulation of MDSCs, particularly the granulocytic subset. These MDSCs were very
sensitive to LPS stimulation, released large amounts of TNFα, and exhibited anti-tumor
properties. RASV treatment reduced Her-2/neu expressing tumor growth, shifted MDSC
differentiation towards granulocytic MDSCs, and enhanced CTL anti-tumor response. It
is for this reason that Salmonella-based cancer immunotherapies has been pursued
with promising preclinical results192,258. Furthermore, by limiting immune activation
MDSCs play a protective role in sepsis. Delano et al. demonstrated that polymicrobial
sepsis induced significant MDSC accumulation. More reports are surfacing, indicating a
protective role of MDSCs in microbial infections, especially Pseudomonas aeruginosa
colonization in burn victims and Staphlococcus aureus biofilm formation post orthopedic
joint surgery183,195. More recently, it was reported that MDSCs express dectin -1, a nonToll-like pattern recognition receptor for β-Glucans, which are the main components of
numerous bacteria, fungi, and yeast cell wall199. The authors report that whole βGlucans particle (WPG) administration preferentially enhances the survival of
granulocytic MDSCs but does not induce their differentiation. In contrast, WPG
treatment reduced monocytic MDSC survival but promoted differentiation towards
CD11c+F4/80+ non-immunosuppressive cells. Monocytic MDSCs were no longer able to
suppress T cell proliferation in the presence of WPG199. This could be contributed to the
fact that WPG reduced NO and Arg1 expression in monocytic MDSCs while it did not
alter ROS expression of granulocytic MDSCs.
The protozoan parasite, Trypanosoma cruzi is the causative agent of myocarditis
that manifests into Chagas disease. MDSCs comprise the majority of the inflammatory
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cell infiltrates in the heart. The most abundant subset in this case is monocytic MDSCs
(70%) as compared to granulocytic MDSCs (20%)259. Authors of this finding indicate
that this is mainly mediated via CCL2 chemokine. Interestingly, these infiltrating
monocytic MDSCs in the heart are not migrating from the BM but rather being
replenished from the spleen. Like those isolated from the tumor microenvironment, the
infiltrating monocytic MDSCs also express high levels of Arg1 and iNOS, and inhibit T
cell proliferation. Given another report indicating the accumulation of granulocytic
MDSCs in the peripheral organs of T. cruzi infected mice, it is possible that granulocytic
MDSCs and monocytic MDSCs preferentially migrate to specific anatomical sites in a
given disease state259,260.
While the accumulation of MDSCs in parasitic infection has been reported, the
immunomodulatory potential of these cells remained unknown261. However, here we
report the beneficial role of MDSCs in this context in the Th2 helminth Nippostrongylus
brasiliensis. We additionally investigate the mediators and other cell types that are
involved.
2.1.12 Interaction with cells other than T cells
Macrophages
Macrophages are capable of fighting both intracellular and extracellular
pathogens and are thus classified into two distinct subsets based upon the cytokines
required for their activation and the pathogens they target262. Classically activated M1
macrophages are normally activated by IFN-γ or in response to lipopolysaccharides
(LPS) to release NO in targeting intracellular pathogens as well as IL-12 and IL-23263.
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Type I macrophages are characterized as capable of antigen presentation and
promoting T cell proliferation and activity. In contrast, type 2 macrophages are
considered to have poor antigen presentation capability as well as inhibit T cell
proliferation and activity. Upon stimulation by IL-4 or IL-13, alternatively activated (M2)
macrophages secrete IL-10, TGF-β and Arg-1 in response to extracellular pathogens264.
MDSCs have not only been shown to resemble M2-like macrophages but also interact
with macrophages. MDSCs decrease IL-12 production by macrophages and skew their
differentiation towards an M2 phenotype. Macrophages in turn promote MDSC IL-10
production265. Although the authors of this study did not differentiate the subset of
MDSCs, it can be deduced based on morphology and cytokine production that this
interaction is mainly within the monocytic MDSC fraction. In Staphylococcal aureus
biofilm infections of orthopedic joints, M1 macrophages are essential for clearance of
the bacteria. Recruitment of MDSCs into the joint causes the skewing of macrophages
to the M2 phenotype. This MDSC induced M2 macrophage skewing severely limits the
ability of the immune system to clear the infection, thus inducing a persistent, chronic
infection266.
Dendritic Cells
Another cell known to interact with MDSCs is DCs. DCs are professional APCs
that identify, process, and present antigens to naïve, resting T cells267. This is critical for
the generation of an appropriate immune response. MDSCs secrete IL-10 that inhibits
toll like receptor (TLR) ligation and subsequent IL-12 production by DCs. This in turn
reduces DC mediated T cell activation268. While MDSCs as a group have been shown to
limit DC maturation, a recent group indicates CD14+ human monocytic MDSCs impair
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the quality of a DC vaccine. The authors indicate that monocytic MDSCs not only
prevent DC maturation but also antigen presentation and migration269. Interestingly,
MDSCs can be converted to DCs. Two studies have been done to this effect, one
indicating the requirement of NKT Cells and a-galactosylceramide; and another
suggesting interaction of iNKT with CD1d on MDSCs252,270.
Mast Cells
Recent findings are beginning to suggest that mast cells (MCs) contribute to the
recruitment and activity of MDSCs193,271,272. While MCs have well been documented to
mediate allergic inflammation, their demonstrated involvement with neoplastic disease
is more recent. Here, we investigate the novel interaction between the MDSC and the
MC.
2.1.13 Introduction to the Mast Cell
MCs are large, granular, long-lived cells that typically reside in sites that interface
with the environment such as the skin and mucosa of the respiratory and GI tracts273,274.
MCs originate from the BM and terminally differentiate in the tissues274. MCs serve as
important sentinel cells and accumulate in the tissues in response to inflammation275.
MCs are induced by cytokines IL-3, SCF, IL-4 and IL-9275. MCs are critical regulators of
innate and adaptive immunity. Mast cells express FcεRI, the high affinity receptor for
IgE. Antigen-specific IgE binds to FcεRI and upon encounter with the antigen; IgE
cross-links the receptor inducing MC activation and degranulation. This degranulation
is responsible for a wide variety of allergic reaction such as life-threatening
anaphylaxis275. They are key regulators of the anti-parasitic immune response276–278
through the production of cytokines, and effector cell recruitment, including MDSCs261.
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It has been long known that increased MC numbers at the tumor site correlates with
negative prognosis278,279. This was presumably thought due to their secretion of various
pro-inflammatory cytokines, MCs have also been shown to secrete mediators such as
5-LO and IL-17 to recruit MDSCs to the tumor site272,279.
Mast Cell secreted histamine on MDSC function
Activated MCs secrete histamine, proteases, and lipid-derived mediators. The
biogenic amine, histamine, is considered a major mediator released by MCs. Histamine
acts on a spectrum of cell types through GPCRs, known as HR1–4. The expression
profile of the HRs determines the net effect on cell growth, motility, phenotypic
alterations, and signaling mechanisms280–282. Through effects on target cells, histamine
induces vasodilation, vasopermeability, smooth muscle contraction, and mucus
production283. Numerous studies have linked excessive histamine production to allergic
reactions, infections, and tumor growth284,285. Myeloid cells have been reported to
express HRs and HDC, the enzyme required for histamine synthesis286. Histamine, in
turn, protects myeloid cells against apoptosis and promotes cytokine production. In fact,
co-culture of monocytes with histamine has been shown to increase IL-10 and inhibit IL12, thus skewing toward Th2 immunity287. Thus, histamine can alter the cytokine milieu,
transcription factors, and signaling pathways important for MDSC accumulation288.
Mast Cell secreted IL-13 on MDSC function
IL-13 is a cytokine made by many cell types including MCs289,290. IL-4 and IL-13
are both Th2-polarizing cytokines with overlapping roles291,292. IL-4 binds IL-4 receptor
subunit alpha (IL-4Rα) complexed to both the common gamma chain as well as IL-13
receptor subunit alpha (IL-13Rα). IL-13 is only able to bind to IL-4Rα with IL-13Rα.
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However the downstream signaling appears to be divergent dependent on which ligand
is bound291,292. IL-13 is primarily responsible for the “weep and sweep” associated with
intestinal parasitic clearance289,290. This includes enteric nerve stimulation and goblet
cell hyperplasia289,290. The role of IL-13 in the context of neoplasia has been a
controversial one. Initial studies found beneficial roles for both IL-13 and IL-4 in tumor
rejection292–295. These effects were noticed mainly in tumor lines that were genetically
engineered to overexpress the cytokine292,293. Currently, the evidence demonstrating
IL-13 as tumor promoting is becoming more and more abundant296–298. Phase I/II clinical
trials are even underway for use of IL-13-PE (Cintredekin besudotox) in patients with
metastatic and locally advanced adrenocortical carcinoma (ACC) and other advanced
solid tumors with high expression of IL13Rα2299. Human studies of pancreatic,
esophageal, and gastric tumors show that increased IL-13 in plasma is directly
correlated with MDSC levels and increased mortality296. IL4Rα is expressed on MDSCs
and is related to the suppressive nature of the cells300. IL-13 signaling through IL-4Rα
on MDSCs induces increased production of Arg1, thus, increasing T cell suppression300.
Mice deficient in IL-4Rα have decreased Arg1 expression in the tumor
microenvironment and decreased tumor growth in a mouse model of glioma301.
Additionally, with blockade of IL-4Rα and subsequent loss of IL-13 signaling, 4T1 tumor
progression is delayed. MDSC apoptosis is increased as well as CD8+ T cell infiltration
to the tumor site298. The source of IL-13 has been debated, until recently when MCderived IL-13 was shown to play an important role in tumor-genesis of pancreatic ductal
adenocarcinoma297. The function of IL-13 in tumor development seems to be closely
related to the source, timing of expression, dosage, as well as the molecular and
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cellular environments301. Other than induction of Arg1, thus increasing suppressive
capabilities of MDSCs, the role of IL-13 in MDSC function is largely unknown182.
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Chapter 2: Methods and Materials
2.2.1 Mice
Mice were kept at Virginia Commonwealth University (VCU) in accordance with the
humane treatment of laboratory animals set forth by the National Institutes of Health
and the American Association for the Accreditation of Laboratory Animal Care. C57BL/6
ADAM10Tgs were generated by the VCU Transgenic Mouse Core, as previously
described247. C57BL/6 WT mice, Pmel-1 and KitWsh/Wsh mice were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA). Cpa3cre; Mcl-1fl/fl mice302 (C57BL/6
background) were generously provided by Dr. Stephen Galli (Stanford University,
Stanford, CA, USA). All mouse protocols were approved by the VCU Institutional
Animal Care and Use Committee.
2.2.2 Cell Lines
Mouse bone marrow-derived MCs (BMMCs) were derived from femurs of WT mice and
cultured in cRPMI 1640 containing 10% FBS, 2mM L-glutamine, 100 U/mL penicillin,
100µg/mL streptomycin, 1mM HEPES (Quality Biological, Gaithersburg, MD,USA), and
1mM sodium pyruvate (Cellgro, Herndon, VA, USA). Cultures were supplemented with
IL-3-containing supernatant from WEHI-3 cells (1ng/mL) and stem cell factor containing
supernatant from BHK-MKL cells (10ng/mL). Mature BMMCs were used after 28 days
of culture. The LLC cell line was obtained from the American Type Culture Collection.
The B16-melanoma cell line was maintained in DMEM with 10% FBS, 1% penicillin,1%
streptomycin, and 1% L-glutamine. B16 melanoma and GM-CSF–B16 cells were
provided by Harry D. Bear, MD, PhD and maintained as previously described303.
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2.2.3 Isolation of MDSCs and AT, T cell depletion, and dye labeling.
Spleens were harvested from ADAM10Tg or LLC-bearing WT mice, depending upon
the experimental protocol. They were then dispersed into single-cell suspensions and
filtered through 70-μm nylon mesh strainers (Invitrogen). Erythrocytes were lysed using
an ammonium chloride potassium lysing buffer (Quality Biological). T cells were
depleted using CD90.2 magnetic depletion (Miltenyi Biotec, Auburn, CA, USA),
according to the manufacturer’s protocol. Gr-1+, Ly6G+, or Ly6C+ cells were purified
from ADAM10Tg spleens using the EasySep PE-Selection kit (Stemcell
Technologies,Vancouver, BC,Canada), according to the manufacturer’s protocol. For
AT studies, 10 × 106 ADAM10Tg MDSCs were injected into the tail vein of each
experimental group every 3 days. For T cell depletion, mice were injected i.p. with 200
μg anti-CD4 (GK1.5) and anti-CD8 (2.43) antibodies on days −3, −2, −1, 0, 5, and 10.
For AT of dye-labeled MDSCs, cells were stained with the PKH26GL dye-linker kit
(Sigma-Aldrich, St. Louis, MO, USA), according to the manufacturer’s protocol.
2.2.4 Arginase1 and iNOS detection
MDSC cytoplasmic extracts were prepared from isolated ADAM10Tg- and LLC-bearing
hosts and tested for urea production (DARG-200; BioAssay Systems). NO was
measured using Greiss Reagent (G7921; Molecular Probes).
2.2.5 T cell suppression assays
For polyclonal T cell activation, CD90.2+ T cells were sorted from spleen and activated
with immobilized anti-CD3 (10μg/mL) and soluble anti-CD28 (1μg/mL) in 96-well plates.
Sorted MDSCs (Ly6G+, Gr-1+, and Ly6G−) from ADAM10Tg or LLC tumor-bearing mice
were then added at increasing T cell/MDSC ratios. For Ag-specific T cell suppression
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assays, soluble gp100 (1μg/mL) was added to defined ratios of pmel-1 transgenic
splenocytes and ADAM10Tg MDSCs. After 54 hours of culture, 1 mCi [3H] thymidine
was added to each well for an additional 18 hours, and thymidine incorporation was
measured.
2.2.6 BMMC co-culture with ADAM10Tg MDSCs
BMMCs were derived from femurs of WT naive mice cultured in complete RPMI 1640
containing 20% WEHI-3–conditioned medium over a 4-wk period. They were
resuspended at 0.5 × 106 cells/mL, loaded with 0.5μg/ml mouse IgE, and cultured with
MDSCs at a 1:1 ratio in 10ng/mL IL-3 and 10 ng/mL GM-CSF overnight. MCs were
activated by DNP-human serum albumin (20–100 ng/mL), and supernatants were
collected 6 or 18 hours after cross-linking for ELISA.
2.2.7 Migration Assays
B16 (2x105), BMMC, or media alone were loaded into the lower well of 8µm transwell
plates (Corning, Herndon, VA, USA). MDSCs (2x105) were loaded into the upper well.
Plates were incubated for 4 h at 37°C, and the lower well was harvested for flow
cytometry.
2.2.8 Survival curve and proliferation assays
MDSCs were cultured in cRPMI with 1, 5, 10, or 100µM histamine (Calbiochem, San
Diego, CA, USA). For survival curves, counts were made with trypan blue dead cell
exclusion, and cell concentration was 1 x 106/mL in 5mL. For proliferation, MDSCs were
pre-cultured for 15 min with 10µM CT, CIM, or alone, before histamine addition. Cell
concentrations were 50,000 cells/well in a 96-well plate. After 48 h, a 24-hour pulse of
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[H3]-thymidine, 1 mCi/mL (Perkin Elmer, Waltham, MA, USA), was used. Plates were
harvested using a Filtermate cell harvester onto GF/C plates and read using a
TopCount plate counter (Perkin Elmer).
2.2.9 Adoptive immunotherapy of B16 melanoma
T cells were prepared for adoptive immunotherapy (AIT), as previously described303.
Recipient mice were injected i.v. with 0.25 × 106 B16 cells. One day prior to AIT, mice
were treated i.p. with 2 mg cyclophosphamide (CYP) and 1.2 mg gemcitabine (GEM)
and were treated every 5 days with GEM only.
2.2.10 PCR and quantitative PCR
PCR
Genotyping and PCR were run as described in section 1.2.2. Primers are listed in
Table 4.
qPCR
MDSCs were isolated, as described previously, and cultured with 100 µM histamine for
24 hours. Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies,
Grand Island, NY, USA). RNA (400 ng/l) was reverse-transcribed using the iScript
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Primers for running an iQ SYBR
Green Supermix (Bio-Rad) qPCR assay were purchased from Integrated DNA
Technologies (Coralville, IA, USA). Probes were purchased from Applied Biosystems
(Life Technologies, Grand Island, NY, USA) Primers and Probes are as listed in Table
4. Results were analyzed with Bio-Rad iQ5 Real-Time PCR software (version 2.0). Fold
variation was determined using ΔΔCt method of analysis.
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2.2.11 Flow cytometry
Sample preparation
Cell isolation and labeling were conducted as described previously in section 1.2.4 and
1.2.6.
Immunohistochemistry
Sample preparation and staining as in section 1.2.6
Antibodies
Antibodies are listed in Table 5.
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Table 4. List of primers for PCR and qPCR
PCR
ADAM10Tg Forward

5’-CCA ACA GTG TTA ATT CTG CTC C-3’

ADAM10Tg Reverse

5’-TTC TTT CAG CCA GAG TTG TGC G-3’

Cpa3-cre Forward

5’-CGA TGC AAC GAG TGA TGA GG-3’

Cpa3-cre Reverse

5’-GCA TTG CTG TCA CTT GGT CGT-3’

oIMR5147

5’-GCA GTA CAG GTT CAA GCC GAT G-3’

oIMR5148

5’-CTG AGA GTT GTA CCG GAC AA-3’
qPCR

Arg1 Forward

5’-GAC CAC AGT CTG GCA GTT GG-3’

Arg1 Reverse

5’-TGG TTG TCA GGG GAG TGT TG-3’

iNOS Forward

5’-CAC CCC AAG TTC GAC TGG TT-3’

iNOS Reverse

5’-CTA AAG GGA CAG GCG CTG AA-3’

IL-13

Mm00434206

IL-4

Mm00445259

GAPDH

Mm99999915
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Table 5. List of antibodies used for flow cytometry
Specificity

Clone

Label

Source

Mouse-Arg1

9819S

unlabeled

Cell Signaling

Mouse-HRH2

M-19

unlabeled

Santa Cruz

Mouse-HRH3

C-20

unlabeled

Santa Cruz

Mouse-HRH4

M-12

unlabeled

Santa Cruz

Mouse-Gr1

RB6-8C5

FITC, PE

Biolegend

Mouse-Ly6C

HK1.4

APC

Biolegend

Human-CD15

W6D3

PerCP/Cy5.5

Biolegend

Mouse-CD11b

M170

Pe/Cy7

Biolegend

Human-CD33

WM-53

Pe/Cy7

Biolegend

Mouse-HRH1

Polyclonal

Pe/Cy5

Bioss

Human-CD11b

ICRF44

APC

eBioscience

Human-CD14

61D3

PE

eBioscience

Mouse-Ly6G

1A8

FITC

BD Biosciences

Goat-IgG

Polyclonal

FITC

Santa Cruz

Rabbit-IgG

Poly 4064

Dylight 649

Biolegend

Human-CD34

561

FITC

Biolegend

103

2.2.12 N. brasiliensis infection, GEM treatment, CET treatment, CIM treatment, B16
melanoma or LLC injection, and AT of MDSCs
Eggs per gram of feces enumeration
N. brasiliensis larvae were generously provided by Joe Urban (Agriculture Research
Station, Beltsville, MD) and were maintained as previously described304. Each
experimental group of mice was infected with ∼650 stage 3 larvae (L3) N. brasiliensis.
Fecal egg burdens were enumerated on days 5–13. Fecal pellets were collected from
mice and weighed. Fecal weight determined calculated amount of flotation solution
(saturated sodium chloride solution in diH2O) to be added. Feces were dissolved in
500µL diH2O for approximately 30mins. Flotation solution was then added. [(Fecal
weight (grams) x 60mLs)/1gram]-.5mLdiH2O= x mL flotation solution. Feces solution
was then agitated by vortex for 5 seconds and 1mL was immediately removed and
loaded in the chamber of a McMaster counting slide. Eggs within counting grid were
enumerated three times per feces solution sample. Eggs per gram of feces (EPG) were
calculated by averaging individual counts and multiplying by 400193,305.
L4 and L5 enumeration
Groups of animals were euthanized on day 2 post-infection and lungs were removed.
Lungs were cut with scissors into approximately 5mm pieces and immersed in 0.5%
PBS agarose spread over cheesecloth and allowed to solidify. Cheesecloth bundles
were hung in the top of 50mL conical tubes filled with 37°C PBS. Tubes were placed in
a 37°C incubator for 4 hours. Lung worms were removed with a transfer pipette and
enumerated from the bottom fraction of the PBS with a dissecting microscope.
Additional animals were euthanized on day 7 post-infection, and the proximal halves of
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the small intestines were harvested. Intestinal pieces were cut into 1 cm sections, sliced
longitudinally and opened to expose the inter lumen. Sections were placed lumen side
down on cheese cloth. Cheese cloth bundles were suspended from tops of 50mL
conical tubes filled with pre-warmed PBS. After incubation for four hours at 37°C, adult
worms were removed from the bottom fraction of PBS and enumerated using a
dissecting microscope.
Serum collection, drug administration, and AT of MDSCs
Serum was collected by tail vein nick, days 7 or 14 post-infection. Serum was collected
by cardiac puncture at the termination of the experiment. For mice injected with GEM,
1.2 mg was injected i.p. starting on day 0 and repeated every 5 d throughout the
experiment. For AT studies, WT mice were injected with 5–10 × 106 naive ADAM10Tg
MDSCs via tail vein injection starting at day -1 of infection and repeated every 3 days
thereafter. For mice treated with CT, 0.5 mg/kg was injected i.p., starting on Day -1 and
repeated daily. For mice injected with CIM, 20 mg/kg was injected i.p., starting on Day 1 and repeated every 2 days.
B16 melanoma or LLC injection
For B16 melanoma or LLC, mice were injected i.v. with 250,000 cells, monitored daily,
and killed after 3 weeks; lungs were harvested and weighed to determine degree of
colonization. Or lung nodules were counted, as previously described303,306; if too many
to count, they were assigned a count of 250. For LLC, at the termination of the
experiment, lungs were filled by tracheal perfusion with 5% India ink solution and then
removed and fixed in Feketes buffer.
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2.2.13 Human MDSCs
Human studies were conducted under appropriate Institutional Review Board-approved
protocols. All patients gave informed consent for this research. Blood (20 mL) was
collected in ETDA-coated vacuum tubes from allergic patients, identified as
symptomatic or non-allergic controls, and PBMC were isolated using Ficoll-Paque
separation medium (GE Healthcare, Buckinghamshire, UK).
2.2.14 Statistical analysis
P values were calculated using unpaired two-tailed Student’s t-tests or unpaired MannWhitney analysis in GraphPad Prism v5. Error bars represent the SEM or SD between
samples as noted in figure legends. P < 0.05 is considered statistically significant.
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Chapter 3: Results
2.3.1 Mast Cells critically augment MDSC activity
MDSCs from ADAM10Tg mice are phenotypically and functionally analogous to tumorinduced MDSCs
Although MDSC accumulation is a byproduct of ADAM10 overexpression in early
hematopoietic progenitors, ADAM10 expression is not altered in these cells247. To
ascertain whether ADAM10Tg-derived MDSCs are functional, ex vivo T cell suppression
assays were performed. ADAM10Tg MDSCs inhibited T cell proliferation of both
ADAM10Tg and WT purified T cells under polyclonal (Figure 15A,B) and Ag-specific
(Figure 15C) conditions in a manner parallel to tumor-derived MDSCs (Figure 15D).
Tumor-derived MDSCs can be divided into granulocytic (CD11b+Ly6Ghigh) and more
immunosuppressive monocytic (CD11b+Ly6Chigh) subsets307. Accordingly, monocytic
MDSCs possessed more suppressive potential. Furthermore, similar to T cells from
tumor-bearing hosts, ADAM10Tg T cells exhibited reduced levels of L-selectin (CD62L), a receptor required for homing of naive T cells to the LNs (Figure 15E, F)198.
MDSCs impair the T cell response through the activity of arginase 1 and inducible NO
synthase. Accordingly, ADAM10Tg MDSCs had levels of these enzymes that were
comparable to tumor-derived MDSCs (Figure 15G,H)191. These ex vivo observations
indicate that MDSCs present in tumor-free ADAM10Tg animals behave similarly to
tumor-derived MDSCs.
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Monocytic MDSCs promote B16 metastasis
We used the B16 melanoma model to examine in vivo activities of MDSCs from
ADAM10Tg mice. B16 was injected i.v.; although not a true metastasis, this allows
comparison of tumor colonization into the lung with and without MDSCs and is
commonly used to assess AIT303. When challenged with B16, ADAM10Tg animals were
more susceptible to metastasis than were WT controls (Figure 16A). The ADAM10Tg
animals had tumor nodules that were too numerous to count and were consequently
assigned a count of 250. Parallel to the ex vivo assay, the suppressive activity of
MDSCs was attributed to the monocytic population. When WT mice were challenged
with B16 and AT of either monocytic or granulocytic MDSCs, melanoma metastasized
more aggressively in mice given the monocytic subset, and granulocytic MDSCs had no
effect (Figure 17A). AIT exerted a minimal effect on ADAM10Tg mice, suggesting that
the presence of MDSCs diminished the activity of adoptively transferred T cells.
Although AIT treatment did not completely abolish metastasis in WT lungs, it induced a
significant decrease in metastatic lesions. Given that lympho-depleting chemotherapy is
known to enhance AIT308, the protocol was modified to incorporate CYP and GEM. CYP
lympho-depletes recipient mice, permitting homeostatic proliferation of transferred T
cells; GEM preferentially decreases MDSC levels in tumor-bearing mice309,310. CYP and
GEM alone and in combination in WT mice did not significantly alter metastasis,
indicating that they have minimal effects on tumor cells (Figure 17C). However, GEM
selectively diminished the MDSC population in ADAM10Tg mice without affecting
lymphocyte levels (Figure 17B). ADAM10Tg mice treated with GEM alone exhibited an
antitumor response comparable to WT counterparts, demonstrating that T cell function
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is restored upon MDSC depletion (Figure 16B,C). Additionally, the combination of
GEM, CYP, and AIT (tri-therapy) resulted in complete regression of metastasis in both
WT and ADAM10Tgs (Fig. 16B, C). Figure 16D illustrates the significant abrogation of
metastasis arising from tri-therapy. Ideal AIT would use tumor-specific T cells and
chemotherapy. Thus, the AIT protocol was adjusted to incorporate pmel-1 mice that are
TCR transgenic for gp100 melanoma peptide303. Similar results were observed, in that
successful AIT required MDSC depletion (Figure 17C). Thus, MDSCs in ADAM10Tg
mice are functionally analogous to tumor-derived MDSCs, promote tumor metastasis,
and compromise the efficacy of tumor immunotherapy.
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Figure 15. MDSCs from ADAM10Tg mice are phenotypically and functionally
analogous to tumor-derived MDSCs.
(A) Proliferation of WT and ADAM10Tg (B) T cells or (C) pmel-1 TCR transgenic
splenocytes in the presence of increasing amounts of CD11b+ MDSCs (Ly6G+ (dotted
line),Ly6G-(dashed line), or Gr-1+(solid line)); WT and ADAM10Tg T cells were
stimulated with immobilized anti-CD3 and soluble anti-CD28. (D) Tumor-derived
MDSCs were purified from LLC bearing mice and used in suppression assays with
Pmel1 splenocytes at increasing ratios (T cells or splenocytes: MDSCs, *p<0.05). All
Pmel-1 splenocytes were stimulated with soluble gp100. (E) Cell surface expression of
L-selectin (CD62L) by CD4+ and CD8+ (Isotype control (grey filled), WT (solid line) and
ADAM10Tg (dashed line) (F) gated T cells from peripheral LNs. Lysates of MDSCs
derived from LLC bearing WT hosts and ADAM10Tg MDSCs were analyzed for the
activity of (G) Arginase by urea production and (H) Nitric oxide by Greiss Reagent. The
data is representative of at least three independent experiments with splenocytes from
three or more mice.
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Figure 16. MDSC depletion restores the antitumor response and prevents
metastatic progression of B16 melanoma in ADAM10Tg mice
(A) Number of lung metastases in WT and ADAM10Tg animals challenged with B16
melanoma with (filled bars) or without (open bars) AIT (A), as described in Materials and
Methods. Number of lung metastases of WT (B) or ADAM10Tg (C) mice challenged
with B16 and treated as in (A), with the addition of CYP (C) and GEM (G). (D)
Representative lungs of WT and ADAM10Tg mice with AIT, with and without CYP and
GEM. Data represent five mice/group. *p < 0.05 versus respective untreated controls.
ND, None detected.
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Figure 17. Gemcitabine selectively depletes MDSCs, which allows for effective
AIT with tumor specific T cells
(A) Quantification of B16 lung metastasis in WTC57 with AT of either granulocytic
(CD11b+Ly6G+) or monocytic (CD11b+Ly6C+) MDSCS. (B) Cytometric analysis of
peripheral blood leukocyte levels in ADAM10Tg mice following i.p. injections with
gemcitabine (upward arrow) every five days for three weeks, *p<0.05. (C) Number of
B16 lung metastases in mice treated with AIT comprised of pmel-1 transgenic T cells
and chemotherapeutics as described in Methods. More than five mice were used per
group in three independent experiments. *p<0.05 in comparison to respective untreated
controls and #p<0.05 in comparison to respective AIT+ CYP treatment.
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MDSCs enhance the immune response against N. brasiliensis
Next, we examined the effect of MDSCs on the immune response in anti-parasite
immunity. Although MDSC accumulation following N. brasiliensis infection has been
reported261, the direct immunomodulatory role of MDSCs in anti-N. brasiliensis
responses has not been examined. In N. brasiliensis infection, a WT response is
characterized by production of Th2-associated cytokines that ultimately mediate adult
worm clearance 10–12 d post-inoculation311. Following N. brasiliensis challenge,
ADAM10Tg animals had significantly reduced fecal egg counts compared with WT
controls (Figure 18A). This is highly correlated with 50% reduction in L5 adult worm
burden in ADAM10Tgs (Figure18B) and a 25% reduction in L4 stage worms in the lung
(Figure 18C). This indicated that MDSCs may facilitate parasite clearance. To
determine whether the increased worm clearance correlated with an increase in Th2
cytokines, we examined a panel of Th2 cytokines. Analysis of peak infection (day 7)
serum levels of IL-4, IL-5, and IL-13 demonstrated significantly enhanced levels in N.
brasiliensis-infected ADAM10Tg animals compared with infected littermates (Figure
19). Additionally, IL-17 and IL-33, which were reported to recruit MDSCs, were also
elevated in serum of ADAM10Tg mice271,312. On Day 14, mesenteric lymph nodes
(MLN) were taken from N. brasiliensis infected ADAM10Tg mice and LM controls.
These nodes were stained for Gr-1 to elucidate location of MDSCs (Figure 20).
To determine whether enhanced N. brasiliensis clearance is dependent on
MDSC activity, MDSCs were depleted from ADAM10Tg mice. GEM treatment resulted
in elevated egg counts in ADAM10Tg mice similar to WT levels (Figure 21A).
Additionally, N. brasiliensis infection resulted in a modest 4–5-fold increase in MDSCs in
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WT spleens from days 0 to 14. This level of WT MDSCs is sufficient to promote N.
brasiliensis clearance and prevent a chronic infection (Figure 21B). However, GEMmediated MDSC depletion in WT mice significantly exacerbated the peak level of N.
brasiliensis infection (Figure 21C). We additionally examined the intestines of mice
treated with GEM to confirm that off-target effects were not responsible for results seen.
MCs are an important mediator of N. brasiliensis clearance and MCs per villus/crypt unit
were not adversely affected with GEM treatment (Figure 21D). Taken together, the
data indicate that the enhanced immune response in ADAM10Tgs is a consequence of
elevated MDSC levels.
Next, to eliminate off-target effects of GEM, ADAM10Tg MDSCs were purified
and adoptively transferred to WT mice over the course of N. brasiliensis infection. Like
the MDSCs that were observed accumulating following N. brasiliensis infection, the
transferred MDSCs also contained both Ly-6G+ and Ly6C+ populations. AT of MDSCs
resulted in significantly reduced egg counts, comparable to ADAM10Tgs (Figure 22A).
Additionally L5 adult worms were reduced, but L4 lung worms were not (Figure 22B,C).
This indicates that AT MDSCs do not reach the level needed to decrease lung worms
by Day2. To confirm our findings with MDSCs were not only a result of ADAM10Tg
MDSCs, MDSCs were harvested from spleens and tumors of LLC-bearing mice and
injected i.v. into WT mice during N. brasiliensis infection. Tumor derived MDSCs were
able to additionally mediate N. brasiliensis clearance confirming that ADAM10Tg
MDSCs are analogous to tumor-derived MDSCs (Figure 22D).
Granulocytic MDCSs mediate N. brasiliensis clearance in a T cell-independent fashion

117

To determine which MDSC subset was responsible for this observation, MDSCs
were purified based upon Ly6G and Ly6C expression and adoptively transferred into
WT N. brasiliensis-infected mice. The Ly6Ghigh population had the same effect as did
total Gr-1+–purified MDSCs, whereas the adoptively transferred Ly6Chigh population had
no effect. This indicates that the granulocytic population of MDSCs mediates the anti-N.
brasiliensis immunity (Figure 23A). The direct role of MDSCs was further supported in
WT mice that were T cell depleted. Flow cytometry confirmed T cell depletion (Figure
24). These mice exhibited the same rapid rate of clearance as WT adoptively
transferred with MDSCs (Figure 23B). As expected, N. brasiliensis clearance was
significantly slower in T cell-depleted WT mice without AT of MDSCs (Figure 23B) and
chronic, unresolved infection was evident by L5 adult worms on Day 14 (Figure 23C).
Mast Cells are essential for MDSC-mediated parasitic clearance
Mucosal MC hyperplasia is a hallmark of gastrointestinal helminth infection that
enhances the immune response, leading to parasite clearance277,313. Mice deficient in
MCs exhibit delayed clearance kinetics314. Given that MCs mainly produce Th2polarizing and proinflammatory cytokines and that MCs chemoattract MDSCs, we
examined whether the interaction between the two cell types could be contributing to
the enhanced N. brasiliensis expulsion. Surprisingly, AT of MDSCs into MC-deficient
mice did not enhance N. brasiliensis expulsion, indicating that an MDSC/MC interaction
is critical for MDSC-mediated anti-N. brasiliensis responses (Figure 26A-C). To
confirm that this was not unique to KitWsh/Wsh mice, which have other hematopoietic
issues, two studies were done. KitWsh/Wsh mice, which were reconstituted with WT
BMMCs, responded to AT of MDSC with enhanced parasite clearance (Figure 26C). In
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addition, another strain of MC-deficient mice, Cpa3cre; Mcl-1fl/fl (C57BL/6 background)
was tested. These mice express Cre recombinase under the control of the Cpa3
promoter. C57BL/6-Cpa3cre; Mcl-1fl/fl mice are severely deficient in MCs and basophils
with no other apparent hematologic changes302. Similar to KitWsh/Wsh mice, AT of MDSCs
also failed to clear N. brasiliensis in the Cpa3cre; Mcl-1fl/fl mice. These studies further
confirm that MCs are required for MDSC-mediated parasite clearance (Figure 26D). To
assess this interaction ex vivo, MCs were co-cultured with MDSCs. This resulted in a
synergistic increase in IL-6, IL-13, TNFα, and MIP-1α (Figure 27).
MCs also contribute to MDSC-mediated immune suppression in B16 melanoma
Given that MDSCs require MCs to enhance anti-N. brasiliensis immunity, the B16
metastasis study was re-evaluated in MC-deficient mice. Several groups demonstrated
that MCs recruit MDSCs, which accumulate in the tumor microenvironment and
correlate with poor prognosis. In addition, MC-deficient mice have decreased rates of
tumor growth that increases to WT levels subsequent to MC reconstitution315.
Therefore, we anticipated that B16 melanoma cells would metastasize more slowly in
KitWsh/Wsh mice compared with WT controls, but it would be enhanced with MDSC AT.
KitWsh/Wsh and WT mice were injected with B16, with and without AT of MDSCs. WT
mice were more susceptible to B16 metastasis compared with KitWsh/Wsh mice. Upon
MDSC AT, WT mice exhibited similar levels of tumor nodules as did B16 ADAM10Tgs,
indicating the direct contribution of MDSCs to the immune response. However, much to
our surprise, AT of MDSCs into KitWsh/Wsh mice failed to increase B16 metastasis
(Figure 28). Thus, these results demonstrate that MDSCs promote B16 melanoma
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metastasis in an MC-dependent manner and indicate that MDSC/MC interactions
significantly enhance the MDSC-mediated suppression of antitumor immunity.
MCs promote MDSC trafficking and parasite clearance
Given the literature highlighting MCs as attractants of MDSCs and the
importance of MDSC recruitment in an immune response, the trafficking behavior of
MDSCs was analyzed after AT in the presence or absence of MCs. MDSCs were
labeled with the PKH26GL lipid dye and AT by i.v. injection into naïve mice. As shown in
Figure 29A and B, 18 h post-AT, MDSCs preferentially trafficked to the liver; this
agrees with other published results316. To determine whether MDSCs exhibit similar
trafficking patterns during the course of N. brasiliensis infection, MDSCs were labeled
and infused concomitant with N. brasiliensis challenge in WT and MC-deficient KitWsh/Wsh
mice. As with naive mice, MDSCs trafficked to liver in infected WT mice. However, the
accumulation of MDSCs in the liver was reduced significantly in KitWsh/Wsh mice,
indicating the role of MCs in MDSC recruitment (Figure 29C–E). The PKH26GL dye
used for labeling does not affect MDSC functionality, as labeled cells were fully capable
of reducing parasite egg burden in the feces (Figure 30). Livers of KitWsh/Wsh mice on
Day7 post N. brasiliensis infection were sectioned and stained for Gr-1 expressing
MDSCs. The immunohistochemistry reinforces finding of reduced migration MDSCs to
the liver (Figure 31). These results were supported by in vitro migration assays, in
which MDSCs exhibited a high degree of migration toward MCs (Figure 32). This is
consistent with published literature, indicating that MDSCs traffic to the liver in tumor
models and that MCs secrete mediators from the liver through the bile317.
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We next wanted to see if MDSC accumulation and migration to the liver are MCdependent during tumor development. A model of B16 melanoma metastasis was used.
In B16 melanoma, WT lung colonization is exacerbated with the AT of MDSCs. While in
Cpa3cre; Mcl-1fl/fl MC-deficient mice, AT of MDSCs did not cause increased lung
colonization, confirming previous data published with the KitWsh/Wsh mice (Figure
33A)193. Additionally, MDSCs are reduced in liver but not in spleen over WT mice, with
or without AT of MDSCs (Figure 33B).
MDSC interaction with MCs maintains the granulocytic population in vitro.
Since MCs are required for MDSC effects in vivo, we wanted to look at
MC/MDSC co-cultures in vitro. We cultured MDSCs for five days in culture with and
without MCs in media supplemented for MC growth, then looked at the subpopulations
of MDSCs. Without MCs, the granulocytic MDSC population does not survive in vitro.
However, in the presence of MCs, the granulocytic MDSC population is maintained in
vitro (Figure 34).
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Figure 18. ADAM10Tg mice are resistant to N. brasiliensis infection
(A) Eggs per gram of feces (EPG) were determined at the indicated times in WT and
ADAM10Tg mice upon infection with 650 N. brasiliensis L3 worms. (B) WT and
ADAM10Tg mice were examined on day seven for adult worm recovery and (C) on day
two for L4 lung larval stage as described in Materials and Methods. . *p<0.05;
**p<0.005. Error bars are ± SEM. Data represents five mice per group.
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Figure 19. ADAM10Tg MDSCs have increased cytokine expression over WT
during N. brasiliensis infection.
Day 7 serum from ADAM10Tg or WT mice infected with N. brasiliensis. Cytokine
analysis on serum was performed using a Milliplex Mouse Cytokine Kit. *p<0.05. Error
bars are ± SEM. Data represents five mice per group.
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Figure 20. MDSCs accumulate in mesenteric lymph nodes in N. brasiliensis
infection
MLNs were harvested from WT or ADAM10Tg mice on Day 14 post N. brasiliensis
infection. MLNs were sectioned and stained with anti-Gr1 (blue) and anti-CD3 (red).
Pictures are representative of 5 mice per group.
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Figure 21. Gemcitabine depletion of MDSCs restores WT response to N.
brasiliensis infection to ADAM10Tg mice.
(A) ADAM10Tg mice were treated with GEM during N. brasiliensis infection. EPG were
enumerated. Data represents at least five mice per group and two independent
experiments. (B) Spleens of mice were harvested at day 14 post N. brasiliensis infection
and percent Gr-1+CD11b+ MDSCs were gated off of total live cells. Plots are
representative of five mice per group. (C) WT mice were treated with GEM during N.
brasiliensis infection. EPG were enumerated. (D) Day 15 post infection, N. brasiliensis
infected ADAM10Tg mice with or without GEM. Proximal half of the small intestines
were stained with toluidine blue to enumerate mast cells. Mast cells from ten villus/crypt
units (VCU) were counted per mouse. Data represents at least five mice per group.
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Figure 22. Adoptive transfer of MDSCs from ADAM10Tg mice or LLC-tumor
bearing mice induce increased parasitic clearance of N. brasiliensis.
(A) EPG were determined at the indicated times in WT and WT mice with AT of
ADAM10Tg MDSCs upon infection with 650 N. brasiliensis L3 worms. (B) WT and WT
mice with AT of ADAM10Tg MDSCs examined on day seven for L5 adult worm recovery
or (C) L4 lung worm recovery. (D) EPG were determined at the indicated times in WT
and WT mice with AT MDSCs from LLC-tumor bearing mice. *p<0.05, **p<0.005. Error
bars are representative of ± SEM. Data represents at least five mice per group and at
least two independent experiments.
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Figure 23. Granulocytic MDSCs are responsible for MDSC enhanced parasitic
clearance in a T cell independent manner
(A) Enumerated EPG of infected WT mice with AT of either the CD11b+Ly6GhighLy6Clow
or CD11b+Ly6GlowLy6Chigh population of MDSCs. (B) EPG of WT mice, with or without
MDSC AT, and with or without depletion of CD4 and CD8 T cells, as described in
Materials and Methods. (C) In T cell depleted mice, L5 adult worms were enumerated
on Day 14 to confirm clearance or chronic infection. . *p<0.05, **p<0.005. Error bars
are representative of ± SEM. Data represents at least five mice per group.
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Figure 24. T cell depleting antibodies completely deplete T cells.
Peripheral blood of WT and T cell depleted mice after injection with CD4 and CD8
depleting antibodies prior to N. brasiliensis infection for experiment in Figure 23. (A)
Percent positive for B220. (B) Percent positive for CD4. (C) Percent positive for CD8.
Flow cytometry plots are representative of at least five mice per group.
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Figure 25. Monocytic MDSCs promote B16 melanoma colonization to the lungs.
Quantification of B16 lung metastasis in WT/C57 with AT of either granulocytic MDSCs
(CD11b+Ly6G+) or monocytic MDSCs (CD11b+Ly6C+), as described in Methods. More
than five mice were used per group in three independent experiments. *p<0.05 in
comparison to respective granulocytic MDSC group.
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Figure 26. MCs are required for MDSC-mediated N. brasiliensis clearance
(A) Enumerated EPG on days noted of MC-deficient KitWsh/Wsh mice, with or without
MDSCs and infected with 650 N. brasiliensis L3 worms. (B) Adult worms enumerated on
day 7. (C) KitWsh/Wsh mice were reconstituted with BMMC as described in Methods and
Materials. Reconstituted mice were AT with or without MDSCs and infected with N.
brasiliensis. Significance refers to reconstituted KitWsh/Wsh mice with AT of MDSCs as
compared to KitWsh/Wsh mice with AT of MDSCs. (D) MC-deficient Cpa3cre, Mcl-1flox/flox
mice were infected with N. brasiliensis, with or without AT of MDSCs, and EPG were
enumerated on noted days. The data represent at least five mice per group. *p< 0.05,
**p< 0.005, ***p<0.005.
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Figure 27. MC/MDSC interaction augments cytokine production.
BMMCs were co-cultured with ADAM10Tg MDSCs, as described in Materials and
Methods. Supernatants were collected and analyzed for the production of IL-6 (A), IL-13
(B), MIP-1α (C), and TNFα (D). The data represent pooled spleens of at least three
mice/group. *p < 0.05 versus MCs alone. Figure courtesy of Johanna K. Morales and
John J. Ryan, Virginia Commonwealth University, Richmond, VA, USA.
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Figure 28. MC/MDSC interaction is required for MDSC-mediated immune
suppression.
Photographic representation (A) and quantification (B) of B16 lung metastasis in control
C57 and KitWsh/Wsh mice, with and without AT of MDSCs. The data are representative of
at least five mice/group. *p < 0.05 versus WT alone or KitWsh/Wsh with MDSCs.
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Figure 29. MDSCs preferentially migrate to the liver in a MC-dependent manner
(A) WT mice given labeled MDSCs, analyzed 18 hours later. MDSC in liver, peripheral
blood (PB), spleen, and bone marrow (BM). Data compiled in B. (C) Wsh or WT was
given labeled MDSCs, infected with N. brasiliensis, and examined for MDSC staining on
Day 7. Cell percentage of PKH26GL+ cells out of total Gr1+CD11b+ cells (D) and
number (E) from C. (F). MDSCs were given on Days -1, 2, and 5. *P<0.05;
***P<0.0005. Mean ± SD; n=5/group.
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Figure 30. PKH26GL+ MDSCs are functional
WT mice with or without AT of labeled MDSCs on Days -1, 2 and 5. Mice infected with
N. brasiliensis and examined for EPG on Day 7. *P<0.05. Mean ± SD; n=5 mice/group.
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Figure 31. MDSCs do not traffic to livers of MC-deficient mice during N.
brasiliensis infection
WT or Wsh mice with AT of MDSCs on Days -1, 2, and 5 were infected with N.
brasiliensis on Day 0. Livers were sectioned and stained with Gr-1+ (green) MDSCs.
Pictures are representative of five mice per group.
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Figure 32. MDSCs migrate preferentially to mast cells
MDSCs placed in top well of 8µm transwell plate. B16 melanoma, MCs or media alone
were placed in the bottom well. Four-hour MDSC migration was assessed by flow
cytometry. *P<0.05. Mean ± SD; n=5/group.
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Figure 33. MCs are required for MDSC-mediated tumor progression
(A) Cpa3creMcl-1fl/fl (MC-/-) or WT Mice were challenged with B16 melanoma
concomitant with or without MDSCs. Mice were sacrificed and lung tumor colonies
were enumerated. (B) Liver and spleen were examined for MDSC accumulation.
*P<0.05, n= at least four mice per group.
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Figure 34. Mast cells help maintain the granulocytic population of MDSCs in vitro
MDSCs were cultured with and without MCs, in media containing IL-3 and SCF to
maintain MC survival. Culture was maintained for 5 days and then harvested for flow
cytometric analysis. Live cells were assessed for CD11b staining. CD11b+ cells were
gated to look at the Ly6G+ or Ly6C+ distribution.
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2.3.2 Mast cell histamine promotes immunoregulatory activity of MDSCs
MDSCs express HR1 and HR2
Given the contribution of histamine to MDSC activity, cell proliferation, and Th2skewed immune responses280,286, we examined whether histamine could serve as a
potential mediator in the MC/MDSC cross-communication. Liver MDSCs were
examined, as they were the population most affected in MC-deficient mice. They
express HR1–3 but not 4 (Figure 35A). Splenic MDSCs express high levels of HR1, as
shown in Figure 35B. Additionally, purified MDSCs express detectable HR2 and 3 but
not 4 (Figure 35C).
Histamine induces MDSC proliferation and differential gene expression in monocytic
versus granulocytic MDSCs
As shown in Figure 36A and B, in vitro exposure to histamine promoted survival
and proliferation of MDSCs in a dose-dependent manner. The contribution of histamine
was confirmed using CT, CIM, HR1, and HR2 antagonists, respectively. As shown in
Figure 36C, CT and CIM inhibited histamine-stimulated cell proliferation. Both subtypes
of MDSCs are responsive to histamine; however, the monocytic subset is significantly
more sensitive to the proliferative effects of histamine than are granulocytic MDSCs
(Figure 36D).
Given the ability of histamine to induce MDSC proliferation in vitro, a logical step
was to examine its role in modulating markers of MDSC activity. Accordingly, monocytic
or granulocytic MDSCs were cultured with 100 µM histamine, as in Figure 36A, and
analyzed for expression of Arg1 and iNOS via qPCR. It has been documented that

156

MDSC immunosuppression largely results from impairment of T cell activity modulated
by these enzymes162,318. In the presence of histamine, we observed a fivefold increase
(ΔΔCt method)319 in the expression of Arg1 and a twofold increase in the expression of
iNOS in monocytic MDSCs over granulocytic MDSCs. However, the granulocytic
MDSCs exhibit a fivefold decrease in the expression of Arg1 and a threefold decrease
in the expression of iNOS, exhibiting striking differential gene expression between the
two populations (Figure 37A,B).These data are reinforced by intracellular flow
cytometry, showing increased protein expression of Arg1 by monocytic MDSCs when
exposed to histamine in vitro but unchanged expression by the granulocytic MDSC
(Figure 38A, B).
Arg1 and iNOS are essential for classical MDSC-mediated T cell suppression,
whereas IL-13 and IL-4 are important Th2 cytokines involved in N. brasiliensis
clearance. With addition of histamine, granulocytic MDSCs—the population important
for augmented parasitic clearance—increased IL-4 expression fourfold and IL-13
expression over 200-fold compared with monocytic MDSCs (Figure 37C).
Histamine antagonist prevents MDSC-mediated N. brasiliensis expulsion and tumor
progression
To confirm the effects of histamine on MDSC activity in vivo, mice were infected
with 650 L3 N. brasiliensis, a Th2 helminth. MDSCs were AT i.v. in conjunction with CT,
CIM, HR1, or HR2 antagonists, respectively. Administration of CT or CIM significantly
abrogated the ability of MDSCs to increase the clearance of N. brasiliensis (Fig. 39A,
B). This was correlated with reduced-infiltrating MDSCs in the liver (Figure 39C) and
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diminished phenotypic conversion toward granulocytic MDSCs (Figure 39D), which is
the important phenotype for N. brasiliensis clearance193.
As histamine induces increased iNOS and Arg1 message (Figure 37A, B), both
important for MDSC-induced T cell suppression, we analyzed whether histamine
blockade affected MDSC-induced tumor progression. A mouse model of melanoma was
used (B16). This model does not naturally accumulate large numbers of MDSCs, so AT
of MDSCs was used to increase MDSC numbers. Mice receiving AT with MDSCs and
treated with CIM had significantly reduced colonization to the lungs with B16 melanoma
compared with mice that received MDSCs but no CIM, as determined by lung weight
(Figure 40). CIM alone had no significant effect on tumor burden in the absence of AT
of MDSCs. This is consistent with data showing similar results using a model of murine
Lewis lung carcinoma, a model with natural accumulation of MDSCs, where CIM
treatment resulted in reduced tumor size320.
MDSCs are increased in allergic patients
Allergy is a MC-mediated, Th2-dependent immune response. Allergic patients
experiencing symptoms have increased levels of circulating MC-derived histamine321.
Additionally, Deshane et al.322 describe MDSCs as being involved in Th2-driven airway
hyper-responsiveness. To elucidate the translational relevance of our findings, we
isolated PBMC from patients currently experiencing allergy symptoms and non-allergic
controls, as determined by a patient questionnaire. Patients that reported taking
antihistamines were excluded from the study. PBMC was examined by flow cytometry;
human MDSCs are defined as CD34- CD33+CD11b+ cells220. Monocytic MDSCs are
defined as CD34-CD11b+CD14+ and granulocytic MDSCs as CD34158

CD11b+CD15+220(Figure 42). Allergic patients were found to exhibit 40% more
circulating MDSCs than controls (Figure 41A, B). Interestingly the monocytic subset of
MDSCs appeared to be the dominant subpopulation in the controls, but was not
elevated significantly in allergic patients (Figure 41C). However, the granulocytic
MDSCs, which are the population implicated to be more important in Th2 responses,
such as helminth immunity, were increased significantly with 20% more in the allergic
patients compared with controls (Figure 41D). MDSCs are elevated in the peripheral
blood of patients with cancer. To elucidate the response of human MDSCs to histamine,
MDSCs were sorted from the blood of cancer patients and stimulated with or without
histamine. Histamine promotes increased survival of human MDSCs at 48 hours over
media alone (Figure 43).
IL-13-/- mice have reduced MDSC accumulation in the periphery
Given the striking trafficking data and the emerging role of MC-IL-13 in tumor,
mice deficient in IL-13 (IL-13-/-) were injected s.c. with LLC. In this model, MDSCs were
generated by the BM, but they were unable to escape out of the blood and traffic to the
liver as indicated by a higher percentage of MDSCs in the peripheral blood (PB) and
fewer in the liver compared to tumor-bearing WT mice (Figure 44A,B). Interestingly,
despite increased PB MDSCs, the IL-13-/- mice had smaller tumor volume compared to
WT. These findings introduce a novel hypothesis that MC-secreted IL-13 recruits
MDSCs out of the circulation and into MC resident tissues, where they further increase
their suppressive properties through IL-4Rα signaling and enhance development of
tumor metastasis. This hypothesis is reinforced by preliminary data using a LLC
colonization model in which IL-13-/- mice had dramatically fewer tumor colonies in the
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lungs over WT (Figure 44C), and fewer MDSCs in the liver (Figure 44D). Interestingly,
these IL-13-/- mice had significantly increased PB MDSCs over WT (Figure 44D).
Backcrossing the IL-13-/- mice to the ADAM10Tg has allowed us to generate IL13-/- MDSCs as well as observe the effects IL-13 has on MDSC development.
ADAM10TgIL-13-/- mice have reduced MDSCs levels in the liver and spleen, as
compared to ADAM10Tgs (Figures 45 and 46). Yet, BM precursors to CMPs are
unaffected (Figure 47). This shows that MDSC development is unaffected and points
to alterations in MDSC trafficking or survival.
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Figure 35. MDSCs express HRs
A. HR expression on liver MDSCs as compared to secondary alone (shaded). B. H1
receptor expression on splenic ADAM10Tg MDSCs was determined by comparing HR1
staining on (line) MDSCs and comparing it to HR1 staining on GR1+CD11b- cells
(shaded). HR2 (C), HR3 (D) and HR4 (E) presence was determined by flow cytometry
of isolated MDSCs after 12 hours of culture in cRPMI. (Shaded area represents
secondary antibody alone) Three independent experiments.
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Figure 36. Histamine increases MDSC survival and proliferation
(A) Survival assessed by trypan blue exclusion over time course of MDSCs alone
(circle) or with histamine (triangle). (B and C) Proliferation assays of MDSCs cultured
alone, with histamine (H), or in combination with indicated agents, as measured by
counts per minute (CPM). (D) MDSCs were cultured with histamine or media. *P<0.05;
**P<0.005; ***P<0.0005. Mean ± SD; n=10/group and at least two independent
experiments.
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Figure 37. Histamine influences MDSC gene expression
Ly6C+ or Ly6G+ MDSCs were cultured ± histamine and analyzed (48 h) for Arg1 (A) or
iNOS (B) message. Fold change of histamine-treated/media alone (A and B). Fold
change of IL-13 and IL-4 message from histamine treated Ly6G+/Ly6C+ cells (C). After
normalization to GAPDH, data were analyzed using the ΔΔCt method.***P<0.0005.
Mean ± SD; n=5 from two experiments.
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Figure 38. Ly6C+ MDSCs express increased Arg1 protein with Histamine
MDSCs were isolated from ADAM10Tg spleen and treated with histamine for 12 hours.
Arg1 expression was determined by utilizing intracellular flow cytometry. Ly6C+CD11b+
(A.) or Ly6G+CD11b+ (B.) MDSCs with histamine treatment (dashed line) or without
(solid line), as compared to secondary alone (shaded).
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Figure 39. HR1 and HR2 antagonists blocks MDSC mediated N. brasiliensis
clearance
A, B. Eggs/gm feces in N. brasiliensis infected, ±MDSCs (M) on indicated days and
±daily CT treatment (A) or every other day CIM treatment (B). C. Day 14 analysis of
total MDSCs. D. Flow cytometric determination of liver monocytic or granulocytic
populations. *P<0.05, ***P<0.0005. Mean ± SD, n≥5 with two independent
experiments.
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Figure 40. HR antagonization inhibits MDSC mediated tumor progression
Mice were challenged with B16 concomitant with MDSCs in the presence or absence of
cimetidine (CIM), an HR2 antagonist. Mice were subsequently sacrificed and their lungs
weighed for B16 colonization. Error bars represent Mean ± SD. *P<0.05. n=at least five
mice per group.
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Figure 41. Allergic patients have increased circulating MDSCs. Symptomatic
allergic patients were compared with non-allergic controls.
Cells were isolated from peripheral blood gating strategy (Figure 41). Percent total
MDSCs (B) and subpopulations, CD14+ (C) or CD15+ (D), were determined by flow
cytometry. (A) Representative allergic patient versus control and (B–D) compiled.*P <
0.05. Mean ± SD. Allergic patients, n=6; controls, n=6.
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Figure 42. MDSC gating strategy for allergic patient study.
CD34- cells were gated off of the live cell population and CD33+CD11b+ dual positive
MDSCs were analyzed (as shown in Figure 40A,B). For subpopulations, this was
further extrapolated by looking at the CD11b+ CD15+ or CD11b+CD14+ populations and
analyzed (as shown in Figure 40A,C,D)
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Figure 43. Human MDSCs have increased survival in the presence of histamine.
MDSCs sorted as HLA-DRlo/-CD11b+CD33+ from peripheral blood of a stage 1 breast
cancer patient. Cells were stained for flow cytometry prior to culture and after 48 hours
of culture with 100µM histamine or in media alone. Patient data is representative of two
independent experiments. Data is courtesy of Kyle K. Payne and Masoud Manjilli,
Ph.D. at Virginia Commonwealth University, Richmond, VA, USA.
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Figure 44. IL13 is important for MDSC-driven suppression of tumor immunity
A. IL13-/- or WT Mice were challenged with LLC s.c. tumors. Tumor volume (A) and
percent Gr1+CD11b+ cells in spleen/liver (B) were assessed. C. Mice were challenged
with LLC i.v. and lungs were infused with India ink to visualize tumor, representative
lungs. D. Percent Gr1+CD11b+ cells in spleen/lungs were analyzed by flow cytometry.
Error bars represent Mean ± SD. *P<0.05. n>5 mice/group.
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Figure 45. IL13 deficiency decreases MDSC accumulation in the liver
A,B. IL13-/- or WT naïve mice liver by flow cytometry and C,D. IL-13-/-ADAM10Tg or
ADAM10Tg. Livers stained for Gr-1+CD11b+ of total live cells (A) and Ly6C+Ly6G+ of
total CD11b+ cells (B). Representative flow cytometry plots.
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Figure 46. IL13 deficiency decreases MDSC accumulation in the spleen
A,B. IL13-/- or WT naïve mice spleen by flow cytometry and C,D. IL-13-/-ADAM10Tg or
ADAM10Tg. Spleens stained for Gr-1+CD11b+ of total live cells (A) and Ly6C+Ly6G+ of
total CD11b+ cells (B). Representative flow cytometry plots.
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Figure 47. IL13 deficiency does not affect committed progenitor cells of the bone
marrow
A. IL13-/- or WT naïve mice BM by flow cytometry and B. IL-13-/-ADAM10Tg or
ADAM10Tg. BM from Lineage- of total live cells and divided into c-kit and sca-1
staining. Representative flow cytometry plots.
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2.3.3 Discussion
The ADAM10Tg mouse affords a unique tool to characterize the immunemodulatory potential of MDSCs in an environment free of established tumor. Because
the ADAM10Tgs suffer no confounding pathology, this was an ideal system in which to
elucidate the immunomodulatory roles of MDSCs. We used this system to investigate
roles for MDSCs in both neoplasia and helminth infection. In B16 metastasis, monocytic
MDSCs strongly suppressed the immune response, whereas granulocytic MDSCs failed
to promote metastasis (Figure 25). However, in N. brasiliensis infection, the
granulocytic MDSCs enhanced the anti-parasitic immune response, and the monocytic
MDSCs had no effect (Figure 23). AT studies demonstrated that this differential
immune regulation by MDSCs occurs in an MC-dependent manner. The ex vivo coculture studies indicate that MDSC/MC interactions may modulate immune responses
by increasing cytokine production. MDSCs traffic to MCs, affording a synergistic Th2skewed immune response. Although undesirable in the context of neoplasia, the
observed response is ideal in helminth infections. Overall, this data is indicative that
inhibition of MC function may serve as a novel target to inhibit MDSC activity.
The use of AT of labeled MDSCs allowed examination of their trafficking pattern
and migration during parasitic infection. Previous literature indicates that during tumor
progression, MDSCs traffic and accumulate in the liver in addition to the tumor site,
where they inhibit Kupffer cells and T cells to dampen anti-tumor immune
responses316,323,324. Similarly, in our N. brasiliensis infection model, MDSCs
preferentially migrated to the liver (Figure 29A, B). Previous work has shown that liveraccumulated MDSCs produce an array of proinflammatory and regulatory cytokines and
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chemokines in response to tumor challenge316. This would argue that the liver is a
critical site for MDSC function. In models of MC deficiency, where MDSCs do not traffic
to the liver, MDSCs do not function as efficiently193. MCs are seen in normal liver
surrounding the vessels and the bile ducts in the portal tracts as well as to a lesser
extent in the hepatic parenchyma325. It has been reported that hepatic MCs release
histamine and other mediators through the portal bile ducts and into the bile317.
Therefore, we hypothesized that MDSCs may interact with hepatic MCs in the liver and
become further activated. The attraction between these two cells may explain that in the
absence of MCs, MDSC migration to the liver and parasite expulsion are reduced
significantly (Figure 29).
MCs and histamine have been shown to play an important role in parasitic
clearance. Increased numbers of MCs and concentrations of histamine are positively
correlated with natural helminth resistance324. The role of histamine in parasitic infection
has been ascribed to smooth muscle contraction to enhance the “sweep” portion of the
“weep and sweep” method of parasitic clearance, acting in conjunction with IL-13/IL4326,327. Taken in conjunction with the positive correlation of histamine levels and
parasitic resistance, this could imply that natural immunity in these animals may not only
be a result of the effect of histamine on smooth muscle cells but also effects via MDSC
activation and proliferation. Whereas potentially, this could be tested using mice
deficient in HDC, the secondary increase in goblet cells seen in these mice would be a
complicating issue328. To our knowledge, the response to helminth infection has not
been reported in these mice.

188

The addition of histamine to MDSCs protected against cell death and increased
cellular proliferation in vitro (Figure 36A, B). Furthermore, histamine enhanced
expression of T cell suppression markers Arg1 and iNOS in monocytic MDSCs and
decreased expression of these markers in granulocytic MDSCs (Figure 37A, B). As a
result of these findings, T cell suppression by monocytic MDSCs should be increased
after exposure to histamine or culture with MCs. These studies are currently underway.
The granulocytic MDSCs increase IL-13 and IL-4 expression over monocytic MDSCs
when exposed to histamine. IL-13 is essential in N, brasiliensis infection for worm
expulsion responsible for increased mucus production and enteric nerve
stimulation291,292. This expression reinforces the differential roles that both subsets of
MDSCs play193,329. These studies are supported by a recent publication, in which
histamine blockade with CIM increased MDSC apoptosis, reduced Arg1 and iNOS
enzyme expression, and decreased MDSC accumulation in a mouse model of LLC320.
These results indicate that MCs enhance site-specific migration and as a result of
histamine secretion, induce increased MDSC proliferation and differential gene
expression. We hypothesize that in liver, as well as other sites of immune response,
resident MCs attract MDSCs and activate them via histamine release. This affords the
production of soluble mediators that can act locally and distally by secretion into the bile
in our parasitic model. Given our findings and other published studies on MDSCs, the
following model is suggested (Figure 48). MDSCs secrete Th2 cytokines, notably IL-4
and IL-13, which promote Th2 differentiation, along with IL-6 and TGF-β that
chemoattract additional MCs. The T cells not only contribute to the pool of IL-4 and IL13 but also increase IgE synthesis. IgE, in turn, further activates MCs. These events
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afford a self-sustaining and synergistic cycle of MC/MDSC activation, resulting in
increased survival and proliferation/activation of MDSCs, in addition to a Th2-skewed
immune response. This Th2-skewed immune response is detrimental in the setting of
allergic disease or neoplasia but beneficial for parasite clearance.
The importance of the histamine/MDSC interaction was demonstrated
dramatically in that histamine blockade, with HR1 and HR2 antagonists, reversed in
vitro the proliferative effects of histamine (Figure 36C) and reversed in vivo MDSCmediated clearance of parasites, similar to the deficit in MDSC functions found in MCdeficient mouse models (Figure 39A, D). Impressively, HR2 blockade also decreased
lung tumor burden in a B16 melanoma model (Figure 40) and other tumor models320. In
addition to having the same effect on parasite clearance, HR1 and HR2 blockade
decreased liver MDSC accumulation significantly (Figure 39B). This suggests that HR1
and HR2 have overlapping roles in the MDSC/MC interaction and when blocked, result
in reduced total MDSC function. The HR1 antagonist, CT, has been shown previously to
affect migration of other cells of myeloid lineage, such as monocytes, in vitro and could
be responsible for the reduced trafficking when the drug is used330,331. HR2 antagonists
have been shown to affect production in T cells of IL-13, IL-4, and IL-5, all cytokines
important in N. brasiliensis infection291,292. In this manuscript, we show that granulocytic
MDSCs are producing IL-4 and IL-13 message after histamine addition (Figure 37C),
and this finding suggests that CIM may work by reducing MDSC IL-4 and IL-13
production. Whereas the MC/MDSC interaction is multifaceted, we propose that MCderived histamine drives distinct MDSC subpopulations to differential gene expression,
inducing phenotypic activation that further directs the activity of the MDSC.
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Up-regulation of MDSCs in patient peripheral blood has been detected in many
cancers332–334 and suggested as a marker of poor prognosis335. The link between
inflammation and cancer has been studied heavily in the last decade. MC and MDSC
interactions can potentially serve as a bridge between allergic inflammation and
tumorigenic host responses279,336,337. This is the first report that patients with allergic
inflammation have increased circulating MDSCs (Figure 41A, B). Taken together, our
results have important implications for regulation of MDSC survival, trafficking, and
activity via antihistamines for disease states, in which the accumulation of MDSCs is
detrimental to the host.
IL-13, as mentioned earlier, is a Th2 cytokine that is functionally redundant with
IL-4338. Both IL-4 and IL-13 bind IL-4Rα, a subunit that complexes with either common
γ chain, IL-13Rα1 or IL-13Rα2. IL-4 can bind IL-4Rα complexed with either common γ
chain or IL-13Rα1. But, when complexed with IL-13Rα2, only IL-13 will bind it, thus
inducing IL-13 specific effects338. The bulk source of IL-13 in the body is made by Th
cells, but IL-13 is also secreted by mast cells339,340. Interestingly, in a model of peanutinduced allergy in the gut, it was uncovered that IgE mediated MC-degranulation
through FcεRI induced IL-13 production by the MC and that this IL-13 production was
essential for the development of the intestinal allergic responses to peanut340.
Interestingly, IL-13 from the MC drove primarily CCL2 (MCP-1) production. Most
importantly, in a model where MC-deficient mice were reconstituted with IL-13-/- MCs, so
that only MC-IL-13 was absent, mice completely failed to develop allergic diarrhea340.
In other studies, IL-13 has emerged as a key driver of CCL2 expression339–342. IL-13
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drives CCL2 expression in the human endothelium in vitro, as well as the bronchiolar
and intestinal epithelium in mouse models of allergic disease in vivo341,342.
The liver is emerging as a protective niche for MDSCs343,344. MDSC depletion by
anti-Gr-1 administration fails to eliminate them from the liver in tumor-bearing mice343.
The accumulation of MDSCs in the livers of these mice seems to be CCL2/CCR2
dependent343. CCL2 is a chemokine that binds to CCR2. MDSCs have been shown to
express CCR2345. Elevated levels of CCL2 in the circulation of breast cancer patients is
been correlated with poor prognosis345. CCR2-/- or CCL2-/- mice both have reduced
tumor burden and reduced trafficking of MDSCs345. In mouse models of hepatocellular
carcinoma, CCR2+ MDSCs migrate in vivo in response to the ligand CCL2346,347. CCR2/-

mice additionally exhibit deficiencies in MDSC migration to hepatocellular carcinoma

tumor sites347. Hepatocytes have been shown to make CCL2 and recruit myeloid cells in
humans with obesity and murine models of this disease. This recruitment promotes
hepatic steatosis348. This CCL2/CCR2 dependent accumulation in the liver is
additionally seen in mouse models of colitis343.
Data from Figure 44 shows that IL-13-/- mice have reduced tumor burden in
primary and metastatic models. Interestingly, these mice have increased MDSC levels
in the circulation. We hypothesize that this reduction in MDSC numbers in the tissues,
but increase in circulation is a result of a disrupted CCL2 chemokine gradient. This
disruption results in excess MDSCs stuck in the circulation, where they eventually
perish. Further study is underway to confirm this theory, as well as to determine if MCIL-13 is the driving source for the CCL2 dysregulation.
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Figure 48. Model of MDSC/MC interaction
MCs are required for MDSC activity. MCs in the liver release IL-13, which induces
production of CCL2 by hepatocytes. This creates a chemokine gradient that increases
migration of CCR2 expressing MDSCs, resulting in accumulation in the liver. MCs
release mediators, such as histamine, that induce MDSC activation, proliferation, and
Th2 cytokine production. This enhanced cytokine production culminates in Th2-skewed
immune responses that promote allergy and parasitic clearance and diminish antitumor
responses.
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Section 3
Chapter 1: B1 B cell IgE production in helminth infection
3.1.1 Introduction to B1 cells
B cells are divided into multiple lineages. There are four mature B cell lineages
in the mouse: FO B cells (B2 cells), MZ B cells, B regulatory cells (B reg), and B1
cells349. MZ B cells and B1 cells are both termed innate-like B cells. B1 cells are distinct
from B2 cells in the fact that B1 cells can self-replenish and are long lived. Murine B1
cells are found mainly in the pleural and peritoneal cavities350,351. They are derived from
the fetal liver and exist in a self-replenishing B1 cell pool. B1 cells have also been
shown to transport and present antigen352,353. They are delineated from B2 cells by
expression of CD23 and CD11b. B1 cells are CD23-, CD11b+, B220int, CD19+, IgMhigh
and IgDlo 354. CD5 is a marker that subdivides the two distinct B1 populations. B1a
cells are CD5+, while B1b cells are CD5-.
In these cells the BCR repertoire is enriched for highly poly-specific receptors
with low-affinities to a broad range of antigens355. Antibody generation in these cells
generally occurs without T-cell help, SHM, or affinity maturation, and class switching
was thought to be limited349. These cells produce low affinity or ‘natural’ antibody
important in immediate response to pathogens356–359. In vitro studies with B1 cells have
mainly linked them with IgM antibody production, but in vivo studies hint that B1 cells
can generate other isotypes. In vivo B1a cells and B1b cells seem to both be linked to
antibody production, but each cell tends to lean towards promotion of certain classes of
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antibody. B1a cells are linked to in vivo production of IgG2a, IgG2b and IgG3, while
B1b cells were previously linked to in vivo production of IgG1 and IgE360,361.
B1 cells were first described in 1983362. Since then, B1 cells have been
described in resistance to intestinal flora, defense from viral pathogens, generating
autoimmune responses and responding to parasites363–366. B1 cells are well known
secretors of IgM and gut IgA, but direct evidence of IgG or IgE production is only hinted
at in a few papers367. Balb/c Xid mice carry an X-linked mutation that prevents B1 cell
development. When these mice are infected with T. cruzi, they display significantly
lower levels of specific and non-specific antibody368. Additionally, in a mouse model of
Schistosomiasis, which is a Th2 infection characterized by high IL-4, IL-5, and nonspecific IgE, B1b cells have been shown to stain positive for IgE and thus be capable of
IgE production369. Next, Mice injected with Natterins, a protease that induces a strong
antibody driven-Th2 response similar to DerP1, B1b cells are dramatically increased in
the peritoneal lavage. In this model B1b cells stimulate ASCs to make increased IgE370.
Lastly, ES-62 is a phosphoryl choline (PC)-containing glycoprotein that is secreted by
filarial nematodes. ES-62 induces B2 cell hypo-responsiveness. Interestingly, ES-62
activates B1 cells to proliferate and mice treated with this glycoprotein still have high
IgE371. These cases argue that B1 cells may play an important role in producing
immunoglobulin, but don’t definitively show that B1 immunoglobulin production is
accounting for the increases seen.
B1 cells are described as being activated to produce antibody in a few different
ways. Cytokine IL-5 paired with IL-6 induces B1 cells to make in vivo IgA in the
gut350,370. IL-5 alone stimulates B1 cell proliferation in both B1a and B1b subsets, in
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vivo, as they both express IL-5 receptor350. IL-5 in conjunction with IL-4 or IL-4 in
conjunction with CD40L stimulation by T cells was shown to induce B1 cells to make
IgG1 or IgE in vitro372. Kaneko et al. claimed that anti-CD40 and IL-4 stimulation on B1
cells has the potential to produce more IgE than B2 cells372. Unfortunately, B1 cells
were sorted out the peritoneal cavity based only upon CD5loB220int expression372.
Hastings et al. in 2006 showed that a population of B2 cells exists in the peritoneal
cavity that expresses both CD5lo and B220int expression. They are segregated from B1
cells by CD11b expression. These peritoneal B2 cells survive in vitro culture and
produce antibody373. This indicates that B2 cells cannot be ruled out of the population
sorted by Kaneko et al. due to the fact that they did not sort based on CD11b staining.
Both subsets of B1 cells additionally express IL-9 receptor, and IL-9 transgenic mice
have been shown to have dramatically increased B1 cells. These mice additionally
make increased antibody in response to antigen stimulation. But, in vitro B1
proliferation or antibody production was unsuccessful361. Excitingly, a new study was
just released by Ghosh et al., which showed that during a model of fungal asthma, B1
cells in the pleural cavity secreted IgE into the BALF. µMT mice have a disruption in the
µ heavy chain causing a block in B cell development at the pre-B cell stage374. But
surprisingly develop a population of CD19+CD9+IgD+CD23- B1 cells375. Since these
mice lack evidence of any B2 cells, IgG and IgE production can be contributed to the B1
cells in vivo375. In all, in vivo models hint that B1 cells may be able to produce IgG and
even IgE, but more extensive evidence is needed, as well as successful in vitro culture.
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3.1.2 Introduction to IgE
IgE is the first line of defense against intestinal helminths. IgE levels are tightly
regulated, being the Ig with the lowest levels in vivo376. Interestingly, only very small
amounts of antigen are detected by IgE, making it a “gatekeeper” of sorts, being the first
to detect foreign particles in areas of interface with the environment. When these
foreign particles are innocuous, such as pollen, cat dander or peanut proteins, IgE
moves from beneficial to potentially life threatening. IgE mediates allergic responses
from mild reactions to severe, such as allergic rhinitis, atopic dermatitis, urticaria,
asthma, and anaphylactic shock377.
IgE controls the immune system in one of three ways described here. First,
antigen specific IgE is loaded onto MCs or basophils, FcεRI, where it can stay for up to
21 days waiting to bind to antigen, cross-link the FcεRI and degranulate the cell378. This
releases mediators such as histamine, lipid mediators, and other biologically active
products immediately, while additionally activating the MC or basophil to induce late
stage cytokine production377. All of this induces the symptoms of various allergic
diseases depending upon the location of the reaction. Second, circulating IgE can bind
to its antigen creating an IgE-immune complex. IgE immune complexes are then picked
up by circulating FO B cells via CD23, the low affinity IgE receptor (FcεRII). These
CD23+ B cells then traffic to the splenic follicles, where antigen transfer ensues
(described further in section 4) and subsequent rapid increases in specific CD4+ T cell
proliferation and antigen-specific IgG responses occurs379. Third, circulating IgE can
bind to CD23 on B cells, inducing a negative regulatory response to shut down and
control excessive IgE synthesis145.
198

There are two ways for a B cells to class switch to IgE. The first and more
traditional route is through the intermediate γ heavy chain (µ to γ to ε)380. This route of
CSR is mediated in the GC and induces high-affinity antibodies380. The high levels of
IgE production seen in helminth infections is not always high-affinity. A considerable
amount of the IgE is considered to be low-affinity. This low-affinity IgE is thought to be
mediated from a direct µ to ε switch380. We hypothesize that B1 cells generate IgE
through this mechanism.
3.1.3 Correlation between allergy and helminth infections
One in five children in industrialized countries suffers from allergic diseases such
as asthma, allergic rhinitis and eczema381. In these industrialized countries, helminth
infection is greatly reduced and when observed it is commonly associated with a
reduced parasite burden382. One billion individuals are heavily infected with helminth
worldwide and are rarely affected by allergic disease172. Many epidemiological studies
have proven this correlation382,383. Allergic diseases share many factors with helminth
infections, including a similar cytokine milieu and most importantly up-regulation of
IgE382,383. These factors induce the symptomology of allergic disease, yet in helminth
infected individuals, are protective against this symptomology382,383. This is despite
helminth being the strongest natural promoter of IgE synthesis384. It is well established
that parasite-specific IgE is important for anti-helminth immunity, but helminthes are
also known to elicit large amounts of polyclonal or non-specific IgE in the serum of
infected individuals. This has been thought to be a protective response384. Helminth
evolution has selected this trait that benefits parasite life and reproduction, assisting the
helminth in immune evasion384.
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Utilizing the intestinal helminth N. brasiliensis we show that B1 cells sorted from
peritoneal lavage of WT infected mice produce high levels of IgE in culture, whereas B1
cells from uninfected mice do not. We additionally show that this phenomenon is
augmented with the addition of myeloid derived suppressor cells (MDSCs). MDSCs
have been shown to accumulate in parasitic infection. Extensive myeloid cell infiltration
and proliferation has also been associated with B1 cell accumulation in a mouse model
of Schistosomiasis369. These cells are most commonly associated with
immunosuppressive activity. But, we have shown that these cells play an
immunosupportive role in the clearance of intestinal helminthes.
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Chapter 2: Methods and Materials
3.2.1 Mice
Mice were kept at Virginia Commonwealth University (VCU) in accordance with the
humane treatment of laboratory animals set forth by the National Institutes of Health
and the American Association for the Accreditation of Laboratory Animal Care. C57BL/6
ADAM10Tgs were generated by the VCU Transgenic Mouse Core, as previously
described247. C57BL/6 WT mice were purchased from The Jackson Laboratory (Bar
Harbor, ME, USA). All mouse protocols were approved by the VCU Institutional Animal
Care and Use Committee.
3.2.2 Isolation of MDSCs and AT, T cell depletion, and dye labeling
Spleens were harvested from ADAM10Tg. They were then dispersed into single-cell
suspensions and filtered through 70-μm nylon mesh strainers (Invitrogen). Erythrocytes
were lysed using an ammonium chloride potassium lysing buffer (Quality Biological). T
cells were depleted using CD90.2 magnetic depletion (Miltenyi Biotec, Auburn, CA,
USA), according to the manufacturer’s protocol. Gr-1+ cells were purified from
ADAM10Tg spleens using the EasySep PE-Selection kit (Stemcell
Technologies,Vancouver, BC,Canada), according to the manufacturer’s protocol. For
AT studies, 10 × 106 ADAM10Tg MDSCs were injected into the tail vein of each
experimental group every 3 days.
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3.2.3 ELISA
Total IgE ELISA
Plates were coated with mouse anti-mouse IgE (B1E3; in house) at 5µg/mL in BBS (see
previous section 1.2.5 for recipe) and incubated at 37°C for 1 hour. Plates were then
washed three times with ELISA wash (section 1.2.5). Plates were blocked (section
1.2.5) for 1 hour at 37°C and were washed as above. Samples were added at various
concentrations, diluted in block. Mouse IgE anti-DNP (in house) standards started at
1µg/mL and were serially diluted in block. Plates were incubated and washed as
previous. Biotinylated rat anti-mouse IgE (R1E4; in house) was added at 1:2000
dilution in block. Plates were incubated as previous. Plates were then washed five
times with ELISA wash and the detection antibody, streptavidin conjugated to alkaline
phosphatase (AP) (Southern Biotech) was added at 1:400 diluted in block. Plates were
again incubated as previous and were then washed five times with ELISA wash.
Substrate buffer (section 1.2.5) was added at 100µL/well and incubated for 15 minutes
at room temperature in the dark. When plates were fully developed, they were read at
405nm-650nm.
Total IgG1 ELISA
Plates were coated with mouse anti-mouse IgG (Southern Biotech) at 5µg/mL in BBS
(see previous section 1.2.5 for recipe) and incubated at 37°C for 1 hour. Plates were
then washed three times with ELISA wash (section 1.2.5). Plates were blocked (section
1.2.5) for 1 hour at 37°C and were washed as above. Samples were added at various
concentrations, diluted in block. For standard curve, normal mouse IgG1 (Southern
Biotech) was used. Plates were then incubated as previous. Plates were washed three
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times with ELISA wash and goat-anti IgG1-AP was diluted in block (1:400 dilution)
(Southern Biotech). After 1 hour incubation at 37°C, plates were washed and
developed with phosphate tablets (Sigma-Aldrich) dissolved in substrate buffer
(section1.2.5). Absorbance at 405nm-650nm was measured.
3.2.4 Flow cytometry, cell sorting and immunohistochemistry
Flow cytometry
Cell isolation was conducted as previously described in section1.2.4 and stained as in
section1.2.6.
Cell sorting
Cells were isolated from peritoneal lavage (PL) fluid. RBC lysis was done as in section
1.2.4. PL cells were stained as described in 1.2.6 and sorted on the Aria II (BD
Biosciences) into FBS coated 15mL conical tubes.
Immunohistochemistry
Organs were harvested, prepared and stained as described in section 1.2.6.
Antibodies
Antibodies used are listed in Table 6.
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Table 6. Antibodies used in section 3
Specificity

Clone

Conjugate

Company

Flow Cytometry and Cell Sorting
Mouse-IgE

23G3

FITC

Southern Biotech

Mouse-CD5

53-7.3

PE

Biolegend

Mouse-

RA3-6B2

APC

Biolegend

Mouse-CD11b

M170

PE/Cy7

Biolegend

Mouse IgM

R-MM1

PerCP/Cy5.5

B220/CD45R

Immunofluorescence
Mouse-GL7(B and T

GL7

FITC

Biolegend

Mouse-CD3

1445-2C11

PE

Biolegend

Mouse-

RA3-6B2

PE

Biolegend

cell activation
antigen)

B220/CD45R
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3.2.5 B1 cell culture
Sorted B1 cells, B1a, B1b or B2 cells were set up in 96 well cell culture plates at
50,000cells/well. Cells were incubated in cRPMI 1640 containing 10% FBS, 2mM Lglutamine, 100 U/mL penicillin, 100µg/mL streptomycin, 1mM HEPES (Quality
Biological, Gaithersburg, MD,USA), and 1mM sodium pyruvate (Cellgro, Herndon, VA,
USA) Cell cultures were supplemented with either CD40L-transfected Chinese hamster
ovary (CHO) cells as a B cell stimulant (6x104cells/well) or with 2µL/mL of stimulating
anti-CD40 antibody (Invitrogen) and when noted, IL-4 (10,000U/mL; NIH) for nine days.
Cell-free supernatants were then harvested and analyzed for IgE production by ELISA.
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CHAPTER 3: Th2 helminth infected mice induce a strong B1 cell IgE response
that is augmented by MDSCs.
3.3.1 ADAM10Tg mice lack B2 cell development, but elicit a strong IgE response
during N. brasiliensis infection
ADAM10Tg mice lack B2 cells but have an intact B1 cell compartment
ADAM10Tg mice lack B2 cells due to a defect in hematopoiesis (discussed in
section 2). In Figure 49, overexpression of the transgene markedly reduced the levels
of pro/pre B cells and immature B cells (B220hiIgM+) in BM. This led to a near complete
loss of peripheral B cells in secondary lymphoid organs (Figure 49). Analysis of B cells
from peritoneal fluid revealed that levels of B1a (B220intCD11b+CD5+) and B1b cells
(B220intCD11b+CD5-) in ADAM10Tg mice were not significantly altered compared to
littermate (LM) controls, whereas B2 cells (B220hiCD11b-CD5-) were nearly absent
(Figure 50). Thus, the block in B cell development was specific to BM-derived B2 cells.
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Figure 49. ADAM10 Overexpression blocks B2 B cell development
(A) Flow cytometric analysis of pro/pre B cells (B220+IgM+) and immature B cells
(B220hiIgM+) in BM of littermate (LM) and ADAM10Tg progeny. (B) Flow cytometric
analysis of CD3+ T cells and B220+ B2 cells in the spleen of ADAM10Tgs or LMs. Data
representative of three independent experiments.
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Figure 50. ADAM10 overexpression does not affect B1 cell development
Flow cytometry on B cell subsets in peritoneal lavage fluid. Panels are gated on B220+
cells. B2 cells: B220hiCD11b+ CD5+, B1a cells: B220intCD11b+CD5+, B1b cells:
B220intCD11b+CD5+. This is representative of at least three experiments.
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ADAM10Tg mice have increased B1 IgE production
As described in section 2, the ADAM10Tg mouse has an over accumulation of
MDSCs in vivo. Mice were infected with N. brasiliensis to ascertain the role of MDSCs
in Th2 helminth infection (section 2). A hallmark of N. brasiliensis infection is high IgE
levels. Helminth infections are some of the most potent natural inducers of IgE
synthesis. Knowing that the ADAM10Tg mouse lacked BM-derived B2 cells, all
antibody production in the mouse is attributed to B1 cells. Throughout the infection, IgE
levels were measured in the serum of ADAM10Tg mice versus WT mice with intact B2
cell development. Surprisingly, in the absence of B2 cells, the ADAM10Tg mouse has
equivalent and at some time points, significantly increased total IgE (Figure 51). These
mice additionally had augmented parasitic clearance with decreased worm burdens at
L4 in the lung, L5 adult worm in the intestine and egg production in the feces (Figure
18). This indicates that amplified IgE levels were not due to elevated worm burden.
ADAM10Tg mice lack GC development
To confirm that CSR is occurring outside of GCs to produce IgE, N. brasiliensis
infected ADAM10Tg mice were euthanized on day 14 post-infection and MLNs were
harvested. MLNs are the principle draining LNs during the intestinal helminth infection.
MLNs were examined for GL7, an activation antigen expressed on GC B and T cells.
In ADAM10Tg mice, no GC cells were found (Figure 52). This confirms the hypothesis
that B1 IgE production is occurring outside of normal GC development. MLNs were
additionally examined for B220 and CD3 to look at LN structure (Figure 53). B220
staining was evident in small pockets of the ADAM10Tg node, representing fetal liver
derived B1 B cells colonizing the MLNs (Figure 53). CD3+ T cells form pocket-like
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structures behind the B1 cells. ADAM10Tg MLNs are also filled with Gr-1+ MDSCs as
evident in Figure 20.
B1 cells from WT N. brasiliensis infected mice stain positive for IgE
To further understand if this B1 IgE production was specific to ADAM10Tg mice,
we infected C57B/6 WT mice with N. brasiliensis. On day 7 post-infection, peritoneal
lavage (PL) fluid and spleens were examined for B cell distribution (Figure 54) and
each population was further assessed for IgE staining to help delineate the major
population responsible for IgE production (Figure 55). Since, SHM, CSR and GC
response usually take longer we were unable to detect B2 IgE staining. Interestingly,
B1a cells stained positive for IgE, confirming that in WT mice, B1 cells are capable of
IgE production. This early IgE is majorly attributed to B1a cells, but B1b cells
additionally stained positive for IgE. Interestingly, the populations of B1 cells in the
spleen had a higher percentage of IgE positive staining within the small populations of
B1 cells (Figure 55). This IgE staining cannot be cytophilic IgE, as B1 cells are CD23
negative354.
B1 cells from N. brasiliensis infected mice make IgE in vitro after stimulation with IL-4
and anti-CD40
We next wanted to isolate B1 cells to see if we could induce IgE production in
vitro. B1 cells were sorted from PL fluid of N. brasiliensis infected C57B/6 WT mice.
Both B1 cell populations were sorted, B1a (B220int CD11b+ CD5+) and B1b (B220int
CD11b+ CD5+). Cells were plated in vitro with anti-CD40 alone or anti-CD40 and IL-4.
After nine days, cell-free supernatants were assessed for total IgE production by ELISA.
Extremely large amounts of IgE were detected in supernatants from B1a cells and B1b
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cells. Although both B1 populations made IgE, B1a cells, by far, made the highest IgE
(Figure 56). Moreover, without addition of IL-4, B1 cells did not make any detectable
IgE. To confirm that B1 IgE production is dependent on signals first experienced in
helminth infection, we sorted B1 cells from naïve C57B/6 WT mice. B1a and B1b cell
populations made significantly less IgE from naïve mice than when sorted from N.
brasiliensis infected mice (Figure 57). This leads us to believe that possible cytokine
signals, such as IL-5 or IL-4, induced in parasite infection are required for the B1 switch
to IgE production.
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Figure 51. ADAM10Tg mice make increased IgE during N. brasiliensis infection
Serum was collected from ADAM10Tg (open square) or WT (closed circle) mice on
days indicated over the course of N. brasiliensis infection and assessed for total IgE by
ELISA. IgE was assessed on days indicated by ELISA. *p>0.05; n= at least five mice
per group.

214

*

215

Figure 52. ADAM10Tg mice lack GCs
MLNs were harvested on day 14 post N. brasiliensis infection. MLNs were sectioned
and stained with GL7 (green). Pictures were taken with a 10x objective and are
representative of at least three independent experiments.
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Figure 53. ADAM10Tg mice lack normal secondary lymphoid architecture
MLNs were harvested on day 14 post N. brasiliensis infection. MLNs were sectioned
and stained with B220 (red) or CD3 (green). Pictures were taken with a 10x objective
and are representative of at least three independent experiments.
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Figure 54. Peritoneal lavage and spleens from N. brasiliensis infected mice
contain B1a, B1b and B2 cells
PL fluid and spleens were harvested from N. brasiliensis infected mice on day 7 postinfection. A. Flow cytometry plots of four mice showing PL fluid B1 and B2 cell
populations from total live cells (top), PL distribution of B2, B1a and B1b cells gated
from B220+ population (middle) and splenic distribution of B2 and B1 cell populations
from total live cells (bottom). B. PL and spleen B1 and B2 cell percentages compiled.
C. PL B2, B1a, and B1b cells percentages complied. n= four mice per group.

220

A

PL
B1

B2

B2

B1

B1

B2

B1

B220

B2

CD5

PL
B1a

B1a

B1a

B1a

B1b

B1b

B1b

B1b

Spleen
B1

B2

B1

B2

B220

B2

CD11b

B

C

221

B1

B2

B1

Figure 55. B1a cells from peritoneal lavage and spleens of N. brasiliensis infected
WT mice stain for IgE
PL fluid and spleens were harvested from N. brasiliensis infected mice on day 7 postinfection. PL (A) or spleen (B) is shown in histograms representing IgE staining. B2
cells (black filled) are gated from Figure 54A (top for PL and bottom for spleens). B1a
cells (green) and B1b cells (red) were gated as in Figure 54A (middle) for spleens and
PL. C. Complied percentages of IgEhigh staining cells, as represented by black bars in
(A) and (B). *p>0.05, ***p>0.0005; n=four mice per group. Statistics compare B1a vs
B1b bars in both PL and spleen.
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Figure 56. B1 cells sorted from peritoneal lavage fluid of N. brasiliensis infected
mice make IgE in vitro after stimulation
PL fluid was sorted on day 7 post infection with N. brasiliensis. B1a cells were sorted
as B220intCD11b+CD5+ cells. B1b cells were sorted as B220intCD11b+CD5- cells.
Sorting was accomplished with 95% accuracy. Cells were plated at 50 thousand/well
and stimulated with anti-CD40 and with IL-4 (red) or without IL-4 (blue) for 9 days as
described in Methods and Materials. Total IgE was assessed from cell-free
supernatants by ELISA.***p>0.0005; n= three replicates per group. nd=none detected.
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Figure 57. Naïve B1 cells secrete very little IgE without N. brasiliensis infection
PL fluid was sorted. B1a cells were sorted as B220intCD11b+CD5+ cells. B1b cells
were sorted as B220intCD11b+CD5- cells. Sorting was accomplished with 95%
accuracy. Cells were plated at 50 thousand/well and stimulated with anti-CD40 and
with or without IL-4 for 9 days as described in Methods and Materials. Total IgE was
assessed from cell-free supernatants by ELISA. n= three replicates per group. nd=none
detected
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MDSCs enhance B1 IgE production in WT mice
To investigate whether MDSC accumulation during parasitic infection correlated
with increased IgE, we administered GEM. GEM selectively depletes MDSCs without
affecting lymphocyte levels309,310. With GEM administration through the course of N.
brasiliensis infection, IgE levels were significantly decreased (Figure 58). This lead to
the hypothesis that B1 cells make IgE during helminth infection and this is augmented
by the accumulation of MDSCs.
B1 cells have augmented IgE production that is independent of IgG1 and GCs
Next we examined IgG1 levels, as they are usually correlated with the increase in
IgE. CSR occurs in the GC from µ to γ and then to ε. High affinity IgE antibodies are
made this way380. CSR outside of the GC results in low affinity, polyclonal antibodies. It
can occur with a direct switch from µ to ε380. It is thought that B1 cells would switch to
IgE in this manner. IgG1 levels in the ADAM10Tg mouse infected with N. brasiliensis
are significantly decreased as compared to WT (Figure 59). GEM treatment does not
alter this (Figure 59). This indicates that B1 cells during helminth infection do not
undergo CSR through the intermediate γ heavy chain.
MDSC AT into naïve mice increases IgE production by B1 cells
Furthermore, since N. brasiliensis infection induced enhanced myelopoiesis and
MDSC accumulation in WT mice (Figure 21), we established the hypothesis that
artificial MDSC accumulation could additionally augment B1 IgE production. To test
this, we injected MDSCs i.p. into C57B/6 WT mice 5 days and 1 day prior to sorting of
B1 B cells from the PL fluid. In Figure 60, we show that MDSC accumulation indeed
increases B1 IgE production
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Figure 58. ADAM10Tg mice make increased IgE during N. brasiliensis infection
that is reduced upon GEM treatment
ADAM10Tg mice were treated with GEM (closed square) as described in Methods and
Materials. IgE was assessed on days indicated by ELISA. *p>0.05; n= at least five
mice per group. Significance in indicates difference between ADAM10Tg and
ADAM10Tg treated with GEM at time points indicated.
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Figure 59. ADAM10Tg mice do not make increased IgG1 and GEM does not affect
total IgG1 levels in N. brasiliensis infection
Total IgG1 levels were assessed by ELISA on days indicated. WT (blue), ADAM10Tg
(red), and ADAM10Tg mice treated with GEM (purple) as described in Materials and
Methods. *p>0.05; n= at least five mice per group. Significance indicates difference
between WT and ADAM10Tg at time point indicated.
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Figure 60. Adoptive transfer of MDSCs into Naïve WT mice induces B1 IgE
production
PL fluid was sorted after AT of MDSCs, days -4 and -1 pre-sort. B1a cells were sorted
as B220intCD11b+CD5+ cells. B1b cells were sorted as B220intCD11b+CD5- cells.
Sorting was accomplished with 95% accuracy. Cells were plated at 50 thousand/well
and stimulated with anti-CD40 and with IL-4 for 9 days as described in Methods and
Materials. Total IgE was assessed from cell-free supernatants by ELISA. *p>0.05; n=
three replicates per group. nd =none detected.
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3.3.2 Discussion
The relationship between helminth infection and high IgE is a strong one. Over
the years, this has been linked to the absence of allergic disease in countries with
widespread parasite infection382,383. Th2 helminthes are strong inducers of IgE384. IgE
made in response to these infections are a mix of non-specific, low affinity IgE and high
affinity, parasite-specific IgE385. Studies show that this ratio of high affinity to low affinity
IgE changes depending on how infected the individual is. Individuals with high parasite
burdens have mostly low-affinity, non-specific IgE. Individuals with a low parasite
burden have increased parasite-specific IgE385.
N. brasiliensis is a Th2 helminth, similar to the human hookworm. In WT
animals, IgE production is not necessary to clear the parasite, as IgE-/- mice clear it
effectively386. It is thought that the induction of the IgE response is an evolutionary
characteristic of the helminth and that induction of large amounts of non-specific and
low-affinity IgE protects it from high-affinity IgE384. Studies with the human hookworm
show the opposite, that a high level of non-specific IgE is associated with decreased
fecundity and reduced growth of adult worms387.
The source of this low-affinity IgE was always thought to be FO B cell in origin.
Until recently, B1 cells have only been hinted at having the ability to class switch to IgE.
Here, we show that ADAM10Tg mice lacking FO B cells induce high levels of IgE in
response to infection with N. brasiliensis (Figure 51). This IgE production correlates
with the increased MDSCs seen in these ADAM10Tg (Figure 51). Additionally, lowaffinity antibody is thought to be mediated through a direct µ to ε-heavy chain switch380.
In our mice we show that IgG1 levels remain unchanged, reinforcing that B1 cells direct
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switch to IgE (Figure 59). This switch additionally occurs outside of the GC response
(Figure 52). We also show that this occurs in WT N. brasiliensis infected mice and can
reproduce it in vitro (Figures 56,60).
In vitro B1 production of IgE required that the mouse be infected with the parasite
before sorting the cells out of the peritoneal cavity. N. brasiliensis infection up-regulates
many cytokines associated with Th2 allergy383. IL-13, IL-4, IL-5, IL-9, IL-33 and IL-25
are all associated with parasitic infection383. Many of these have been previously
associated with B1 cell antibody production or proliferation350,372.
An unknown signal is first needed to activate the B1 to make IgE that is
associated with parasitic infection. MDSCs accumulate naturally in response to
parasitic infection (Figure 21). We hypothesize that MDSCs that accumulate in
helminth infection are the natural source of this signal. ADAM10Tg mice have an overaccumulation of MDSCs and have increased B1 IgE production (Figure 51). In the
absence of parasitic infection, AT of MDSCs directly into the peritoneal cavity of mice
increased sorted B1 IgE production in vitro (Figure 60). This reinforces that MDSCs
may be providing this activation for the B1 cell. In our ADAM10Tg mouse we find
elevated levels of IL-4, IL-5, IL-13, IL-1, and IL-33 (Figure 19). Post-sort, IL-4 is
required for B1 IgE production, but it is not enough to induce B1 IgE in naïve mice
(Figure 56 and 57). Additionally, anti-CD40 is required (Figure 56). This alludes to the
need for CD40 ligand stimulation. Traditionally, the CD4+ Th cell would have been
thought to provide this signal, but many other cells express CD40L, including: mast
cells, DCs, basophils, macrophages, and eosinophils388. So, this signal could come
from many different sources.
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With flow cytometry and in vitro cultures, we show that B1a cells are producing
more IgE than B1b cells (Figures 55 and 56). In previous studies, the B1b cell has
been eluded to as being capable of IgE production360,361. We do not dispute this, as we
additionally see B1b IgE production (Figures 55 and 56). But, our data indicates that
B1a cells may be the source for the majority of B1 IgE. Overall, we definitively show
that B1 cells can switch to IgE during helminth infection and that these cells may be
responsible for the high levels of non-specific IgE found in parasitic infection. We
additionally reveal a novel role for the MDSC as a potent inducer of B1 IgE synthesis.
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Section 4
Chapter 1: CD23+ B cell-derived exosomes mediate IgE-antigen complex
mediated immune stimulation
4.1.1 Introduction
Antibody, in complex with its antigen, provides the immune system with a
feedback response against the complexed antigen. This feedback mechanism results
in immune stimulation or suppression depending upon the antibody class (reviewed
in389). IgE, complexed with antigen, has long been shown to induce a significantly
increased immune response over antigen alone. This response results in increased
antigen specific T cell proliferation and antigen specific IgG in vivo390. The low affinity
receptor for IgE (CD23) is traditionally known for its role in the negative regulation of IgE
synthesis. But, CD23 has additionally been known to internalize IgE antigen complexes
and promote antigen presentation. Extensive studies using CD23-/- animals proved
CD23 to be essential to the immunostimulatory properties of IgE antigen complexes390.
Combining antigen presentation properties of CD23 with the observed
immunostimulation led to the hypothesis that antigen presentation by CD23+ B cells was
responsible for these activities. This hypothesis was challenged by the recent finding
that B cells rapidly transfer the antigen to the spleen391 and were dispensable after 4
hours post IgE antigen complex injection. After that period, DCs were required392.
These intriguing findings suggested that IgE antigen complexes or fragments thereof
were being carried to the secondary lymphoid system, in this case the spleen, by CD23+
B cells and then were being transferred to DCs. This led to the obvious question, what
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is the mechanism of this transfer? Henningson et al392 suggested two possibilities;
trogocytosis by DCs or exosomal mediated transfer from B cells to DCs.
Exosomes are defined as tiny membrane bound particles ranging from 30150nm. Although originally discovered in the 1980s and thought to be primarily for
cellular waste209, exosomal research has undergone a resurgence given the protein and
micro-RNA cargo that is packed into these particles (reviewed in393). In a previous
publication, we demonstrated that CD23 and its protease, ADAM10 were found in B cell
derived exosomes (bexosomes) from both mouse and human B cells35. Additionally,
β2-adrenergic stimulation of B cells further increased both CD23 and ADAM10 levels in
bexosomes394. In this study we show that B cells stimulated with anti-CD40 and IL-4, in
the presence of IgE antigen complexes, release bexosomes that contain both CD23 and
IgE. In agreement with earlier studies395, these bexosomes were capable of directly
stimulating antigen specific T cells in vitro, presumably via the MHC peptide complexes
found on these bexosomes. Intriguingly, this stimulation was greatly enhanced if the
bexosomes were isolated from B cells stimulated in the presence of IgE antigen
complexes, and this enhanced stimulation was CD23 dependent. This data supports
earlier in vitro studies where B cells were shown to directly present IgE antigen
complexes, taken up via CD23, to T cells396. Yet, in vivo, direct injection of bexosomes
did not cause increased T cell proliferation, which agrees with the requirement of
DCs392. In contrast, culture of bexosomes with bone marrow derived DCs (BMDC),
followed by isolation and injection of DCs did directly enhance in vivo antigen specific T
cell proliferation. Overall, this supports the hypothesis that bexosomes are responsible
for antigen transfer from B cells to DCs, thus, providing a mechanism and suggesting a

239

model to explain the importance of DCs in the immunostimulatory activity of IgE
complexes.
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Chapter 2: Materials and Methods
4.2.1 Mice
Mice were maintained in the Virginia Commonwealth University animal facility in
accordance to guidelines for the humane treatment of laboratory animals set forth by
the National Institutes of Health and the American Association for the Accreditation of
Laboratory Animal Care. C57BL/6 and BALB/C mice were purchased from Jackson
Labs; DO11.10 and OTII mice were progeny from breeding pairs purchased from
Jackson Laboratory. CD23 knockout (BALB/C)397 or B cell specific ADAM10 deficient
mice (ADAM10B-/-)(BALB/C backcross at least s6 generations)247 were bred in house.
All mouse protocols were approved by the Virginia Commonwealth University
Institutional Animal Care and Use Committee.
4.2.2 Exosomal Cell Cultures
All fetal bovine serum (FBS) used in exosome cultures was first centrifuged at
100,000xg for 1 hour to deplete bovine exosomes. Splenic B cells were isolated using
B220 positive magnetic bead selection as per manufacturer protocol (Miltenyi Macs
system) and cultured for 3 days in 6 well plates at 1 x 106 cells/mL in cRPMI 164029
containing 1µg/mL anti-CD40 (HM40-3) (Biolegend) and 10,000 U/mL IL-4 (gift from Bill
Paul NIH). When indicated, 10 µg/ml of anti-TNP- IgE (IGELb4)398 was present. When
larger amounts of exosomes were needed, B lymphoma line M12.4.5 (M12)399 was
used. M12 cells (1 x 106cells/mL – total cell number 3-5 x 108) were cultured for 24 hrs
in cRPMI 1640/10% FCS containing anti-CD40, IL-4, and anti-TNP (IGELb4) or antiDNP IgE (10 µg/mL)398,400.
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4.2.3 Exosomal Isolation
Exosomes were isolated as previously described34. Briefly, apoptotic bodies in cell free
supernatants were removed by centrifugation at 27,000 x g for 20 minutes. Finally,
exosomes were harvested by spinning at 100,000 x g for 1 hour; the exosome pellet
was resuspended in 5 mL of HBS plus 2mM Ca2+ and pelleted again at 100,000 x g for
1 hour. Final exosome pellet were resuspended in HBS plus 2mM Ca2+ and then
passed through a 0.2μm filter to remove particles larger than 200 nm and to assure
sterility. Bradford Assay exosome yields were approximately 1.0-1.62 µg/µL, from B cell
cultures and about 10-fold higher with M12 cultures depending upon original cell
number.
4.2.4 Western Blotting
Western Blots were performed using 10% Bis-Tris gels and a mini gel system (Life
Technologies). Equal amounts of exosome protein (20 µg) were loaded. NuPage MES
SDS Running Buffer and NuPAGE MES Transfer Buffer were used according to
manufacturer’s instructions. After electrophoresis and transfer to nitrocellulose paper,
blocking was performed using 5% powdered milk solution /0.05% v/v Tween-20 (two
hours) followed by the primary antibody incubation (1 hour minimum) followed by HRP
secondary antibody. Detection was observed by appropriate film exposure. Antibodies
used were as follows: Mouse anti-mouse MHCII H2-I/Adβ (5K43) (Santa Cruz); Rabbit
anti-mouse IgE (Fc specific) (Acris); goat anti-rabbit HRP (Southern Biotech); Rabbit
anti-mouse CD23 as described401.
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4.2.5 Specific T cell proliferation:
In vitro
DO11.10 T cells were isolated using magnetic bead selection (Miltenyi Macs)B220+,
CD11b+ and CD11c+ cells were depleted and then CD4 positive T cells were isolated
using L3T4, non-activating selection. Bexosomes (15-20 µg /100 µL) were added to 1 x
105 DO11.10 T cells in a final volume of 200 µL cRPMI/well in 96 well plates; TNP or
DNP-OVA was added in indicated amounts. After 96 hours, cells were pulsed with 1
μCi/well of [H3]-thymidine for 24 hours (Perkin Elmer). Plates were then harvested using
a Filtermate cell harvester onto GFC plates. Assays were read using a Topcount Plate
Counter (Perkin Elmer, Waltham, MA).
In vivo
(B cell specific ADAM10 deficient) ADAM10B-/-BALB/C or WT BALB/C mice were
injected with IgE immune complexes (20 µg TNP-OVA + 50 µg anti-TNP-IgE392. For
bexosome or BMDC derived dexosome experiments, bexosomes were added to the DC
cultures for 24 hours. After washing, LPS was added and cultures were continued for
72 hours and dexosomes were then isolated by centrifugation. Dexosomes, BMDCs or
bexosomes or were i.v. injected into BALB/C mice that had been adoptively transferred
(AT) with DO11.10 total splenocytes 24 hours previous. After 3 days, DO11.10 cell
numbers

in

the

spleen

were

determined

immunohistochemistry as described392.
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4.2.6 Flow Cytometry/Immunohistochemistry
Single cell suspensions were labeled with antibodies for cytometric analysis. Antibodies
included unlabeled anti-mouse FcγR (2.4G2), FITC-conjugated anti-mouse D011.10
(KJ1-26) (Biolegend), and PE-conjugated anti-mouse CD4 (145-2C11) (Biolegend).
Flow cytometric analysis was performed using the Canto (BD Biosciences). Data
analysis was conducted using FlowJo software v7.6.5 (Tree Star). Sections were
prepared from frozen tissue and fixed with cold Acetone. Sections were blocked using
5% normal horse serum plus 1.5% BSA. Sections were stained using Biotinylated antiDO11.10 (KJ1-26) followed by Streptavidin-APC and anti-B220-PE (RA3-6B2)
(Biolegend). Slides were cover slipped utilizing Vectashield Hardset (Vector Labs) and
imaged on the Leica TCS-SP2 AOBS CLSM Confocal laser-scanning microscope.
4.2.7 BMDC culture
Mouse bone marrow-derived dendritic cells (BMDC’s) were derived from femurs of WT
mice and cultured in complete RPMI (cRPMI) 1640 containing 10% FBS, 2mM Lglutamine, 100 U/mL penicillin, 100µg/mL streptomycin, 1mM HEPES (Quality
Biological, Inc.), and 1mM sodium pyruvate (Cellgro). Cultures were supplemented with
IL-4 1ng/mL (Peprotech) and GM-CSF 50ng/mL (Peprotech).
harvested after 6 days of culture395.
4.2.8 Statistical Analysis
Analyzed as in section 1.2.8.
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Mature BMDC were

Chapter 3: IgE/Antigen Complexes stimulate OVA specific T cell proliferation
4.3.1 Results and Discussion
IgE is associated with bexosomes in a CD23 dependent manner.
As mentioned, CD23 and ADAM10 are both found associated with bexosomes35.
In order to determine if IgE is additionally associated, B cells were stimulated with antiCD40

IL-4 in the presence of IgE/Ag ICs. After 48 hours of culture, bexosomes were

isolated by centrifugation. Equal amounts of protein were analyzed by Western blotting.
Figure 61A shows that IL-4 stimulated B cells increases bexosomal CD23 levels. The
blot indicated equal MHC class II expression. Interestingly, MHC class II levels were
not increased by IL-4, in contrast to the well-known cell surface increase induced by this
cytokine. In an earlier study using LPS as the activator35, we found that ADAM10 was
needed for bexosomal CD23 expression. With anti-CD40, CD23 is present even if
ADAM10-/- B cells are used; although the CD23 expression level is lower (data not
shown). This indicates that CD40 activation is more efficient in allowing CD23
incorporation into bexosomes. In Figure 61B, the blot is examined using an ε-specific
anti-IgE antibody, and lane 1 shows a strong 85Kd band indicates the presence of IgE.
The amount of IgE was additionally increased in the presence of IL-4 (lane 2). This
band was not present when B cells lacking CD23 were used (lanes 3 and 4) regardless
of IL-4 stimulation. Thus, CD40-mediated CD23+ B cell activation results in release of
bexosomes that contains CD23 and bound IgE. To examine if bexosomes additionally
expressed co-stimulatory molecules in addition to MHCII, Bexosomes were blotted for
CD80 and CD86 expression (Figure 62).
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Increased in vivo antigen specific T cell proliferation is seen with bexosomes from antiCD40/IL4 activated B cells when IgE/antigen complexes are present in the culture.
As mentioned above, bexosomes are known to induce antigen specific T cell
proliferation if isolated from B cells cultured in the presence of the specific antigen395.
The finding (Figure 61) that CD23 and IgE are present in bexosomes suggests that
MHC class II peptide loading should be enhanced when IgE complexes are included in
the culture. That this is indeed true is shown in Figure 64A where the initial B cells
were cultured with increasing amounts of antigen (TNP-OVA) alone or the same plus
anti -TNP-IgE. With B cells from either BALB/C or C57BL/6 mice and the corresponding
strains of OVA-specific T cells, DO11.10 (Figure 64A) or OTII (Figure 65), increased
specific T cell proliferation is seen when antigen specific IgE is present in the cultures.
This data looks quite similar to the studies that initially demonstrated the enhanced
antigen-presentation by IgE complexes with CD23+ B cells396 and relates to enhanced
MHC class II loading due to the increased antigen found in the endosomal
compartments. Confirmation that both IgE and CD23 are necessary for the bexosomal
induced T cell proliferation is shown in Figure 64A where increased T proliferation is
only seen when both are present. To determine whether ADAM10 was also needed for
the enhancement of presentation, we turned to in vivo studies. WT or B cell-specific
ADAM10 deficient (ADAM10B-/-) BALB/C mice were i.v. injected on day -1 with 30 million
DO11.10 total splenocytes. On day 0, they were i.v. injected with anti-TNP IgE/TNPOVA complexes (Methods). Three days later, OVA-specific T-cell proliferation was
determined by flow cytometry and immunohistochemistry. WT mice injected with
IgE/Antigen complexes had increased DO11.10 proliferation, as indicated by the
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number of antigen specific T cells in the spleen, as compared to WT OVA injected
(Figure 64B). This was as expected. But, the ADAM10B-/- mice had significantly more
DO11.10 proliferation than did the WT. This finding was further confirmed by
immunohistochemistry, where proliferation differences generally look more pronounced.
The enhanced OVA-specific DO11.10 cell number in the T cell region of the spleen of
the ADAM10B-/- was clearly evident (Figure 64C). Thus, B cell ADAM10 is clearly not
necessary for IgE antigen complex stimulation since this enhancement is seen. As the
ADAM10B-/- mice have been shown to have enhanced CD23 expression56, we
hypothesize that the increased CD23 leads to still further IgE-antigen incorporation with
enhanced MHC class II loading in the endosomal compartment, leading to the results
shown in Figure 64B and C. These studies also indicate that MZB are not necessary
for IgE-antigen complex immunostimulation, since MZB are absent in ADAM10B-/mice56. It also agrees with the observation that IgE complexes were found bound to
mainly FO B cells and not to MZ B cells392.
Bexosomes must first go through DCs in order to stimulate T cells in vivo.
To directly test if bexosomes from B cells activated with anti-CD40 and IL-4
would stimulate T cells in vivo, bexosomes were isolated from B cells activated as in
Figure 64A with IgE/OVA complexes. They were injected into BALB/C mice AT with
OVA-specific DO11.10 cells. This was ineffectual, so to increase the level of bexosomes
for injection, 3 x 108 M12.4.5 cells were activated instead of primary B cells.
Bexosomes were isolated and injected into the OVA-specific T cell AT mice. In neither
situation did we observe increased levels of OVA-specific T cell proliferation when the
spleen was examined 3 days post bexosome injection (data not shown). We
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considered that the most likely reason for this failure was that the bexosomes were not
efficiently crossing the HEV to enter the peri-arteriolar lymphoid sheath (PALs) tissue.
To increase chance for HEV crossing, bexosomes were cultured with LPS activated
BMDCs, and DC were isolated 3 days post culture with bexosomes. In contrast to
directly injected bexosomes, passage of the bexosomes through DCs, with injection of
the DCs did cause a small but significant increase in OVA-specific proliferation, as
determined by flow cytometry (Figure 66). This increase was significantly higher than
what was seen by control DCs isolated from LPS activated cultured with the same
amount of TNP-OVA alone or increased amounts. While the increase in T cell
proliferation was not as dramatic as seen when directly injecting IgE immune complexes
(Figure 64B and Figure 66), the results are clearly compatible with exosomes being
responsible for the transfer of antigen to DCs as described by Henningsson et al392.
Thus, we propose the following model (Figure 67): IgE immune complexes are picked
up by CD23+ B cells and this allows efficient transfer into the spleen. Once there,
bexosomes are released and picked up by DCs which then activate antigen specific T
cells and subsequently give the enhanced humoral response that is seen in IgE antigen
complex injected animals396. Future studies could examine ways to increase transfer of
the bexosome incorporated MHC class II cargo to DCs. If successful, this would allow
immunization strategies that take advantage of the IgE immune complex stimulation that
would bypass any difficulties seen by FcεRI interaction with IgE and antigen, and still
allow efficient sensitization with low amounts of antigen.
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Figure 61. IgE and CD23 are associated with bexosomes
(A) Bexosomes were isolated from B cell cultures stimulated with anti-CD40 ± IL-4 or
IgE as indicated. Equal bexosome protein was loaded on each lane and the blot was
probed with polyclonal anti-CD23. Blot was stripped and probed with anti-MHC class II
and the result is shown at the bottom of (A). (B) Exosomes from B cell cultures
stimulated with anti-CD40 and IgE (All lanes). IL-4 stimulation is as indicated. Lanes 1
and 2 are bexosomes from WT mice, Lanes, 3 and 4 are bexosomes from CD23-/- mice.
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Figure 62. Bexosomes express co-stimulatory molecules CD80 and CD86
B cells were cultured in exo-free cRPMI under stimulation conditions with anti-CD40 and
IL-4. Exosomes were isolated after several centrifugation steps. Western blotting was
performed on (1) whole B cell lysates or (2) B cell derived exosomes lysates.
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Figure 63. B cell derived exosomes by electron micrograph
For the negative staining, exosomes were placed on formvar-coated 150-mesh copper
grids. The grid, formvar side to the sample, was then placed on top of the drop of
sample and allowed to rest for 1 minute. Next a drop of the stain was placed on the
parafilm and the grid was put on top of it for 1 minute. After 1 minute, the grid was
picked up, and the excess stain was wicked off. The grid was then allowed to dry
completely before scoping. Final developing solutions were tested: 1% Uranyl acetate,
which gave a grainy image, and 1% Phosphotungstic acid at pH 7.0.
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Figure 64. Bexosome-induced antigen specific T cell proliferation is enhanced by
IgE, only when CD23 is present and in vivo IgE immune complex T proliferation is
enhanced in ADAM10B-/- mice
(A) B cell cultures stimulated as in Methods. B cells were incubated with or without IgE
for 24 hours and then IgE/Ag ICs were added. Bexosomes were isolated. B cells were
from either WT or CD23-/-mice. Bexosomes and purified Ag-specific DO11 T cells were
cultured for 3 days and proliferation determined using a [3H]-thymidine pulse (Methods).
(B,C) On day -1 WT or ADAM10B-/- mice were given Ag-specific DO11 T cells and on
day 0 immunized with IgE/Ag ICs (Methods); on day 3, spleens were removed and
examined for expanded Ag specific DO11+ CD4+ T cells by flow cytometry (B) or
immunohistochemistry (C). *p>0.05, ***p>0.0005; n=at least five per group
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Figure 65. Bexosome-induced antigen specific T cell proliferation is enhanced by
IgE in C57BL/6 model of OVA-specific T cell proliferation
B cell cultures stimulated as in Methods. B cells were incubated with IgE for 24 hours
and then IgE/Ag ICs were added. Bexosomes were isolated. B cells were from WT
C57BL/6 mice. Bexosomes and purified Ag-specific OTII T cells were cultured for 3
days and proliferation determined using a [3H]-thymidine pulse (Methods).
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Figure 66. Increased in vivo T proliferation with i.v. injected DCs incubated with
bexosomes
In vitro differentiated LPS activated DCs were incubated with bexosomes stimulated
with IgE/Ag ICs plus 10µgOVA, 10µgOVA or 300µg OVA for three days. DCs were
harvested and equivalent cells were injected into mice AT with DO11 cells. Spleens
were assessed by flow cytometry on Day 3. Percent DO11TgTCR+ cells out of total
CD4+ T cells were plotted. *p>0.05; n=5 per group
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Figure 67. Model for the mechanism of IgE immune complex mediated humoral
immunity enhancement
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